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Abstract
The emergence of advanced DNA sequencing methods has presented disruptive opportunities in
biotechnology, establishing the foundation for the personalized medicine industry. Since the completion of
the Human Genome Project, the number of genomes sequenced has grown exponentially and the sequencing
price has dropped precipitously. To make personalized medicine a reality, there is a need for a large collection
of sequenced genomes in order to link specific genes to diseases. IonSeq seeks to be the leading DNA
sequencing service, employing new semiconductor- based sequencing technology offered by Ion Torrent, to
help pharmaceutical companies generate these libraries of genomes for their drug-development processes. To
support sequencing reliability and throughput, IonSeq will explore such technical details such as chip
configuration, insertion kinetics, signal generation, base-calling methods, and accuracy metrics. IonSeq will
prove a 40 genome/day output, made possible by the massively parallel procedure employed by the
sequencers. IonSeq will sequence each genome at a price of $2,000 while the cost of ‘manufacture’ will only be
$645. Series A will consist of a $3,682,886 investment and will yield the investors a MIRR of 102.98% over
four years. The Series B investment will total $4,510,491 and result in a 93.43% MIRR over a three period. The
NPV by the time of liquidation or acquisition event will be $39,322,347, at a conservative projected growth
rate of 5%.
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1. ABSTRACT 
The emergence of advanced DNA sequencing methods has presented disruptive 
opportunities in biotechnology, establishing the foundation for the personalized medicine industry.  
Since the completion of the Human Genome Project, the number of genomes sequenced has grown 
exponentially and the sequencing price has dropped precipitously.  To make personalized medicine 
a reality, there is a need for a large collection of sequenced genomes in order to link specific genes 
to diseases. IonSeq seeks to be the leading DNA sequencing service, employing new semiconductor-
based sequencing technology offered by Ion Torrent, to help pharmaceutical companies generate 
these libraries of genomes for their drug-development processes.  To support sequencing reliability 
and throughput, IonSeq will explore such technical details such as chip configuration, insertion 
kinetics, signal generation, base-calling methods, and accuracy metrics. IonSeq will prove a 40 
genome/day output, made possible by the massively parallel procedure employed by the 
sequencers. IonSeq will sequence each genome at a price of $2,000 while the cost of ‘manufacture’ 
will only be $645. Series A will consist of a $3,682,886 investment and will yield the investors a 
MIRR of 102.98% over four years. The Series B investment will total $4,510,491 and result in a 
93.43% MIRR over a three period. The NPV by the time of liquidation or acquisition event will be 
$39,322,347, at a conservative projected growth rate of 5%.  
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2. INTRODUCTION 
The market for personalized medicine is booming, and faster, more efficient sequencing 
methods are at the forefront of this revolution in genetics. Ion Torrent, a subsidiary of Life 
Technologies, has developed DNA genome sequencing machines that are capable of providing quick 
and relatively inexpensive sequences of large genomes. With these machines gaining popularity 
among research labs, pharmaceutical companies, and clinical medicine, there is a greater demand 
for not only faster but more accurate sequencing and for the development of clinical data generated 
from genome sequencing. 
To help fulfill this growing demand, a service organization that performs sequencing, led by 
experts in the field, may prove to be a highly profitable venture. In this light, IonSeq is proposed as 
a full-service arm of Ion Torrent, aimed at providing DNA genome sequencing services for 
pharmaceutical companies and finding methods to improve genome throughput. This chapter will 
detail the context within which IonSeq will be starting its venture.
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2. A. PURPOSE OF GENOME SEQUENCING 
 
The major goal of the Human Genome Project, and of all major genomic sequencing 
research, has been to gain a fundamental knowledge of the human body. Before the Human Genome 
Project was even completed, small companies such as Myriad Genetics began to offer an easy way 
to administer genetic tests that can identify certain diseases such as cancer or degenerative 
disorders.  
 Utilizing genetic information, it is speculated that health care professionals will eventually 
be able to predict an individual’s predisposition for certain diseases, potentially creating 
opportunities for early intervention to either minimize the impact of the disease or avoid it 
completely. All disease related genetic variants will be detected, and this will enable the 
development of rapidly emerging medical fields like personalized and predictive medicine, new 
fields that allow for a completely new level of precision to determine what medical treatments are 
appropriate for particular individuals. This is a revolution in biomolecular sciences, allowing for the 
development of a "’new taxonomy’ that defines disease based on underlying molecular and 
environmental causes, rather than on physical signs and symptoms”1 
 The National Academy of Sciences continues to stress the importance of data availability in 
future medical research. While part of this research will come from a greater understanding of 
biomolecular reactions within the body, a larger part relies on the ability to see the underlying 
genetic code that relates to certain diseases. Personalized medicine will also exist in the form of 
pharmacogenomics, where genetic information will be used to select the most appropriate drugs to 
prescribe to a patient to minimize hazardous side effects and maximize beneficial effects. 
                                                             
1 National Academy of Sciences. Division on Earth & Life Studies, Board on Life Sciences. (2013). Toward precision 
medicine: Building a knowledge network for biomedical research and a new taxonomy of disease . Retrieved from National 
Academy of Sciences website: http://dels.nas.edu/Report/Toward-Precision-Medicine-Building-Knowledge/13284 
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Development of this knowledge is already underway. As of October 2012, there are over 150 drugs 
in development targeting or paired with certain genes2.  
2. B. BASICS OF GENOME SEQUENCING 
 
DNA sequencing can involve sequencing of a whole genome or portions of a genome, such 
as the exome, all exons of the genome, or the transcriptome, all protein coding regions of the 
genome. Regardless, there are three general steps in all DNA sequencing methods – sample 
preparation, physical sequencing, and reassembly. During the sample preparation stage, a large 
sample of DNA is broken up into small fragments; each fragment is clonally amplified hundreds of 
thousands of times and then processed for sequencing. The fragmentation process is random, 
resulting in many overlapping fragments. In the sequencing phase, the individual bases in each 
fragment are identified by using the fragment as a template to sequence its complementary strand. 
The number of bases identified on a single template is defined as the read-length. During 
reassembly, bioinformatics software is used to align the overlapping reads, which allows the 
original genome to be assembled as a continuous sequence. Often times, the reassembly is 
accomplished by aligning the fragments to a reference genome if one exists. Longer the read lengths 
result in easier reassembly. More overlap between the fragments results in greater coverage, 
defined as the average number of times an individual base has been sequenced. This will ultimately 
improve the accuracy of the final aligned genome.  
 
                                                             
2 The pharmacogenomics knowledgebase. (n.d.). Retrieved from http://www.pharmgkb.org/ 
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Figure 1: Hierarchical sequencing is a long process that allows for more accurate DNA mapping. 
Shotgun sequencing allows for higher throughput but at the expense of ease of mapping. 3 
 
There are two primary strategies for genome sequencing: hierarchical sequencing and 
whole-genome shotgun sequencing as shown in Figure 1. In hierarchical sequencing, the genome is 
broken up into segments, approximately 200,000 bases in length. These fragments are ligated into 
bacterial vectors and cultured to form libraries. The fragments are organized to form a low 
resolution physical map of the genome. Since there is significant overlap in the segments, only those 
that form the minimum tiling path may be selected to be sequenced. These segments are now 
broken up into even smaller fragments, sequenced, and then assembled to form continuous 
stretches of DNA. The fragments are then reassembled to give the sequences of the entire genome. 
Hierarchical sequencing is an extremely long and laborious process, but it is the most accurate 
method of mapping sequenced DNA fragments to portions of the genome. This method was 
employed in the Human Genome Project launched in 1990. 
The shotgun approach skips the vector library creation steps and directly breaks up the 
entire genome into short sequenceable fragments about 500 base pairs (bp) in length. This makes 
reassembly more difficult and powerful computer algorithms are required for reassembly once the 
                                                             
3 Gibson G, Muse SV. A Primer of Genome Science. Third Edition. 2009. Sinauer Associates, Inc. Publishers. Sunderland, 
Massachusetts, USA. 
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sequences of each fragment are obtained. However, this approach yields considerably higher 
throughput as the time consuming steps present in hierarchical sequencing are avoided. Therefore, 
the shotgun approach is adopted by most genome projects in research centers around the world. 
However, hierarchical sequencing has its merits, especially when sequencing the genome of an 
organism for the first time because no reference genome exists. But in all other applications, such as 
the one described in this report, the shotgun approach is employed because it is faster, less 
expensive, and more efficient. 
2. C. HISTORY OF GENOME SEQUENCING  
 
The history of DNA sequencing has been built with the contribution of many minds. Today, 
IonSeq is able to base its fundamental technologies off the work of many its predecessors. IonSeq is 
motivated by the same goal: seeking to further the knowledge of the human species and advance 
medical treatments to improve the quality of life for the billions of lives on this planet.  
While the structure of DNA as a double helix was established in 1953, the earliest form of 
genome sequencing technology would not take shape until decades later. In 1972, Walter Fiers, 
from the University of Ghent, sequenced a single RNA gene of a virus, named Bacteriophage MS24, 
and through the rest of the 1970s, more progress led to the development of rapid DNA sequencing 
technology. The DNA sequencing movement was further accelerated by the development of 
recombinant DNA technology, allowing DNA to be extracted from non-viral sources. At this time, 
two technologies came to surface: Sanger sequencing and Maxam-Gilbert sequencing. 
2.C.I. FIRST GENERATION ADVANCEMENTS IN GENOME SEQUENCING 
 
At the MRC Centre of Cambridge, Frederick Sanger published a method for DNA Sequencing 
with chain-terminating inhibitors, while Walter Gilbert and Allan Maxam at Harvard developed a 
                                                             
4 Min, J. W., Haegeman, G., Ysebaert, M., & Fiers, W. (1972). Nucleotide sequence of the gene coding for the bacteriophage 
ms2 coat protein. Nature, 237, 82-88. doi: 10.1038/237082a0 
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method for sequencing using chemical degradation. Sanger sequencing uses the original DNA 
strand as a template. A number of complementary strands are built starting from the 5’ end, and are 
each terminated at different points on the 3’ end. In regular DNA, the bases are referred to as 
deoxyribonucleotides (dNTP) or nucleotides. The addition of a dNTP allows the DNA chain to 
continue its growth in a regular manner. In Sanger sequencing, the template DNA is exposed to a 
low concentration of dideoxyribonucleotides (ddNTP), which has one less oxygen atom. When a 
ddNTP is incorporated, or added to the strand, the chain ends. Using a probabilistic model, chains 
that end at each base in the DNA strand are generated. The ddNTPs are radioactively labeled, and 
the strands of varying sizes are run through an electrophoresis gel to separate them by relative 
sizes. The radioactive signatures for each band on the gel can then be read to determine the 
sequence of the DNA. 
The Maxam-Gilbert sequencing method breaks up the DNA into fragments. The DNA is pre-
treated such that the breaks, induced by four separate reactions, would occur only after specific 
bases. The concentration of the modifying chemicals is controlled to induce on average one 
modification per DNA molecule. Similar to the Sanger method, the 5’ end of each fragment was then 
radioactively labeled, and then the sequence was deduced by determining the sizes of the 
fragments using slab gel electrophoresis. The sequence was then derived from the sizes of the 
fragments. Since its development, the Maxam-Gilbert method has fallen out of favor due to the 
technical complexity prohibiting the production of standard molecular biology kits, the use of 
hazardous chemicals, and the sheer number of reactions necessary that impede proper scale-up. 
Sanger sequencing was adopted as the primary technology in the first generation of DNA 
sequencing given its higher accuracy and low radioactivity.  
Throughout the 1980s, scientists performed sequencing manually. The process was labor-
intensive and time consuming and had very low throughput. In the 1990s several advances were 
made that allowed automation of Sanger sequencing, which saw the birth of the first generation of 
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high throughput sequencing. The first such machines were introduced by Applied Biosystems in 
19875. The automation replaced slab gel electrophoresis with capillary electrophoresis and made 
use of fluorescently-labeled ddNTPs, which removed the need to read the gels manually. Now, 
“trace files” with four colored peaks indicating the position of each base could be generated, and the 
sequence could directly read from the file. The first machine, named AB370, was able to read 
500,000 bases a day, on read lengths of 600 bases. The latest model from Applied Biosystems, 
AB3730xl, is able to read 2.88 million bases per day, and reads in lengths of 900 bases. However, 
there has been little advancement with this technology since 1995.  
2.C.II. NEXT GENERATION GENOME SEQUENCING 
 
Even with automation and advancements in sequencing technology, Sanger sequencing 
using capillary electrophoresis still costs $30-$50 million to sequence a complex genome6. Unless 
the cost decreased, it would not be possible to make wide-scale use of genome sequencing in 
treatment of diseases. High-throughput technologies that employed massively parallel sequencing 
were developed to lower the cost of DNA sequencing beyond standard dye-terminator methods.  
The leaders of this second generation of genome sequencers were the 454 Life Sciences 
platform, the Illumina Genome Analyzer, and the ABI SOLiD System. These next generation 
sequencing technologies primarily differ from the Sanger method in aspects of paralleling analyses 
of many small sequences, resulting in higher throughput and reduced cost. Over the past decade7, 
these systems have achieved significant improvements in read length and accuracy and have also 
reduced the cost of genome sequencing while yielding increased throughput. 
 
                                                             
5 Liu, L Yinhu Li, Siliang Li, et al. (2012). Comparison of next-generation sequencing systems. Journal of Biomedicine and 
Biotechnology, 2012, Retrieved from http://www.hindawi.com/journals/bmri/2012/251364/ 
6 Gibson, G., & Muse, S. (2009). A primer of genome science. (3 ed.). Sunderland, Massachusetts, USA: Sinauer Associates, 
Inc. Publishers. 
7 Liu, “Comparison”, 2012 
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2.C.III. THE HUMAN GENOME PROJECT 
 
With the advancements in DNA technology, and a greater understanding and acceptance of 
DNA as the “code of life”, it was natural that interest grew in sequencing human DNA. It was and 
still is anticipated that advanced knowledge of the human genome will provide new areas for 
progress in medicine and biotechnology. The earliest reports even state that “knowledge of the 
human is as necessary to the continuing progress of medicine and other health sciences as 
knowledge of human anatomy has been for the present state of medicine"8. 
In 1990, the US Department of Energy and the National Institutes of Health formally 
founded the Human Genome Project, a $3 billion endeavor projected to be completed in 15 years. 
This was not only a United States sponsored venture; researchers from the United Kingdom, France, 
Australia, Japan, and many other countries joined this substantial undertaking. The Human Genome 
Project employed hierarchical sequencing as it allowed accurate mapping and high quality 
sequences with less than 1 error per 40,000 bases9. This approach also made it possible to share 
the workload across research centers around the world. 
A “rough draft” of the genome was finally published in 2000, made possible by major 
advances in computing technology. Frustrated at the slow pace of the government-sponsored 
genome project, in 2000, a private biotechnology firm, Celera Genomics, launched a parallel human 
genome project and employed the whole-genome shotgun approach. Because of their higher 
throughput and powerful bioinformatics software, they were able to catch up to the Human 
Genome Project by 2001 at only a tenth of the cost – $300 million. However, Celera had 
unrestricted access to the Human Genome Project progress data, which handily served as reference 
                                                             
8 Mendelsohn, M. L., et al. Department of Energy Office of Energy Research Office of Health and Environmental Research, 
Subcommittee on Human Genome of the Health and Environmental Research Advisory Committee (1987). Report on the 
human genome initiative office of health and environmental research: Report on the human genome initiative office of health 
and environmental research. Retrieved from website: 
http://www.ornl.gov/sci/techresources/Human_Genome/project/herac2.shtml 
9 Mardis ER. Next-Generation DNA Sequencing Methods. Annual Review of Genomics and Human Genetics. 2008. 9: 387-
402. 
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for their shotgun sequencing methods. Nevertheless, Celera’s contribution considerably accelerated 
the process and the essentially complete sequence was announced in 2003, two years ahead of 
schedule. By 2006, the sequence of the last chromosome was published.  
2.C.IV. THE ARCHON GENOMICS X PRIZE 
 
Upon the completion of the Human Genome Project, the X Prize Foundation, based in Playa 
Vista, California, announced the Archon Genomics X Prize in October of 2006. The X Prize was a 
joint effort between the X Prize foundation and the J. Craig Venter Science Foundation, and 
promised a $10-million dollar prize to the first team that could sequence 100 genomes within 30 
days or less, with an accuracy of no more than 1 error in every 1,000,000 bases sequenced, and 
costs no more than $1000 per genome10.  
 
Table 1: Archon X Prize Requirements 11 
 
 
 It is no surprise that the requirements of the Archon X Prize, shown above in Table 1 align perfectly 
with the goals of IonSeq. The Archon X Prize is responsible for spurring the development of so 
many next generation sequencing technologies. As of completion date of this report, the Archon X 
Prize remains to be collected.  
 
                                                             
10 Express Scripts. (2012). Archon genomics x prize competition guidelines. In New York, New York: Retrieved from 
http://genomics.xprize.org/sites/genomics.xprize.org/files/docs/AGXP_Competition_Guidelines.pdf 
11 Ibid. 
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2. D. PROJECT GOALS AND REQUIREMENTS 
 
The primary goal of IonSeq is to achieve unprecedented human genome throughput at a low 
cost and to design operations to deliver accurate sequences for its customers. A brief overview of 
the IonSeq Project Charter is presented below in Table 2. IonSeq will focus on bringing the best 
sequencing services to its clients by focusing on areas where optimizations can be made. The 
$1,000 genome is the XPrize target, but IonSeq will set a per sequenced genome price on the basis 
of achieving the best returns for the company’s investors. 
Table 2: Project Charter for IonSeq DNA Sequencing 
 
Project Charter The IonSeq Approach 
Project Name DNA Sequencing: $1,000 Genomes using Ion Torrent Technologies 
Project Champions Dr. John Crocker 
Project Leaders Kendrick Chow, Tushmit Hasan, Gawain Lau, Joan Liu 
Specific Goals Design a $1,000 genome sequencing process in the context of a service-based 
startup company, capable of sequencing 10,000 human genomes per year 
(equivalent 40 genomes/day for 250 days/year) 
 
Project Scope: In-scope: 
 Optimization of DNA sequencing workflow 
 Error analysis modeling 
 Costing and profitability analysis on current technology and 
optimizations 
Out-of-scope: 
 Manufacturing of Ion Torrent technology 
 Biomedical Analysis of Generated Genome Sequences 
 
Deliverables 
 
 Business opportunity assessment  
 Technical feasibility assessment 
 Full scale service requirements 
 Financial analysis over four year period 
 
Timeline  Year 1: Proof-of-concept, Series A funding for 10 genomes/day, 
2500 genomes/year 
 Year 2: Start-up service for hospitals/labs/clinics. Series B funding: 
40 genomes/day, 10000 genomes/year  
 Years 3: Expand service across the United States. 
 Year 4: Assume acquisition or liquidation event. 
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2.D.I. IONSEQ REPORT ROADMAP 
 
From the next section forward, this report will outline the technical and business 
foundations of IonSeq. Chapter 3 will discuss the background of IonSeq, from a brief history of the 
base technology to factors and requirements that will be of interest to the company. Chapter 4 will 
explore the pre-sequencing steps, including DNA extraction/library creation, emulsion PCR, and 
enrichment. Chapter 5 will go into detail regarding the chip configuration and explore the time 
scale of the steps within the bead loading and sequencing process. Chapters 6 and 7 will derive 
models of the kinetics of nucleotide insertions and signal generation from ISFET sensors, which are 
both important parts of sequencing. Chapter 8 will cover topics involving the reconstruction of the 
genome, including dephasing, base calling, and alignment. Chapter 9 will explore various 
optimization options, including ISFET material selection and other sequencing parameters. Chapter 
10 will describe the market within which IonSeq intends to operate. Chapter 11 will outline how 
IonSeq intends to execute this venture, from establishing an execution timeline to detailing the 
company’s operations. Finally, Chapter 12 will present a comprehensive financial analysis of this 
venture, which will show the strong potential for IonSeq’s success. 
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3. COMPANY BACKGROUND: CREATION OF IONSEQ 
IonSeq is the newest evolution of Ion Torrent. Building on top of the sequencing technology 
of the past generation, IonSeq seeks to access a growing market by providing a full genomic 
sequencing service, thereby simplifying the DNA sequencing process, and increasing the access of 
Ion Torrent’s technology. A major road block in sequencing technology has been the complicated 
work flows12. However, IonSeq will take advantage of the emergence of the desktop sequencing 
market and the new level of ease it has allowed in genomic sequencing. In this chapter, an overview 
of Ion Torrent technologies will be covered and customer and technical requirements will be briefly 
discussed. 
3.A. ION TORRENT 
 
Ion Torrent was founded by Jonathan Rothberg in 2007, in Guilford, CT. Rothberg, who in 
1999 had founded 454 Life Sciences, was no stranger to next generation sequencing. In 2010, Ion 
Torrent was acquired by San Francisco-based Life Technologies.  
                                                             
12 Mulhern, J. (2013, February 18). Ion torrent edges illumina in sales battle of benchtop sequencers, says macquarie 
report. Bio-IT WOrld, Retrieved from http://www.bio-itworld.com/news/02/18/13/Ion-Torrent-edges-Illumina-sales-
benchtop-sequencers-Macquarie.html 
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3.A.I. OVERVIEW OF ION TORRENT TECHNOLOGY 
 
All of Ion Torrent technologies are based on semiconductor sequencing. During the 
polymerization of DNA, hydrogen ions are released, and a change in pH is induced. The Ion Torrent 
system consists of a series of wells, each containing a bead covered with template DNA strands, 
located on a small chip, which is placed in Ion Torrent’s sequencer machine for sequencing.  A 
single nucleotide is introduced to the wells, and if the dNTP is complementary to the leading 
template nucleotide, it is incorporated onto the strand. The remaining unreacted nucleotides are 
washed out of the well, and the next nucleotide flow is loaded. These nucleotide insertions release 
protons, or H+, which trigger an Ion-Sensitive Field Effect Transistor (ISFET). The ISFET is located 
upon a complementary metal-oxide-semiconductor (CMOS), which is able to convert the genetic 
information to digital information. 
The sequencing chemistry is a flow-based chemistry originally introduced in the 454 
sequencing platform. The DNA fragments on the bead are rendered single stranded and primed, 
loaded with polymerase, and sequenced. Each well is monitored for insertion events. If there is an 
insertion, the release of protons from all the strands on the bead creates a positive voltage near the 
gate region of a transistor, which results in a change in the current flowing through the transistor. 
This is the fundamental detection process, which may in turn be converted into a voltage signal by 
collecting the associated current. 
Ion Torrent released their first system, the Ion Personal Genome Machine (PGM), in 
December of 2010. This is the least expensive next generation sequencer on the market, with a list 
price of approximately $50,000. In addition, runs cost between $300 and $750. However, the PGM 
is targeted towards smaller genomes and are unable to handle a full human genome.  
Ion Torrent has introduced three chips for the PGM—the 314, 316, and 318—each with 
greater number of wells and output. The latest, PGM 318, is capable of completing a 100-base read 
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in about eight hours.  Ion Torrent also prepares software that streamlines data analysis and 
preparation kits that accompany the system. The expected output is anticipated to have an accuracy 
of over 99% after alignment. 
In September 2012, Ion Torrent introduced the Ion Proton System which allows for larger 
chips with higher densities needed for exome and whole genome scale sequencing. The Ion Proton 
is substantially more expensive at $149,000 but is capable of generating much larger outputs. The 
first chip, the Proton I is said to be able to give 30x coverage for 2 human exomes, which translates 
to about 60 million bases.13  The Ion Proton System’s next chip, the Proton II is promoted to be 
capable of generating 30x coverage for an entire human genome, or 3 billion bases.  
3.A.II. ION TECHNOLOGY VS. EVERYTHING ELSE 
 
Ion Torrent technology is unique in that no modified nucleotides or optics are used. This 
comes into play especially when considering accuracy. Ion Torrent’s massively parallel technology 
also oversamples the DNA sequence, up to 30x coverage, in independent sequencing reactions to 
allow for high consensus accuracy. In optical DNA sequencing, the basis for other next generation 
technologies, nucleotides are modified with a fluorescent signature which can be captured under 
fluorescence illumination.  However, the modified nucleotides must have their fluorescent 
signatures removed before the addition of a new base, which is sometimes performed incorrectly, 
leading to inaccurate reads. In addition, there are special cases where a series of the same base 
occurs in a row, such as AAA or TTTT. These are known as homopolymers. With the introduction of 
the correct nucleotide, the entire homopolymer chain is incorporated at once, instead of one at a 
time. In optical systems, it is difficult to quantify the increase in intensity of light from 
homopolymer insertions. In the semiconductor system, the measured pH difference and the 
resulting voltage difference can be more reliably related to the length of the homopolymer. 
                                                             
13 Ng, S. B., Turner, E. H., & et al, (2009). Targeted capture and massively parallel sequencing of 12 human 
exomes. Nature, 461, 272-276. doi: 10.1038/nature08250 
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Ion Torrent technology is also superior in terms of speed and scalability. Due to the number 
of reactions involved in traditional sequencing technologies, there is a considerable delay between 
bases. However, Ion Torrent’s system of flow chemistry is limited only by the kinetics of nucleotide 
insertions and ISFET sensor behavior.  
3.A.III. CUSTOMER NEEDS ANALYSIS 
 
Customers require accurate sequencing – 10 errors per million bases or a Phred rating of 
Q50. A full definition of the Phred scale and derivation of error rates are covered in Section 8.D. 
They will not require full analysis of sequenced genomes, but merely the raw data generated from 
sequencing runs. Clients will not require long base reads, and the company will not be tailoring to 
customers for de novo sequencing, but for human genome sequences, where there are sequenced 
human genomes available for comparison and genome reassembly. Furthermore, customers will 
seek a price per sequenced genome under $5,000, preferring a price tag that approaches $1,000 as 
outlined by the Archon X Prize.  
3.A.IV. TECHNICAL REQUIREMENTS 
 
To achieve these specifications, the important parameters IonSeq plans to address include 
polymerase selection, nucleotide incorporation rate, well size, well configuration and density, 
diffusion of protons/nucleotides, and ISFET design. These parameters will be designed to achieve 
accurate sequencing and greater throughput by reducing run times. The following sections will 
explore these parameters in detail.  
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4. PRE-SEQUENCING 
The IonSeq workflow begins with the collection of DNA samples from its clients and moves 
through all the functions necessary to yield a full sequenced, reconstructed human genome, in an 
easy to access file format for the clients’ use. Pre-sequencing makes up an important part among 
the other major elements in the technical workflow, illustrated in Figure 2.  This chapter will 
explore the DNA extraction/library creation, emulsion PCR, and enrichment steps.  
 
Figure 2:  IonSeq workflow. IonSeq will provide clients with an easy way to retrieve raw human DNA 
genome sequence from a DNA sample.  
 
4.A. PRE-SEQUENCING PREPARATIONS 
 
Before the DNA is sequenced, it must be properly shipped to our laboratory facility and 
processed. The process for pre-sequencing, which consists of steps crucial to the success of the 
sequencing run, is thoroughly outlined below. 
DNA 
Extraction, 
Library 
Creation 
Emulsion 
PCR 
Enrichment 
Sequencing 
run 
Base Calling 
and 
Alignment 
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4.A.I. DNA COLLECTION 
 
Upon requesting IonSeq’s services, customers will be mailed a DNA Collection kit that they 
can use to mail back a DNA sample of the genome to be sequenced. IonSeq is exploring a variety of 
DNA Self-Collection Kits, many of which are available and compatible for use with Ion Torrent 
technology. Customers have the option of buying their own DNA extraction kits, or using their own 
DNA extraction techniques, but IonSeq is no longer able to guarantee a high level of accuracy.  
Currenlty, IonSeq’s suggested kit is Oragene’s DNA Self-Collection Kits, which require about 2 mL of 
saliva from the donor14. Other DNA extraction kits that customers may choose to use are Norgen 
Buccal DNA Collection Kit and Isohelix DNA Buccal Swabs. The DNA sample will be mailed back to 
IonSeq in a shipping container that was provided along with the DNA collection kit.  Upon receiving 
the sample, the DNA must be purified and incubated overnight at 50°C before extraction15. 
4.A.II. DNA EXTRACTION  
 
DNA extraction will be carried out as an automated process using the Magtration® System 
12GC instrument manufactured by PSS Bio Instruments. This process will be completed in IonSeq’s 
laboratory. The device is a bench top unit, and uses paramagnetic-particle technology to purify DNA 
from the Oragene solution and can purify up to 12 Oragene samples in 30 minutes, using an elution 
volume of 200 µL16.  In a test study done by PSS Bio Instruments, which manufactures the 
Magtration® Systems, the following scattergram of DNA yields was generated, and is shown in 
Figure 3 below17.  From the 200 µL sample, the median yield of usable DNA is 3.8 µg, sufficient for 
the rest of the preparation steps. 
                                                             
14 Lem, C. S. (2009). Magtration System 12GC: Application data - DNA from Saliva. PSS Bio Instruments technical bulletin 
(101305), 2 
15 Ibid. 
16 Lem (2009). Magtration 
17 Lem (2009), Magtration 
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Figure 3: Scattergram of DNA yields from 200 μL of Oragene/saliva sample. The horizontal line 
represents the median yield of 3.8 μg18. 
 
4.A.III. DNA FRAGMENT LIBRARY PREPARATION 
 
This step is also carried out in the IonSeq laboratory and involves the most “wet-lab” work. 
First, the DNA is fragmented to appropriately sized, blunt-ended DNA fragments. The fragment DNA 
is ligated to Ion-compatible adapters, followed by nick repair to complete the linkage between 
adapters and DNA inserts. For barcoded libraries, Ion Xpress™ Barcode Adapters are available. 
 
4.A.III.1) DNA FRAGMENTATION  
 
The DNA has to be broken down into short fragments that can be easily sequenced. 
Fragmentation is a random process, hence there is considerable overlap between many of the 
fragments as shown Figure 4 below.  
 
Figure 4: DNA fragmentation is necessary to allow for easier handling of long genomes . This results 
in overlap that increases sequencing coverage and improv es sequencing accuracy. 
                                                             
18 Lem (2009), Magtration 
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The DNA is fragmented using a BioRuptor® UCD-600 NGS Sonication System. The device 
accepts input amounts of 100 ng or 1 μg of genomic DNA and fragments the DNA into 100, 200 or 
300 base-read fragments. Table 3 shows the library sizes that must be aimed for in order to achieve 
the desired target read lengths. The recommended read length for the fragment libraries is 200 bp, 
as will be discussed in detail later in the Dephasing Model section in Chapter 8.A. 
 
Table 3: Library sizes that must be aimed for in order to achieve the desired target read lengths 19 
 
 
 
The fragmentation profile, the distribution of fragment sizes, can be assessed using a Bioanalyzer® 
instrument. The samples then must be further prepared using manual procedures and various kits.  
 
4.A.III.2) END REPAIR 
 
During fragmentation, the shearing process does not make clean cuts and often the ends of 
the fragments are damaged. The 5’ and 3’ ends may contain phosphate or hydroxyl overhangs that 
will block the ends and interfere with the amplification and sequencing steps downstream. Hence, 
the ends of the library fragments must be repaired. This is performed hands-on using the end 
repair buffers and end repair enzymes provided in the Ion Plus Fragment Kit.  
 
4.A.III.3) ADAPTER LIGATION, NICK REPAIR, AND BARCODING 
 
After the ends are repaired, adapters must be ligated on either of the fragments such that 
they can be attached to beads for clonal amplification, which is discussed in section 4.A.iv. The 
adapters are short segments of DNA of known sequences. Two different adapters are used, and one 
of the adapters is usually modified with a bioton on the 5’ end. The biotin attaches to the 
                                                             
19 Life Technologies. (2012). Ion xpress plus gdna fragment library preparation. In Life Technologies. 
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streptavidin-coated beads on which the fragments will be clonally amplified.  IonSeq will use the 
Ion Plus Fragment Library Kit, which contains standard A and P1 adapters. It also contains DNA 
ligase and nick repair polymerases that are necessary to prepare a good adapter-ligated and nick-
translated fragment library. 
During the adapter ligation step, the option exists to use barcoded adapters instead of the 
standard A adapter.  The Ion Xpress™ Barcode Adapters Kit can be used to create barcoded 
libraries. The barcoded adapters contain a special sequence of DNA, typically 40 bases long, that 
will serve to identify the fragment as belonging to a particular genome. This becomes useful if more 
than one genome is sequenced on a single chip, which can significantly increase throughput.  
 
4.A.III.4) DNA PURIFICATION  
 
The Agencourt® AMPure® XP Kit can be used to purify the fragment libraries20. This step is 
necessary because not all fragments get attached to adapters during the previous step, and not all 
fragments get attached to different adapters. Removal of these faulty fragments will help the 
execution of the next steps of the pre-sequencing process. 
 
4.A.III.5) SIZE SELECTION AND LIBRARY QUANTITATION 
 
The DNA fragments can now be size-selected using the Pippin Prep™ instrument available 
from Life Technologies. This gives a tighter size distribution than gel selection and results in a more 
consistent library size. The library is then quantified using quantitative PCR (qPCR) and the Ion 
Library Quantitation Kit. It may be necessary to amplify the library in order to ensure that sufficient 
template preparation reactions can take place on the beads. Appendix A describes how to 
determine if amplification is required. The final step before template preparation is qualifying and 
                                                             
20 Life Technologies, Ion XpressTM Plus 
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pooling the libraries using qPCR and Bioanalyzer® quantitation21. The details of these steps are 
also listed in Appendix B.  
 
4.A.IV. TEMPLATE PREPARATION USING EMULSION PCR (EMPCR) 
 
The next step is to clone the fragments. In emPCR, DNA fragments are amplified to form a 
clonal population on beads. The fragments are denatured to form single strands. The strands and 
beads are mixed in a water-in-oil emulsion such that microreactors are formed in the emulsion 
each containing one strand and one bead, which then anneal. Reagents required for PCR may now 
be added and each strand is clonally amplified to form hundreds of thousands of copies on the 
beads. Figure 5 shows a representation of the emPCR process. 
 
Figure 5: Clonal Amplification of DNA fragments 22 
 
4.A.IV.1) CLONAL AMPLIFICATION AND SAMPLE RECOVERY 
 
This template preparation step can be carried out using the Ion OneTouch™ 2 System which 
integrates multiple manual template preparation steps (loading, clonal amplification and sample 
recovery) into a single system and also enables parallel processing of multiple samples per day 
                                                             
21 Life Technologies, Ion XpressTM  
22 Life Sequencing. (Producer). (2008). empcr to ssdna library. [Print Graphic]. Retrieved from 
http://www.lifesequencing.com/pages/protocolo-de-secuenciacion?locale=en 
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through a modular design23. Before the sample is loaded into the system, the library has to be 
diluted using the appropriated template dilution factor (to give a concentration of ~26 pM). The 
clonal amplification takes place on Ion OneTouch™ 200 Ion Sphere™ Particles. The system recovers 
and enriches the template positive particles and yields about 10-30% of usable beads for 
sequencing.24 Details of calculating the template dilution factor is included in Appendix C. 
4.B. PRE-SEQUENCING  RESULTS 
 
At this juncture, template beads have been produced, with the fragments clonally amplified 
over the entire surface of the bead, numbering into the hundreds of thousands. Figure 6 is another 
representation that shows the bead and clonally amplified strands as well as a brief illustration of 
the complementary sequence to the template strands. This model will be revisited in Chapter 6 
when kinetics of nucleotide insertion will be covered. 
 
Figure 6: This bead has template strands clonally amplified on its surface. In reality, over hundreds 
of thousands of strands would be present.  
                                                             
23 "Ion OneTouch™ 2 System." Life Technologies, n.d. Web. 
<https://products.invitrogen.com/ivgn/product/4474779?ICID=search-product>. 
24 Ion Torrent User Guide. Ion OneTouch™ System. 2012. Publication Part Number 4472430 Rev. E 
LifeTechnologiesCorp YouTube Channel. Watch Ion OneTouch™ technology in action. 
http://www.youtube.com/watch?v=fxCY_f0QaZQ 
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5. CHIP CONFIGURATION, WORKFLOW, AND 
THROUGHPUT 
The sequencing chips are the center of the entire IonSeq sequencing process and the 
foundation of the Ion Torrent technology. On these chips, all of the sequencing of the genome is 
performed.  The DNA template beads are loaded in wells on the chips, nucleotides are flowed 
through the chips, and the ISFET sensors are fabricated in the chips. Understanding overall chip 
configuration will help build ideas of the possible ways to increase throughput via structural 
changes. Furthermore, a key parameter, well diameter, will prove important in proton diffusion and 
signal generation modeling. 
5.A. MANUFACTURING NODE, DIE SIZE, AND OTHER CHIP SPECIFICATIONS 
 
Ion Torrent sequencing chips have evolved since the organization’s inception, changing chip 
sizes, semiconductor manufacturing node, well diameters, and well pitch.  The chip size is reported 
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by its length and width, typically in millimeters.  The semiconductor node is a standard 
manufacturing metric; it represents one half of the shortest distance between identical features 
that can be fabricated. For instance, the 350 nm node indicates that 700 nm is the minimum 
distance between features on a chip; the 110 nm node dictates a minimum distance of 220 nm. Well 
diameter is typically in microns and is one of the key parameters of the sequencing chip. Each 
individual well holds the template bead where the sequencing process occurs.  Well pitch is defined 
as the distance between the centers of neighboring wells.  Table 4 outlines the progress of these 
chips up to the Proton I, which is manufactured using 110 nm node technologies. The previous 
three, the 314, 316, and 318 models, were manufactured using 350 nm standards.25  
 
Table 4: History and Specification of Past Ion Torrent Sequencing Chips2627 
 
Chip Sensor 
Count (106) 
Die Size 
(mm x mm) 
Well 
Diameter (µm) 
Well 
Pitch (µm)  
 
314 
 
 
 
1.2 10.6 x 11.0 3.0 5.1 
316 
 
 
 
6.3 16.9 x 17.1 3.0 5.1 
318 
 
 
 
11.3 16.9 x 17.1 3.0 4.1 
Proton I 165 23.7 x 20.0 1.25 1.68 
 
To understand the limits the manufacturing node imposes upon chip fabrication, the distance edge 
to edge between two wells on a Proton I chip—the difference between the well pitch and well 
diameter—is 0.43 µm, above the 220 nm limit for the 110 nm node. Theoretically, the Proton I 
                                                             
25 Merriman, B., Ion Torrent R&D Team, B., & Rothberg, J. (2012). Progress in ion torrent semiconductor chip based 
sequencing. Electrophoresis, 33, 3397-3417. 
26 Ibid. 
27 Rothberg, Jonathan M, et al. "An Integrated Semiconductor Device Enabling Non-optical Genome Sequencing." Nature 
475 (2011): 348-52. Print. 
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would be limited to a well pitch of 1.47 µm with a well diameter of 1.25 µm. Figure 7 illustrates the 
geometry explained above. 
 
 
 
 
Figure 7: The dotted line indicates the node  while the solid line shows the diameter and pitch. The 
configuration on the right is at the limit of the 110 nm node.  
 
5.B. REVERSE ENGINEERING PROTON II SPECIFICATIONS 
 
The Proton II chip has been touted as the first chip to sequence a full human genome; 
however, it will not be released until Quarter 3 of 2013. Preliminary Ion Torrent specifications state 
660 million wells, using the same 110 nm node on the same chip size of 20 mm x 23.7 mm, without 
providing any information on well size or configuration28. Therefore, using this known information, 
IonSeq can reverse engineer a potential configuration for the Proton II chip. 
As the first step, the potential well arrangements are considered below for the Proton I chip; 
the results of this sizing experiment will help confirm the method for reverse engineering the 
Proton II chip. Two configurations are considered below in  
Figure 8: a square pattern or a hexagonally-packed pattern, as ascertained from the SEM 
image of the Proton I chip in Table 4. 
                                                             
28 Rothberg, Jonathan M, et al. "An Integrated Semiconductor Device Enabling Non-optical Genome Sequencing." Nature 
475 (2011): 348-52. Print. 
1.25 μm 
1.68 μm 
0.43 μm 
1.47 μm 
0.22 μm 
1.25 μm 
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Figure 8: Two different well arrangements on the chip will yield different well densities and lead to 
different overall number of wells on a chip.  
The well-to-well pitch is shown by the solid line, and the dotted line indicates the well diameter. 
Equation 1and Equation 2 are derived well number density expressions for the square packing and 
the hexagonal packing, respectively. 
Equation 1 
                        [
     
   
]  
 
(     ) 
 
 
Equation 2 
                           
 
  
 
        
√       (
     
 )
 
 
 
For the Proton I, Ion Torrent specifications indicate 165 million wells are fabricated on a 
chip of 20 mm x 23.7 mm dimensions. To reproduce this value, the number of wells was determined 
by calculating the density of wells on a square micron basis and multiplying by the area of the chip 
to yield number of wells.   
Table 5: Well Density and Number Results for 1.25 µm Diameter and 1.68 µm Pitch  
 
Proton I Chip Area (106 µm2) Well Number Density (µm-2) Number of Wells (106) 
Square-packed 474 0.354 168 
Hexagonal-packed 474 0.409 194 
 
Table 5 outlines the results of from the rest of these calculations. The hexagonal-packed 
arrangement is too dense to yield the 165 million well specification for the Proton I. However, the 
square-packed configuration yields 168 million wells, correlating very well to the specification. The 
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square-packing, in the case of the Proton I, is the most likely configuration. Furthermore, the well 
density method is validated and can be applied to reverse engineering the Proton II chip. 
For the Proton II, the four-fold increase in well number, from 165 to 660 million wells, 
suggests significant reworking of well geometry.  Several possibilities were considered. First, the 
well diameter was considered to not have changed from 1.25 µm.  In this situation, neither the 
square packed nor the hexagonal-packed configurations are sufficiently dense to permit the 660 
million wells as shown in Table 6 as the pitch is limited by the 110 nm manufacturing node. 
Table 6: Well Density and Number Results for Different Diameters and Pitches 
 
Proton II Chip Area (106 µm2) Well Number Density (µm-2) Number of Wells (106) 
1.25 µm diameter, 1.47 µm pitch 
Square-packed 474 0.463 219 
Hexagonal-packed 474 0.564 267 
0.70 µm diameter, 0.92 µm pitch 
Square-packed 474 1.206 572 
Hexagonal-packed 474 1.392 660 
0.63 µm diameter, 0.85 µm pitch 
Square-packed 474 1.392 660 
Hexagonal-packed 474 1.608 762 
 
Alternatively, setting the pitch size to its minimum limit, as defined by the 110 nm node, it was 
found that the well diameter must be 0.70 µm with a well-to-well pitch of 0.92 µm to yield 660 
million wells in the hexagonal packed organization. For the square-packed arrangement, the 
diameter must be 0.63 µm with a pitch of 0.85 µm. It was decided to adopt the hexagonal packing 
for the Proton II chip due to the proton diffusion considerations with the larger well size as covered 
in Chapter 6. The kinetics and signal generation models will use 0.70 µm as the well diameter. 
To give a sense of the scalability in this node, 1 billion wells requires 0.52 µm diameter 
wells with 0.74 µm pitch. For 1.5 billion wells, 0.39 µm diameter wells and 0.61 µm pitch are 
required.  It is important to understand, however, that while increasing the number of wells by 
shrinking well size and pitch are certainly key design parameters, they have important 
consequences for the emulsion PCR process, sensitive to bead size, and well-to-well crosstalk, an 
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important signal-to-noise consideration when shrinking feature sizes. Switching to a smaller node 
would allow larger wells with smaller pitch lengths. An increase in die size, as well as the change in 
the manufacturing standard, all influence chip cost. For this design, IonSeq will keep the same chip 
size as the Proton I, in order to maintain compatibility with the Proton machines manufactured by 
Ion Torrent. However, for potential solutions, it will consider the use of the 110 nm and 32 nm 
nodes. Pricing, though, will be based off the 110 nm node manufacturing standard.  
5.C. CHIP FLOW PROCESSES 
 
The overall series of steps on the chip are illustrated in Figure 9. This section will describe 
each of the steps and introduce more concepts to be covered later in this report. 
 
Figure 9: Workflow on a Proton Chip 
5.C.I. NUCLEOTIDE FLOW IN 
 
Ion Torrent patents state that the nucleotide fluid flow has “a fluid flow Reynolds number of 
at most 2000, 1000, 200, 100, 50, or 20.”29 To understand the work sequence on a chip, the flows of 
solutions need to be modeled. Flow of nucleotides onto chip surface is indicated as laminar; a 4 
mL/sec flow rate is one of the volumetric flow rates suggested, but this can be taken to be a design 
parameter30. Given the characteristics of the well, and a 1-mm guess for the gap height between the 
cover of the chip and chip surface, the results for the Reynolds number and amount of time it takes 
to fill the open volume of the chip are outlined in Table 7. These time scales confirm the claims 
                                                             
29 Bustillo, J., W. Hinz, K.L. Johnson, J. Leamon, J.M. Rothberg, and J. Schultz. Sequencing nucleic acid comprises disposing 
template nucleic acids into reaction chambers in contact with or capacitively coupled to chemical-sensitive field effect 
transistor. Ion Torrent Systems, assignee. Patent GB2561128-A; GB2461128-B. 15 Dec. 2010. Print. 
30 Ibid. 
Nucleotide Flow In 
Nucleotide Insertion 
and Signal Generation 
Signal Attenuation 
Buffer Flow (during 
Signal Attenuation) 
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made in the patent of the nucleotide flow nearly instantaneously filling the wells on the chip31. 
However, it would be preferable to minimize the amount of time it takes for this to occur. By taking 
about 2.5 times the nucleotide injection rate to 10 mL/s, coverage time shrinks by a factor of 2.5, as 
shown in the tabulated times in the right of Table 7, while maintaining a reasonable, laminar 
Reynolds number. 
Table 7: Flow times to fill chip volume 
 
Volume of Chip (mL) Volumetric Flow In (mL/sec) Reynolds Number Time to Fill (sec) 
0.474 4 183 0.12 
0.474 10 458 0.0474 
 
Next, the flow of nucleotides into individual wells needs to be considered. There are two 
possible means for nucleotides to enter these wells; via diffusion or by a CSTR-like model.  Using 
the diffusivity constant for nucleotides in neutral water, the mean time for nucleotides to diffuse 
into the well is found by the square of the characteristic length divided by the diffusivity constant. 
For the CSTR-model, the volumetric flow rate into the well with zero concentration of nucleotides is 
determined in addition to the residence time, τ. The flow is modeled as a parabolic flow, the velocity 
is taken at a characteristic height equal to the well diameter, and the volumetric flow rate into an 
well, given its opening area, is found.  The residence time is the open volume of a well divided by 
the volumetric flow rate into the well. Using a simple exponential expression, 
              (    
    
 ), with the results shown in Table 8, it was determined that the time to 
reach the concentration of nucleotide flow is greater than the diffusion time. Therefore, it is 
assumed that diffusion dominates, and the nucleotides quickly fill each well within milliseconds. 
Table 8: Times for wells to reach nucleotide flow concentration  
 
Method Diffusivity 
Constant (m2/s) 
Characteristic 
Length (µm) 
Volumetric Flow Rate into 
Well (mL/s) 
Residence Time 
(sec) 
Time to Reach Flow 
Concentration (sec) 
Diffusion 3.68 x 10-10 0.70 --- --- 0.0011 
CSTR --- --- 5.385 x 10-11 0.0033 0.020 
                                                             
31 Bustillo, J., W. 
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5.C.II. NUCLEOTIDE INSERTION, SIGNAL GENERATION AND ATTENUATION 
 
The nucleotide insertions are next in the workflow.  This is the time it takes for complete 
reactions of nucleotides at each position in the strands. It will be shown later in the Kinetics section, 
Chapter 6, that this is on the scale of tens of milliseconds or less (~0.02 seconds). During this 
reaction time, the signal is being generated, which takes around tenths of a second (~0.1 sec). After 
all the nucleotide insertions are completed, the ISFET sensors require settling times. Given the 
parameters stated in the literature and the material used (silicon nitride), as covered in the ISFET 
section, Chapter 7, of this report, such a settling time can be about 6 seconds. 
5.C.III. BUFFER FLOW 
 
Although the signal takes significant time to attenuate, the nucleotides should be washed 
out with a buffer solution prior to complete signal attenuation. Leaving the nucleotide solution in 
place for too long may increase the probability of incorrect base insertion; beginning the flow after 
a period of time sufficient to allow complete reaction will allow full removal of any nucleotides 
during the remaining time allocated for signal attenuation. This is an important step in the 
workflow; if any nucleotides are left over from a previous flow cycle, they could insert erroneously 
and lead to faulty sequences. Following the CSTR model, given a mean residence time of the volume 
of the chip divided by the buffer flow rate, 10 mL/s, it would take about 2 seconds to for the buffer 
flow to completely remove all nucleotides. This is much less than the buffer run time of 4.5 seconds 
required if run at the suggested 4 mL/s rate. Running the buffer during the period of signal 
attenuation would be sufficient to ensure no leftover nucleotides. Overall, the time scales for each 
element of a sequencing cycle are outlined in Table 9. 
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Table 9: Overview of Time Scales for Elements in the Chip Workflow  
 
Step Time (sec) 
Flow in ~0.05 
Diffusion into Well ~0.001 
Nucleotide Insertion ~0.02 
Signal Generation ~0.1 
Signal Attenuation ~6 
Removing All Nucleotides from Well ~2 
Overall Sum ~8.17 
 
Therefore, the time for a cycle is about 8 seconds as the signal attenuation part of the 
workflow dominates this time figure.  The number of flows should be greater than the base length 
of the strands multiplied by the four possible bases. As a sufficient buffer, the number of cycles can 
be doubled to ensure complete sequencing.  Table 10 shows the sizing calculations at 8 seconds per 
cycle, and includes a barcoding variation, as covered in Section 4.A.iii.3), which would allow 
multiplexing genomes on one run and increase the overall base length and run times. 
 
Table 10: Time for Genome Sequencing for various setups 
Description Per Cycle 
(sec) 
Base 
Length 
Cycles Time (hr) 
Proton II - No Barcode 6 200 1600 3.56 
Proton II - Barcode 6 240 1920 4.27 
 
 
The sequencing times correlate with public Ion Torrent data and marketing pitches. The base 
sequencing in the actual Proton machine takes approximately 4 hours of the 8 hour Proton machine 
run time32. The remaining time outside of sequencing is devoted to base-calling, alignment, and 
genome reconstruction. 
5.D. POTENTIAL CHIP THROUGHPUT 
 
IonSeq’s bottom line will rely upon the overall throughput of genomes at an appropriate 
cost. Back of the envelope calculations can give a realistic idea of the throughput for one sequence 
                                                             
32 Ion Torrent. “The Ion Proton System: Rapid genome-scale benchtop sequencing. Specification Sheet.” 2012. 
<www.lifetechnologies.com/proton>. 
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run on one Proton machine. The key parameters for determining overall throughput are the read 
lengths and the percent of active wells. Read length will refer to the length of the DNA template 
fragments on the spheres, and as a rule of thumb, 90% of total wells on the chip are active. The 
remaining inactive wells are used baseline readings for signal processing. Throughput is defined in 
Equation 3 and the number of human genomes is expressed in Equation 4. The human genome is 
taken to be 3 billion bases in length and coverage is defined as the average number of times a 
nucleotide in a template has been read. Higher coverage leads to greater accuracy in realignment. 
 
Equation 3 
           (  )                   
           
   
 
Equation 4 
                       
           (  )     
                    
 
 
The Proton I chip is insufficient for sequencing a full human genome, as seen below, even 
over varying read lengths at 30x coverage. For the Proton II chip, the four-fold increase in the 
number of wells allows it to handle a human genome. Table 11 lays out the expected throughput for 
different chip layouts. A hypothetical, 1 billion well, “Proton III” chip is the only arrangement of the 
three that can handle more than two full human genomes, given the use of barcoding during the 
sequencing run. 
 
Table 11: Throughput of Different Proton System Chips  
 Wells (106) % Active Read length Throughput (GB) Coverage # Human Genomes 
Proton I 165 0.9 100 14.85 30 0.165 
165 0.9 200 29.7 30 0.33 
165 0.9 300 44.55 30 0.66 
Proton II  660 0.9 100 59.4 30 0.66 
660 0.9 200 118.8 30 1.32 
660 0.9 300 178.2 30 1.98 
“Proton III”  1,000 0.9 100 90 30 1 
1,000 0.9 200 180 30 2 
1,000 0.9 300 270 30 3 
 
Areas for significant advancement include shifting to a smaller manufacturing node; this would 
allow for even more wells on the same size chip. For example, at the 32 nm node, 1.5 billion wells, 
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each of diameter 0.54 µm at 0.60 µm pitch, can be achieved on a single chip; at a read length of 200 
bases and 30x coverage, this arrangement can handle 3 full human genomes. 
 
5.E. CONCLUDING THOUGHTS ON CHIP ORGANIZATION AND THROUGHPUT 
 
 After exploring various chip configurations, evaluating each step of the chip workflow, and 
generating back of the envelope throughput calculations, several important findings come to light. 
First, the well diameter of 0.70 µm was determined for the Proton II chip; this value will be used in 
the kinetics and signal generation sections, Chapters 6 and 7. Second, that the bottleneck in the chip 
workflow is the signal attenuation. In Chapter 9, optimization options will consider different sensor 
materials that will work to decrease this attenuation time and decrease overall cycle times.  Third, 
the Proton II is only able to sequence one genome on a chip at a time while a hypothetical Proton III, 
with one billion wells, may be able to handle 2 human genomes on a single chip.  
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6. KINETICS OF NUCLEOTIDE INSERTIONS 
Understanding the behavior of nucleotide (dNTP) incorporation onto the prepared DNA 
strand template is important to modeling the workflow on the Proton chip and designing different 
potential configurations for increased throughput. Building the kinetic model for each base 
incorporation event will prove instrumental in forming the foundation for the signal generation 
covered in the ISFET section. This chapter compares the model results with Ion Torrent published 
literature and allows IonSeq to further solidify the validity of these models. 
6.A. NUCLEOTIDE KINETICS BACKGROUND 
 
The basic mechanism is the nucleophilic attack on the phosphorous of the unbound 
nucleotide, by a hydroxyl group on the nucleotide in the template strand. A phosphodiester bond 
joins the two nucleotides, creating a pyrophosphate leaving group and producing a proton as 
shown in Figure 10. The proton per base incorporated is the measured variable by the 
semiconductor technology in the Proton chip. 
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Figure 10: The mechanism for nucleotide incorporation onto a DNA template strand illustrates the 
production of protons which is key to Ion Torrent technology.  
 
Ion Torrent employs proprietary DNA polymerases, tuned for rapid sequencing with low 
error rates and no proofreading ability33.  IonSeq has been unable to reverse engineer the rate data 
for the polymerases due to the numerous factors involved, which included ISFET sensor dynamics.   
Consequently, relatively fast DNA polymerase data was sought, which provided high fidelity and 
rapid sequencing times in order to maximize accuracy and throughput.  Human mitochondrial DNA 
polymerase fit the desired characteristics and research has yielded comprehensive kinetic data for 
matches (italicized values) and mismatches of then nucleotides as shown in Table 1234. A potential 
alternative would be viral DNA polymerase or similar, such as Phi 29, which are typically much 
more rapid35. However, comprehensive kinetic information was lacking.  The use of human 
mitochondrial DNA polymerase will serve as the basis of the design, but IonSeq will contribute R&D 
resources to developing proprietary polymerase that will give it the competitive advantage. 
The following rate information for human mitochondrial DNA polymerase was collected 
from extensive kinetic work performed at the University of Texas Austin36. The rate constant of 
                                                             
33 Rothberg, Jonathan M, et al. "An Integrated Semiconductor Device Enabling Non-optical Genome 
Sequencing." Nature 475 (2011): 348-52. Print. 
34 Johnson, Allison A., and Kenneth A. Johnson. "Fidelity of Nucleotide Incorporation by Human Mitochondrial 
DNA Polymerase." The Journal of Biological Chemistry 276.41 (2001): 38090-8096. 
35 Esteban, Jose A., Margarita Salas, and Luis Blanco. "Fidelity of Phi29 DNA Polymerase."The Journal of 
Biological Chemistry 268.4 (1993): 2719-726. 
36 Johnson, Allison A., and Kenneth A. Johnson. "Fidelity of Nucleotide Incorporation by Human Mitochondrial DNA 
Polymerase." The Journal of Biological Chemistry 276.41 (2001): 38090-8096. 
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polymerase is given by kpol, and the substrate concentration at half maximum is given by KD. Both of 
these parameters will be used in the standard Michaelis-Menten mechanism for enzymes. 
Table 12 Human mitochondrial DNA rate data 
dNTP : Template Base KD (μm) kpol (s-1) 
A : T 0.8 45 
T : T 57 0.013 
C : T 360 0.038 
G : T 70 1.16 
C : G 0.9 43 
A : G 250 0.042 
T : G 200 0.16 
G : G 150 0.066 
T : A 0.6 25 
C : A 540 0.1 
G : A 500 0.05 
A : A 25 0.0036 
G : C 0.8 37 
A : C 160 0.1 
C : C 140 0.003 
T : C 180 0.012 
 
6.B. NUCLEOTIDE DIFFUSION 
 
The protons that are produced from nucleotide incorporation can follow a few different 
paths the instant after it is produced: diffusing out of the well, remaining in the well, or remaining 
in the well and interacting with the ISFET.  Due to the minuscule volume of each well, which is on 
the order of picoliters, diffusion becomes the predominant effect. The time scale for a proton to 
diffuse out of the well is approximately modeled as the square of the length scale divided by the 
diffusivity of the proton in water as shown in Equation 5. The diffusion of nucleotides is also an 
important consideration, and this mean residence time is given in Equation 6.  Viscosity and pH 
effects on this diffusivity value are other parameters to consider, but in the context of this design 
project, they are assumed to not have an effect due to the relative stability of these values 
throughout the process. For a well size of 0.70 um and the proton diffusivity of water of 9 x 10-9 
m2/s, the mean residence time for a proton is on the order of 10-5 seconds. 
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Equation 5 
                              
  
  
  
Equation 6 
                                 
  
  
  
 
Using the production rate of protons and the impulse behavior – a first order decay process 
– of proton diffusion out of the well, with a characteristic mean residence time outlined above, a 
convolution of the two functions can be performed to create an overall function of proton count in 
the well as a function of time. This will be used as part of the modeling of ISFET signal generation. 
Furthermore, the mean nucleotide residence time can be employed to understand how nucleotides 
can diffuse into the well. The basic convolution process is outlined in Equation 7, where x(t) is the 
number production of the protons from nucleotide incorporation, h(t) is the impulse function of 
proton diffusion out of the well, and y(t) is the number of protons left in the well after diffusion is 
taken into account. These expressions will be outlined in the Kinetics Model section. 
Equation 7 
 
 ( )   ( )  ( )   ∫  ( ) (   )  
 
 
 
 
6.C. KINETICS MODEL 
 
Nucleotide incorporation and generation of protons can be interpreted as a binding model 
of nucleotides to the template that follows pseudo-first order kinetics, as shown in Equation 8. 
Following the binding of the polymerase in the pre-sequencing process, nucleotides attach 
according to Michaelis-Menton kinetics, where the observed rate constant depends upon the 
concentration of nucleotides in Equation 9. The concentration of nucleotides at a given time is 
shown in Equation 10 and the corresponding concentration of protons is illustrated in Equation 11. 
The model will use the rate data for the insertion of nucleotide A to the base T on a template strand. 
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Equation 8 
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Equation 9 
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Equation 10 
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Equation 11  
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In these expressions, the concentrations and KD, the binding constant, are reported in μM 
and the rate constant for polymerization, kpol, and overall rate constant, kobs, are in units of s-1. 
Acknowledging that the observed rate constant has nucleotide concentration dependence, 
the more accurate method would be to integrate as shown in Equation 12 and Equation 13. 
 
Equation 12 
 [    ]
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Equation 13 
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However, it was observed that the observed rate constants do not change significantly 
within the range of nucleotide concentrations expected. As a result, it is assumed that the observed 
rate constant at the initial concentration can be used throughout the kinetic model. 
Using the kinetics model, IonSeq can also address homopolymers, or stretches of DNA that 
have the same base code. For example, if the strand has a 3-base homopolymer sequence of ‘AAA,’ 
the kinetics of nucleotide insertion over that stretch of bases will differ than that for a single ‘A’ 
base or a 2-base homopolymer sequence ‘AA.’  The 1-base case will be considered first. 
6.C.I. N = 1 CASE 
 
For the incorporation of one nucleotide, the n = 1 case, Equation 10 and Equation 11 yield 
the behavior shown in the top and bottom of Figure 11, respectively. 
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Figure 11: (top) For one nucleotide incorporation, the kinetics follow a straightforward, first order 
decay. (bottom) The response of inserted mucleotides, and therefore protons generated, is shown as 
the percent of possible insertion events.  
 
Equation 11, which expresses the resulting proton concentration, can be taken to be the cumulative 
percent of the possible nucleotide insertion events by simply the whole expression by the initial 
nucleotide concentration, [dNTP]0. For example, if there are 100,000 template strands, by a time of 
0.05 seconds, the nucleotides will have inserted into 85% of the total strands. Consequently, 85,000 
protons will have been produced as each nucleotide insertion produces one proton. By a time of 
0.25, all of the strands will have had a nucleotide inserted, and therefore, 100,000 protons will have 
been produced. Substituting Equation 11 into Equation 10, and multiplying by the number of 
strands, yields Equation 14. The (1-e-kt) expression is the percent of strands that have had 
undergone nucleotide insertions.  Figure 13 illustrates the behavior of proton generation for this n 
= 1 case.  
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Equation 14 
 
 ( )                          (         ) 
 
 
Figure 12: Number of protons produced over time for the N = 1 case.  
 
However, this does not yet take into consideration the significant diffusion of protons out of the 
well. The actual quantity of protons that remain in the well is significantly less than shown in Figure 
12. To determine this value, the impulse of proton diffusion out of the well,  
Equation 15, must be considered, where τp is the mean residence time for the proton in water as 
determined in Equation 5. 
 
Equation 15 
 ( )   
 
 
       
 
 
Carrying out the convolution between Equation 14 and  
Equation 15 yields Equation 16, the overall number of protons left in the well.  
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Equation 16 
 ( )            (  
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Figure 13: This proton generation profile over time for n = 1 case shows significantly less protons 
available in the well due to proton diffusion out of the well.  
 
Figure 13 shows that, in reality, only 5 or 6 protons remain (out of the possible 100,000 
protons generated) in the well after accounting for diffusion effects. The sharp drop-off evident in 
the same figure is the due to the fact there is no more proton production once all the possible 
nucleotide insertion events have occurred.  However, due to the sensitivity of the ISFET sensors, as 
explained in Chapter 7, this small number of protons interacting with the sensor surface is 
sufficient for signal generation. 
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6.C.II. N = 2 CASE 
 
To account for homopolymers, the sequencing can be modeled along the lines of residence 
time distribution in series of CSTRs. All the bases in a homopolymer stretch will not react at the 
same time. This can be shown by taking each base position as a CSTR, and the nucleotide 
concentration distribution over time will impact the rate at which each nucleotide incorporates in 
the homopolymer stretch. There is some residence time, the inverse rate constant of base 
incorporation, which serves the residence time in the RTD model. Concentration, over time t, at 
each base position, n, may be described in Equation 17, instead of Equation 10.  
 
Equation 17 
[    ]  [    ]  
       
(     )
   
(   ) 
 
 
For the n = 2 case, a homopolymer sequence of two bases, Equation 17 becomes Equation 
18, which is plotted in green in Figure 14. To determine the overall, cumulative expression, 
Equation 18 needs to be summed with the expression for the n = 1 case, or Equation 10. The 
summed plot, in black, is shown in the top of Figure 14 and expressed in Equation 19. Equation 20 
expresses the concentration of protons produced, simply the difference between the initial 
nucleotide concentration and cumulative nucleotide expression, Equation 19. By dividing Equation 
20 by the initial concentration, the cumulative percent of inserted nucleotides can be derived and 
shown in the bottom of Figure 14. 
 
Equation 18  
[    ]  [    ]  
       (     ) 
Equation 19  
[    ]  [    ]  
        [    ]  
       (     ) 
Equation 20  
[  ]  [    ]   [    ]  
        [    ]  
       (     ) 
 
6. Kinetics of Nucleotide Insertions  Chow, Hasan, Lau, Liu 
 
48 
 
 
Figure 14: (top) For the n=2 homopolymer case, the overall reaction rate , in black, is determined by 
the sum of the blue and green plots.  (bottom) The corresponding cumulative percent of inserted 
nucleotides indicates greater time needed for the n = 2 case  to reach the asymptote, the point where 
all strands have seen nucleotide insertions.  
 
Following the same logic and procedure of n = 1 case, the expression for total protons produced is 
shown in Equation 21, instead of Equation 14. The additional exponential term emerges from the 
CSTR-in-series model and the summation of the concentration expressions as discussed above. 
Because this is the 2-base homopolymer case, the greatest possible number of protons that can be 
produced is double the number of strands.  
 
Equation 21 
 ( )                             (                       ) 
 
Figure 15 compares the production of protons between the n = 1 and n = 2 cases. As expected, the 
ultimate number of protons is doubled for the n = 2 case as there are twice the number of possible 
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nucleotide insertions in the 2-base homopolymer. Also, observing the time of approach to the 
asymptotes, the mean reaction time is doubled for n = 2 case. 
 
Figure 15: Proton production for the n = 1 and n = 2 cases show that the total protons is doubled as 
expected. Furthermore, the mean reaction time for the n = 2 case is twice that of the n = 1 case.  
 
To determine the number of protons left in the well after diffusive effects are considered, it is 
necessary to take the convolution of  
Equation 15, the proton diffusion impulse, with Equation 21, the total proton production 
expression. This results in Equation 22, and this expression is plotted along with a comparison to 
the n = 1 case in Figure 16. 
 
Equation 22 
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      ) (    (    (       ))   )
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Figure 16: Protons left in well after diffusion for the n = 1 and n = 2 cases.  
 
Once again, for the n = 2 case, out of the 200,000 produced protons (100,000 strands for 2-base 
homopolymer), only about 10 to 11 protons remain in the well after diffusion. The sharp drop off 
evident in the figure is attributed to the end of proton production and the diffusion of the remaining 
protons out of the well. 
6.C.III. N = 3 CASE 
 
For the n = 3 case, a homopolymer sequence of three bases, Equation 17 becomes Equation 
23, which is shown in the red plot in Figure 17.  To determine the overall, cumulative expression, 
Equation 23 needs to be summed with the expression for the n = 1 case, or Equation 10, and the n = 
2 case, or Equation 18. The summed plot is shown in the top of Figure 17 in black and in equation 
form in Equation 24. Equation 25 expresses the concentration of protons produced, simply the 
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difference between the initial nucleotide concentration and cumulative nucleotide expression, 
Equation 24. By dividing Equation 25 by the initial concentration, the cumulative percent of 
inserted nucleotides can be derived and is shown in the bottom of Figure 17 for the n = 3 case. 
Equation 23 
[    ]  [    ]  
       
(     )
 
 
 
Equation 24  
[    ]  [    ]  
        [    ]  
       (     )  [    ]  
       
(     )
 
 
 
Equation 25  
[  ]  [    ]   [    ]  
        [    ]  
       (     )   [    ]  
       
(     )
 
 
 
 
Figure 17: For the n=3 homopolymer case, the overall reaction rate, in black, is determined by the 
sum of the blue, green, and red plots, generated from the CSTR-in-series model. (bottom) The 
corresponding cumulative percent of inserted nucleotides indicates greater time needed for the n = 3 
case to reach the asymptote, the point where all strands have seen nucleo tide insertions.  
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Following the same logic and procedure of n = 1 and n = 2 cases, the expression for total protons 
produced is shown in Equation 26, instead of Equation 14 and Equation 21. Once again, there is an 
additional exponential term that emerges from the CSTR-in-series model and the summation of the 
concentration expressions as discussed above. Because this is the 3-base homopolymer case, the 
greatest possible number of protons that can be produced is three times the number of strands.  
 
Equation 26 
 ( )                             (                         
       
(     )
 
 
) 
 
Figure 18 compares the production of protons among the n = 1, n = 2, and n = 3 cases. As expected, 
the ultimate number of protons is tripled for the n = 3 case from the n = 1 case as there are three 
times the number of nucleotides to be inserted for a 3-base homopolymer. Also, observing the time 
of approach to the asymptotes, the mean reaction time is tripled for n = 3 case from the n = 1 case. 
 
Figure 18: Proton production for the n = 1, n = 2, and n = 3 cases show that the total protons is 
tripled as expected for the n = 3 case. Furthermore, the mean reaction time for the n = 3 case is three 
times that of the n = 1 case. 
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To determine the number of protons left in the well afte r diffusive effects are considered, it is 
necessary to take the convolution of  
Equation 15, the proton diffusion impulse, with Equation 26, the total proton production 
expression. This results in Equation 27, and this expression is plotted along with a comparison to 
the n = 1 and n = 2 cases in Figure 19. 
 
Equation 27 
 ( )            (   
         (       (         ) (  (       )    (       (       ))))
 (        )
 )  
 
Figure 19: Protons left in well after diffusion for the n = 1, n = 2, and n =3 cases. 
 
 
For the n = 3 case, out of the 300,000 produced protons (100,000 strands for 3-base homopolymer), 
only about 15 to 16 protons remain in the well after diffusion. The sharp drop off evident in the 
figure is attributed to the end of proton production and the diffusion of the remaining protons out 
of the well. 
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6.D. CONCLUDING THOUGHTS ON THE IMPORTANCE OF KINETICS  
  
Overall, the kinetics of nucleotide insertions is significant for several reasons. To help 
determine the length of time to allow for a nucleotide flow over the chip, the kinetics will show how 
long the reactions take for various lengths of homopolymers. It is essential not to cut short the 
nucleotide flow at the risk of not fully sequencing the strands; furthermore, it is important not to 
keep the nucleotides on the chip longer than necessary as that may increase the probability of 
faulty insertions. From the derivations explained above, a homopolymer of 3 bases will require a 
nucleotide flow for about 0.2 seconds.  Carrying out an extrapolation, it can be estimated that a 
homopolymer of five bases will require 0.3 seconds of nucleotide of flow time. Understanding that 
five percent of the human genome consists of homopolymers of 5 bases or longer, this is an 
important design parameter to consider37.  Also, the consideration of diffusion is crucial considering 
the small length scale of these wells. The convolution calculations performed in this section reveal a 
magnitude of four decrease from the protons produced and the protons that remain in the well to 
be recognized by the ISFET (~100,000 protons to ~10 protons).  Furthermore, the kinetic behavior 
of insertions will serve as a key element in the development of the signals generated from the 
sensors.  
  
                                                             
37 Chan, Eugene Y. "Next-Generation Sequencing Methods: Impact of Sequencing Accuracy on SNP Discovery." DNA 
Medicine Institute. Web. 29 Mar. 2013. 
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7. SIGNAL GENERATION – ISFET TECHNOLOGY 
 In order to convert nucleotide insertions onto the template strands into interpretable data, 
sensors are necessary to measure the protons generated in the wells. These sensors convert this 
information into digital data that can be processed and reconstructed in order to derive the genome 
sequence. This is the area where semiconductor technology merges with genome sequencing to 
form the backbone of high throughput semiconductor-based sequencing. This chapter will cover 
details of the sensors used in IonSeq’s method of sequencing and how the signal generated from 
these sensors can be interpreted as nucleotide insertion events. 
7.A. ISFET BASICS 
 
The fundamental difference that sets Ion Torrent technology apart from other “next 
generation” DNA sequencing competitors is its use of ISFETs, ion-sensitive field effect transistors, to 
measure proton concentrations in each individual well. Upon nucleotide incorporation onto the 
template strand, the generated protons are sensed by the ISFETs underlying each well. Through 
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this process, IonSeq can quickly generate sequences and take advantage of the rapid scalability of 
semiconductor manufacturing. 
 
Figure 20 a. (left) The patent drawing shows the inner construction of the ISFET sensor38.  b. (right) This cartoon 
illustrates the template bead and the generated protons on the surface of the ISFET39. 
 
Each ISFET is structured similarly to typical metal oxide semiconductor field effect 
transistors. The sensor consists of p-type regions, which contain sources and drains (56 and 58), 
and n-type well (54), as shown in Figure 20a. Current flows between the source and drain and is 
modulated by the activity upon the passivation layer, which is an ion-sensitive membrane, exposed 
to the analyte solution above it. Material selection in this passivation layer influences the sensor’s 
sensitivity to specific ions. Using silicon nitride, silicon oxynitride, and other aluminum, silicon, or 
tantalum oxides enable the ISFET to sense protons generated from nucleotide insertions on the 
strands on the template bead, as illustrated in Figure 20b40.  
                                                             
38 Rothberg, Jonathan M., James M. Bustillo, Mark J. Milgrew, Jonathan C. Schultz, David Marran, Todd M. Rearick, and Kim 
L. Johnson. Methods and Apparatus for Measuring Analytes. Life Technologies Corporation, assignee. Patent 8263336. 11 
Sept. 2012. Print. 
39 Merriman, B., Ion Torrent R&D Team, B., & Rothberg, J. (2012). Progress in ion torrent semiconductor chip based 
sequencing. Electrophoresis, 33, 3397-3417. 
40 Rothberg, Jonathan M., James M. Bustillo, Mark J. Milgrew, Jonathan C. Schultz, David Marran, Todd M. Rearick, and Kim 
L. Johnson. Methods and Apparatus for Measuring Analytes. Life Technologies Corporation, assignee. Patent 8263336. 11 
Sept. 2012. Print. 
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At the interface between the solution and this layer, an electric potential difference (Ψ0), in units of 
mV, develops as a direct consequence of the reactions that occur between protons and the surface 
groups. This potential difference is a function of solution concentration. For silicon nitride based 
ISFETs, the important surface reactions include a series of protonation and deprotonation reactions 
as shown by  
Equation 28, Equation 29, and Equation 3041: 
 
Equation 28 
                 
[    ][  ]
[    ]
 
    
    
    
Equation 29 
             
      
[    ][  ]
[     
 ]
 
    
    
    
Equation 30 
       
       
      
[     ][ 
 ]
[     
 ]
 
    
    
    
 
The kinetics of each of these chemical reactions should be considered for a comprehensive 
model.  However, for the purposes of this design, it is assumed that proton donation reactions 
dominate the transient response of the signal over the others and that pH changes are small, 
implying near constant surface potentials and allowing for the linearization of surface reaction 
equations. Our model shows a pH drop of ~0.4 per base incorporation, which is relatively 
consistent with Ion Torrent literature stating ~ 0.2 pH drop. 42 This validates this key assumption. 
7.B. DOUBLE LAYER CAPACITANCE 
 
A “double-layer capacitance” forms as a result of the physical limitations of the ions 
approaching the ISFET surface; these particles cannot come any closer than their ionic radius as 
illustrated in Figure 21. Charge densities, in units of coulombs, on either side of this double layer — 
                                                             
41 Woias, P., L. Meixner, D. Amandi, and M. Schönberger. "Modelling the Short-time Response of ISFET Sensors." Sensors 
and Actuators B: Chemical 24.1-3 (1995): 211-17. Print. 
42 Merriman, B., Ion Torrent R&D Team, B., & Rothberg, J. (2012). Progress in ion torrent semiconductor chip based 
sequencing. Electrophoresis, 33, 3397-3417. 
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in the solution, σdl, and on the surface, σ0 — are related by the double layer capacitance, Cdl, in units 
of farads, and the surface potential, Ψ0.  A change in the charge density on the solution side of the 
double layer is not immediately recognized by the charge density on the surface side; by Equation 
31 below, this change forces surface potential to change.  
Equation 31 
                
 
 
Figure 21: Due to the ions’ shape, they can come no closer than their ionic radius, forming a double layer 
capacitance, identified as the Stern Layer, above the ISFET surface.43 
 
This double layer capacitance is important in generating the signal needed for recording 
each base insertion event. Surface potential, Ψ0, is calculated by considering the sensitivity of that 
potential to pH changes in Equation 32 and Equation 33. 
Equation 32 
   (            )  
   
   
 
Equation 33 
   
   
      
   
 
  
 
In these expressions, α is a dimensionless sensitivity parameter—a typical  value for silicon 
nitride is 0.93—kB is the Boltzmann constant, q is the elementary charge, and T is temperature. 
pHpzc is the pH at point of zero charge, a material-dependent parameter, which is the pH at which 
                                                             
43 "Electrokinetics." MIT Laboratory for Energy and Microsystems Innovation, n.d. Web. 
<http://web.mit.edu/lemi/rsc_electrokinetics.html>. 
7. Signal Generation – ISFET Technology  Chow, Hasan, Lau, Liu 
 
59 
 
there is no surface potential on the ISFET surface. The sequencing will be run at pH of 8, which will 
play a key role in optimizing attenuation time as explained in the Optimization section, Chapter 9. 
Sample materials and their characteristic values are shown in Table 13. IonSeq will take silicon 
nitride as the base case material as expressed in Ion Torrent patent44, but other materials will be 
explored in the Optimization section. 
 
Table 13: Collection of parameters for various ISFET materials 45 
 
 
7.C. SIGNAL GENERATION AND ATTENUATION 
 
Signal generation is modeled as the following. Ψ0(t) is the surface potential function– the 
actual signal –with time dependence, τ is the time constant based upon τ0 – the material-dependent 
theoretical minimum response time – and the bulk solution pH, and ΔΨ0 is the amplitude of the 
disturbance variable—the generation of protons in the well. Equation 34 encapsulates this 
relationship among surface potential, amplitude, and material time constant. 
 
Equation 34 
  ( )      
 
 
   
 
                                                             
44 Rothberg, Jonathan M., James M. Bustillo, Mark J. Milgrew, Jonathan C. Schultz, David Marran, Todd M. Rearick, and Kim 
L. Johnson. Methods and Apparatus for Measuring Analytes. Life Technologies Corporation, assignee. Patent 8263336. 11 
Sept. 2012. Print. 
45 Ibid. 
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 The amplitude is a function of the molar concentration of protons at the passivation surface layer 
as shown in Equation 35, and the material time constant is a function of pH as seen in Equation 36, 
where τ0, again, is the material-dependent theoretical minimum response time. 
 
Equation 35 
          
  
     
 
  
     
   (  
     
     
) 
Equation 36 
       
  
   
 
This results in an involved function for signal, which essentially is a response to the generation of 
protons in the well that approach the passivation layer. 
In these equations, σ0 represents the surface charge density, σdl is the charge density on the 
solution side of the double layer, Cdl,1 is the initial double layer capacitance, and Cdl,2 is the double 
layer capacitance that changes with proton generation. Cdl,2 is, in turn, a function of the Boltzmann 
constant, kB, permittivity of free space, ε0, and the Debye screening length, λ, as expressed in 
Equation 37. 
 
Equation 37 
    
    
 
  
 
The Debye screening length, Equation 38, is a function of the ionic strength of the solution, I, which 
is a function of the charge number of the ionic species, zs, and the molar concentration of those ionic 
species, cs, that are at the passivation layer, in Equation 39.  
 
Equation 38 
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Equation 39 
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For this application, zs, is simply +1 for protons and the molar concentrations of protons are based 
upon the kinetics model in Chapter 6 and the Boltzmann distribution of those protons that reach 
the passivation layer, as expressed in Equation 40. 
 
Equation 40 
[  ]        [ 
 ]      
 
 
   
    
 
7.D. RESULTS OF THE ISFET-SIGNAL MODEL 
 
The signals generated, Ψ0(t), are included below. These results are for the Proton II chip, 
with an estimated 0.70 μm well diameter at pitch of 0.92 μm.  Figure 22 illustrates the signals 
generated for up to 3 base long homopolymers. The signal for each case is dependent on the 
number of protons left in the well as shown in Equation 39. In section 6.C.iii, the number of protons 
in the well after diffusion was illustrated in Figure 19, and shown again for convenience. 
 
Figure 19: Protons left in well after diffusion for the n = 1, n = 2, and n =3 cases.  
 
 
From the kinetic model results, the signals derived from protons interacting with the ISFET sensors 
help identify the extent of nucleotide insertions on the template strands. The MATLAB code used to 
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generate these results are found in Appendix E. The results from Ion Torrent literature, as seen in 
the right of Figure 22, strongly confirm the validity of the IonSeq model. The signal peak is achieved 
under half a second, and signal attenuation makes up a significant part of the model. The signal 
attenuation time can be taken as the time it takes the signal to decrease to just 5% of its peak value; 
for the example provided, the attenuation time is approximately 6 seconds. 
 
  
Figure 22: (Left) Signal generation from the change in proton concentration show increasing amplitudes for 
longer homopolymers.  (Right) The experimental and model signal generated by Ion Torrent reaffirms the 
validity of IonSeq’s model shown on the left.46 
 
In reality, because these ISFET sensors are sensitive, the flows of the nucleotide solutions 
and wash buffers contribute very much to background noise when collecting nucleotide 
incorporation information.  As the bead loading process is probabilistic, typically 10% of the wells 
are not occupied after the loading process.  While this may slightly decrease overall throughput, the 
non-template bearing wells are important in providing baseline readings for the other template-
bearing wells. These signal plots, in practice, are generated by subtracting out the baseline signal 
plots from confirmed empty wells from the wells with template beads.  The model developed here 
does not include these complexities, but is effectively illustrates the end product, the final signal, 
used for base calling and generating the genome’s sequence. 
                                                             
46 Rothberg, Jonathan M, et al. "An Integrated Semiconductor Device Enabling Non-optical Genome Sequencing." Nature 
475 (2011): 348-52. Print. 
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7.E. SHOT NOISE 
 
Due to the nature of the protons interacting with the surface, fluctuations in the current 
generated in the ISFET create shot noise, which may have an effect on signal fidelity. Shot noise is 
classified as instrumental noise and is the unavoidable result of the quantum nature of electric 
charge. The ‘packets’ of charges in the current, created by protons interacting with the sensor 
surface, have their own behavior. The number of electrons, which cross the sensor junction in a 
particular time interval, fluctuates and is not uniform.47 If the number of electrons that cross the 
ISFET junction remains constant, there would exist an underlying, base shot noise that could easily 
be separated from the collected signal. Since this is not the case, noise must be modeled according 
to the standard deviation of the average number of protons generated, which is just the square root 
of the number of protons.  Because the number of protons that remain in the well, as calculated in 
the Equation 16, is just an average, and the number of protons in the well, in reality, fluctuates 
drastically, the total number of protons produced is used in these noise calculations.  Therefore, this 
model dictates that the signal to noise ratio (SNR) is equivalent to the number of protons generated 
divided by the square root of that value. 
 
Equation 41 
    
      
     
 
 
√ 
 √  
 
Over the course of the signal generation model, SNR was calculated from the number of 
protons generated at that point in time.  Figure 23 illustrates the signals for homopolymers up to 
three bases in length, with the thickness that gives the range of shot noise effect (up to 3 standard 
deviations) on the accuracy of the signals generated. 
                                                             
47 Lesurf, Jim. "Sources of Noise." University of St. Andrews, n.d. Web. 7 Apr. 2013. <http://www.st-
andrews.ac.uk/~www_pa/Scots_Guide/iandm/part3/page1.html>. 
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Figure 23: The signal, for up to three homopolymers shown, is sufficiently strong and clear to allow for accurate 
base-calling. 
 
 Shot noise, however, is only one of the different types of noise that can be considered. 
Cross-talk between wells, where protons may be able to diffuse out and into other wells may be an 
issue that emerges with smaller wells. Thermal noise, or Johnson-Nyquist noise, is another 
inevitable characteristic of signal collection from electrical conductors and is the result of the 
thermal agitation of electrons48.  Further exploration in this area is needed for a more complete 
model of noise. 
7.F. ISFET SIGNAL CONCLUSIONS 
 
The model outlined in this chapter demonstrates that distinct signals can be generated 
when protons are produced from nucleotide insertions. Furthermore, it has been shown that the 
signals for homopolymers up to length three bases are distinguishable by the different peak 
heights. This is important in reducing base call errors and improving overall accuracy of a 
sequenced genome. In addition, this model will be crucial to the development of further 
optimizations of this process, as explored in Chapter 9. 
                                                             
48 Lesurf, Jim. "Sources of Noise." University of St. Andrews, n.d. Web. 7 Apr. 2013. <http://www.st-
andrews.ac.uk/~www_pa/Scots_Guide/iandm/part3/page1.html>. 
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8. DATA ANALYSIS AND GENOME CONSTRUCTION 
As the sequencing reactions take place, the signal from the released protons are generated 
as described in Section 7.C. This signal from each micro-well can now be used to keep track of 
which bases were inserted during the sequencing reaction and in which order, hence the sequence 
of the fragment in each well can be deduced. This can be accomplished by through base calling 
algorithms as discussed in Section 8.B.  
However, considerable challenges are posed to signal detection by errors that may occur 
during the sequencing process, so it is important to be able to optimize the variables such as strand 
length, flow time, reaction kinetics, etc in order to produce and detect acceptable signals. A model of 
the sequencing process was created in MATLAB to be able to optimize these variables and the 
model is discussed further in Section 8.A. 
Once the sequence of each fragment is obtained, it is possible to perform realignment to the 
reference genome, discussed in Section 8.C., thus yielding the final sequence for the entire genome. 
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8.A. DEPHASING MODEL 
 
To model the base calling process, IonSeq created a dephasing model using MATLAB. This 
model seeks to simulate the sequencing process as it occurs in each well. It models the sequencing 
process using the Kinetic Monte Carlo Method. The model also quantifies the extent to which 
dephasing occurs during the sequencing process. It allows the user to specify the number of strands 
on the bead, the length of each strand, the number of flow cycles, the flow order of the bases, and 
the flow time for each base. The user may also choose to specify the concentration of the nucleotide 
flow. The code can be found in Appendix F. 
There are hundreds of thousands of identical strands on each bead in each bead, clonally 
amplified from one fragment. Sequencing takes place simultaneously on each strand. In this way, a 
large number of protons are generated such that a perceivable signal can be generated. In theory, 
the sequencing should progress at the same rate on each strand, but if during a particular flow of 
bases, some of the correct bases fail to incorporate, the corresponding strands get out of phase with 
the rest of the strands. This can also happen the wrong base is incorporated into the strand. 
Dephasing has a negative effect on the signal, since it means that there is a lower signal for the 
correct base incorporation. It also contributed to noise because protons are generated during the 
incorrect base flow. Hence it is important to be able to predict what percentage of the strands is 
likely to get dephased and optimize the variables to reduce dephasing.  
8.A.I. THE KINETIC MONTE CARLO METHOD 
 
The Kinetic Monte Carlo Method, employed by the model, accounts for the fact that the 
bases are flowed over the wells for a certain duration of time and that this amount of times affects 
the probability of incorporation of a match or a mismatch. The flow time of each base can be 
thought to be comprised of several tiny time segments. During each time segment, there is a 
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probability of base incorporation at the current position of the polymerase. This probability, as 
shown in 
Equation 42 below, is a function of the observed rate constant, kobs, and the length of the 
time segment, dt, which should be no greater than the inverse of the largest rate constant. 
 
Equation 42 
                    
 
 
The observed rate constant can be calculated from the reaction rate constant, kpol, the concentration 
of the nucleotides, [dNTP], and the dissociation constant, KD, of the polymerase using  
Equation 43. 
 
Equation 43 
     
     [    ]
   [    ]
 
 
 
If, at the current position of the polymerase, the nucleotide that is flowed over the wells is a 
match according to the template strands, the probability of incorporation is typically higher than if 
the nucleotide is a mismatch. This is because the reaction rate constants for matches are typically 
higher than those for mismatches. This means that the mean reaction time, calculated from the 
inverse of the rate constant as in Equation 44 below, is lower for correct matches and higher for 
mismatches. 
 
Equation 44 
                   
 
    
 
 
The dephasing model loops through each time segment. The length of the time segments is 
kept smaller than the smallest mean reaction time. A base incorporation is likely to happen when 
enough time segments have passed that the mean reaction time is achieved.   
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8.A.II. QUANTIFYING THE EXTENT OF DEPHASING 
 
The model keeps track of every time there is a mismatched base incorporated and every 
time a base is failed to be incorporated. It stores the information regarding the position of the base 
in question, the strand in which it is present, the time segment and the base flow during which the 
error occurs. It uses this information to calculate how many strands have become dephased and to 
what extent. If a mismatched base is incorporated then that strand gets ahead of the others, while if 
a base is failed to be incorporated, that strand falls behind. Some strands experience both kinds of 
dephasing and the model generates a distribution of all dephased strands and the extent to which 
they are dephased. 
8.A.III. OPTIMIZING VARIABLES 
 
8.A.III.1) STRAND LENGTH 
 
The model was run using a range of different read lengths, and as expected, it was found 
that the shorter the strand length, the less the dephasing. As the strand length gets longer, there is 
greater probability for errors to accumulate and hence there is greater extent of dephasing. This 
can be seen in Figure 24. 
 
Figure 24: As the strand length increases, the percentage of strands dephased also increases . 
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While shorter read lengths can provide more accurate sequencing results, they are also 
more difficult to realign to a reference genome. Ion Torrent read lengths are generally 200 bp 
long49. However, as can be seen from Figure 25, given the current variables used in the Dephasing 
Model, the strands become 99% dephased for read lengths as short as 100 bp.  
The charts below show the distribution of dephasing for read lengths of 100 bp and 20 bp. 
At 100 bp read lengths, not only are 99% of the strands dephased, but they are dephased by several 
base pairs – as many as 10, although the majority of strands are dephased by 3-5 bp. At 20 bp read 
lengths, only 46% of the strands are dephased, and the extent of dephasing is also considerably less, 
with most strands dephased only by 1 bp. The signal generated for 20 bp read lengths will be 
reliable because 54% of the strands will be providing the correct signal. Although 46% of the 
strands will be providing incorrect signals, since the strands are dephased by different amounts, the 
various incorrect signals will not be as strong thus will not interfere greatly with correct signal 
detection. 
 
Figure 25: Distribution of Dephased Strands. Model run with 100 bp strands (99% dephased) (Left).  
Model run with 20 bp strands (46% dephased) (Right). At the given rate constants, short strand lengths of 
20 bp yield acceptable dephasing. At 100 bp, dephasing becomes problematic.  
 
However, 20 bp is not ideal for the proposed throughput, and it is reasonable to assume that 
the key to achieving longer read lengths lies with the kinetics of the polymerase used for 
                                                             
49 Liu Lin (2012), Comparison 
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sequencing. This will be discussed further in Section 8.A.iii.7. While the dephasing model uses 20 bp 
read lengths given the polymerase rate constants used, the actual process used by IonSeq will use 
read lengths that are 200 bp long. With proper adjustments to the kinetics, the error rate at 200 bp 
can be decreased, as will be further discussed. 
 
8.A.III.2) NUMBER OF STRANDS 
 
The process of clonal amplification by emulsion PCR can yield as many as 10 million copies 
of the strands per bead50. However, the model was run primarily with only 100 copies of the strand 
per bead for the sake of time. The model was also run with 1000 copies per bead and it was seen 
that all other variables remaining unchanged, roughly the same percentage of strands are dephased 
and the distributions of dephased strands were very similar, as shown in Figure 26 below. Hence, it 
was considered safe to assume that the model can be easily scaled with respect to number of 
strands. 
 
 
Figure 26: Number of Dephased Strands. Model run with 100 strands (46% dephased)(Left). Model run 
with 1000 strands (48% dephased)(Right). Note that distribution of dephased strands is similar.  
 
  
                                                             
50 Margulies, M., Egholm, M., & Altman, W. (2005). Genome sequencing in microfabricated high-density picolitre 
reactors. Nature, 437, 376-280. 
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8.A.III.3) NUMBER OF FLOW CYCLES  
 
The number of flow cycles determines the number of times bases are flown over the chip. It 
stands to reason that there may be a need to flow all four bases (A, C, G and T) for each position to 
ensure the correct incorporation at each of them. This calls for a number of flow cycles that is four 
times the length of the fragments.   
 
8.A.III.4) FLOW ORDER 
 
The flow order used in this model was A, C, G, T. Changing, reversing or alternately 
reversing the flow order does not have any effect on the error rate, according to the model. This 
follows intuition because given that the strand sequences are random, they are not biased towards 
any particular flow order.  
 
8.A.III.5) FLOW TIME 
 
It is important to select an optimum flow time for the bases, or the length of time during 
which the bases will flow over the wells. Longer flow times allow for more errors to accumulate and 
shorter flow times might not allow sufficient time for the signal to build up during the flow. The 
model returns fewer errors for shorter flow times, but does not account for signal build-up since 
this aspect was not built into the model. At higher flow times, while the number of strands roughly 
doubles, it is interesting to note that the vast majority of errors are due to incorporations of the 
wrong base rather than failure to incorporate a base. This suggests that the longer time provides 
greater probability of incorporation and while it greatly reduces the chances of a miss, it also 
increases the chances of a wrong insertion, shown in Figure 27 below. As can be seen in Figure 19 
and Figure 22, the time to register the signal peak is roughly 0.25 s51 and this is the recommended 
                                                             
51 Merriman, B., Ion Torrent R&D Team, B., & Rothberg, J. (2012). Progress in ion torrent semiconductor chip based 
sequencing. Electrophoresis, 33, 3397-3417. 
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value, because it is just high enough to register a signal but low enough to avoid large extents of 
dephasing. More favorable kinetics can allow for longer flow times as discussed below. 
 
Figure 27: Dephasing Model Distributions. Model run with flow time 0.05 s (38% dephased)(Top Left). 
Model run with flow time 0.1 s (50% dephased) (Top Right.) Model run with flow time 0.25 s (46% 
dephased) (Bottom Left). Model run with flow time 0.5 s (80% dephased )(Bottom Right). At shorter flow 
times there are more missed incorporations, but less dephasing. At longer flow times th ere are more 
mismatches and greater dephasing.  
 
8.A.III.6) NUCLEOTIDE CONCENTRATION  
 
It is recommended that nucleotide concentrations be below 500 μM.52 The model shows 
that at lower concentrations, there is less dephasing, as seen in Figure 28 below. It is also important 
not to make the concentrations too low, lest there not be enough nucleotides. In addition, as can be 
                                                             
52 Bustillo, J., W. Hinz, K.L. Johnson, J. Leamon, J.M. Rothberg, and J. Schultz. Sequencing nucleic acid comprises disposing 
template nucleic acids into reaction chambers in contact with or capacitively coupled to chemical-sensitive field effect 
transistor. Ion Torrent Systems, assignee. Patent GB2561128-A; GB2461128-B. 15 Dec. 2010. Print. 
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seen from Equation 43 for very low nucleotide concentrations, the observed polymerase rate 
constants will become too small, and the probability of incorporation will also become too small for 
proper incorporation. 
 
 
Figure 28: Distribution of dephased strands. Model run with nucleotide concentration 100 μM (46% 
dephased)(Left). Model run with nucleotide concentration 400 μM (72% dephased)(Right). Note that the 
distributions are only somewhat similar, but the major difference lies in the percent dephased.  
 
To determine the minimum nucleotide concentration required, Equation 45 can be used 
below. 
 
Equation 45 
                         
                                     
                          
 
                                                    
 
 
The concentration of nucleotides flowed in should be at minimum sufficient to account for all 
potential nucleotide insertions. The concentration of bases can be calculated as shown from 
Equation 45 using the reservoir volume, which is the volume over the wells through which the 
nucleotides will be flowed. The actual volume of the wells is negligible compared to the reservoir 
volume as shown in Figure 29 below, and hence does not need to be accounted for. 
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Figure 29: This side view of the sequencing chip shows the reservoir volume to be much greater than 
the volume of the wells. (Not to scale) 
 
As mentioned in Chapter 5 on chip configuration, the dimensions of the chip can be taken to be the 
following in Table 14. 
 
Table 14: Sequencing Chip Dimensions 
 
Die Area 20 mm x 23.7 mm 
Gap Height 1 mm 
No. of wells 660 million 
 
 
If the Dephasing Model is run using 20 bp strand lengths and 100 strands per bead, then the 
minimum concentration required, calculated using the above equations and dimensions, is 4.2 nM. 
This concentration is too small to generate high enough probabilities to ensure base incorporations, 
even correct ones. This is to be expected because the beads are designed to contain hundreds of 
thousands of strands. Hence it was decided to calculate the minimum nucleotide concentration 
using 100,000 strands, the number of strands proposed to be an a template bead. A strand length of 
200 bp was used in the calculation because that is the strand length that will be actually used in the 
process. This yields a minimum nucleotide concentration of 42 μM and to be safe, 100 μM was the 
concentration used throughout all calculations. 
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8.A.III.7) POLYMERASE RATE CONSTANTS 
 
The model used rate constants of human mitochondrial DNA polymerase, as explained in 
Kinetics section, Chapter 6. The table of the constants is reproduced here for convenience.  
Table 12: Human mitochondrial DNA rate data 
dNTP : Template Base KD (μm) kpol (s-1) 
A : T 0.8 45 
T : T 57 0.013 
C : T 360 0.038 
G : T 70 1.16 
C : G 0.9 43 
A : G 250 0.042 
T : G 200 0.16 
G : G 150 0.066 
T : A 0.6 25 
C : A 540 0.1 
G : A 500 0.05 
A : A 25 0.0036 
G : C 0.8 37 
A : C 160 0.1 
C : C 140 0.003 
T : C 180 0.012 
 
However, these rate constants are not particularly suitable for the sequencing reactions in high 
throughput sequencing. The kpol values of some of the mismatch incorporation are rather high. For 
example, the incorporation of G on T has kpol 1.16 s-1 compared to other rate constants on the order 
of 0.001 s-1. The kpol value of the correct incorporation of T on A is also rather low (25 s-1) as 
compared to the other correct incorporation values, which are all closer to 40 s-1. 
Using the kpol values in Table 12, the error rates are incredibly high and more than 95% of 
the strands become dephased. Thus for successful sequencing runs, it is extremely important to use 
better polymerases. Ion Torrent has not released any information regarding the polymerase they 
use, given that it is their trade secret, but it is very likely that the Torrent R&D teams have designed 
their own polymerases by introducing mutations to these polymerases that can have more 
favorable rate constants. 
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Having run the model using different values of the rate constants, it is recommended that 
the kpol values for all mismatches be lower than approximately 0.01 and the kpol values for all 
matches be around the same ballpark as 40. This creates a much better distribution of dephased 
strands and with read lengths of 200 bp only about 40% of the strands become dephased, as in 
Figure 30 below. The better the rate constants, which in our case indicates higher kpol values for 
matches and lower kpol values for mismatches, the fewer the errors will be and also the longer the 
base flow time can be. 
 
 
Figure 30: Distribution of dephased strands. Model run with human mitochondrial DNA rate constants 
with 20 bp read length (46% dephased) (Left). Model run with recommended rate constants with 200 bp 
read length (41% dephased) Note that distribution of dephased strands similar.  
 
With the recommended rate constants, the 200 bp long fragments to be used in IonSeq’s 
process will provide acceptable error rates. In fact, it may even be possible to achieve longer read 
lengths as shown in the Figure 31 below given that even with 300 bp read lengths, less than 50% of 
the strands are dephased. This is a recommended area to be explored in the future to achieve better 
realignment. 
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Figure 31: Percent of strands dephased over different strand lengths shows that a strand length of 
200 bp is acceptable. 
 
 
8.A.III.8) SUMMARY 
 
Using the dephasing model to predict how changing the variables can affect dephasing, the 
following values are recommended for the process in Table 15 below. 
 
Table 15: Summary of Recommended Values based off of Dephasing Model  
 
Target strand length of library 200 bp 
Number of flow cycles 800 
Flow order any 
Flow time 0.25 s 
Nucleotide concentration 100 μM 
 
It is also recommended that efforts be made to design polymerases with favorable kinetics. 
Polymerization rate constants for all mismatches should be at least two orders of magnitude less 
than 1 and these constants for all correct matches should be around the same ballpark as 40 s-1. 
8.B. BASE CALLING 
 
When raw data is generated from the sequencing runs, the servers need to convert that 
information into an actual sequence for distribution to the client. This process includes accurately 
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recognizing homopolymers, distinguishing between single base differences.  There exists a wealth 
of proprietary and open-source base calling algorithms, and there continues to be new algorithms 
developed with advancing next generation sequencing technologies. 
8.B.I. CALLSIM BASE CALLING 
 
One example is the software application CallSim, which uses a base calling algorithm 
applicable to data from the Ion Proton System. The algorithm processes a single read using a Monte 
Carlo approach and is not dependent upon information from any other read in the data set. It 
accounts for the random nature of the polymerase on the DNA molecules associated with a single 
sequencing well. The pseudocode is outlined in Figure 32. 
 
Figure 32: The CallSim algorithm is one of the several available base -calling methods for use with Ion 
Torrent technology53. 
 
 
8.B.II. IONSEQ BASE CALLING 
 
IonSeq’s base calling model is rudimentary, but works well with high fidelity polymerases. 
Via the kinetic Monte Carlo method, there are a certain number of time segments within which base 
insertions may occur. The probability of base insertion is based upon the rate constants, and the 
size of these time segments.  During one nucleotide flow, the number of insertion events is summed 
                                                             
53 Morrow, J., & Higgs, B. (2012). Callsim: Evaluation of base calls using sequencing simulation. . ISRN Bioinformatics, 2012, 
10 pages. doi: 10.5402/2012/371718 
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across all the time segments. This yields total insertion events, which is then divided by the number 
of strands in the model.  This resulting number gives the average number of bases inserted per 
strand. However, this number may prove to be unclear. For example, a value of 2.7 most likely 
corresponds to a value of 3 bases, but a value of 2.45 leaves ambiguity between 2 or 3 base 
insertions.  IonSeq’s base calling algorithm is to round this value to the nearest integer. Table 16 
outlines the steps of the base calling process described above for 50 strands. The “# of Flow Base 
Inserted” column correlates exactly to the “Strand Base” column shown at the right of the table. 
 
Table 16: The Base Calling Process for 50 Strands 
 
Flow 
# 
Flow 
Base 
Time 
1 
Time 
2 
Time 
3 
Time 
4 
Time 
5 
Sum Sum/ 
Strands 
# of Flow Base Inserted Strand 
Base 
1 T 0 0 0 0 0 0 0 0 C 
2 G 76 51 15 5 3 150 3 3 (G) C 
3 C 81 17 2 0 0 100 2 2 (C) C 
4 A 0 0 0 0 0 0 0 0 G 
5 T 0 0 0 0 0 0 0 0 G 
6 G 35 9 6 0 1 51 1.02 1 (G) C 
7 C 0 1 0 0 0 1 0.02 0 T 
8 A 110 34 0 0 0 144 2.88 3 (A) T 
9 T 20 14 8 5 1 48 0.96 1 (T) T 
10 G 1 0 0 0 0 1 0.02 0 A 
11 C 84 10 2 0 0 96 1.92 2 (C) G 
12 A 3 0 0 0 0 3 0.06 0 G 
13 T 2 0 0 0 0 2 0.04 0 C 
14 G 36 12 1 1 1 51 1.02 1 (G) T 
15 C 2 2 0 0 0 4 0.08 0 T 
16 A 119 20 2 0 0 141 2.82 3 (A) T 
 
Figure 33 provides a more visual representation of the base calling results. It shows the raw 
insertion values in the top graph while the base-calling results are shown in the bottom graph. 
Although the graphs look very similar, there are differences in fidelity. The graphs to the left are for 
a lower fidelity polymerase while the graphs to the right are for a higher fidelity polymerase. The 
lower fidelity polymerase yields a noisier collection of raw data, which can lead to incorrect base 
calls. The MATLAB code for this algorithm can be found in Appendix G. 
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Figure 33a: Base calling for slower polymerase rates shows the values of some total insertion events 
to be between integer base values and may lead to incorrect base calls. b: Faster polymerase rates 
reduce this ambiguity in base calling.  
 
Here, there exists significant ambiguity at some base flows, which lead to erroneous base calls, and 
may impact the accuracy of the base calls of later flows. This is the result of relatively slow rate 
constants for correct insertions. If the rate constants for slower correct insertions increased to the 
speed of the other insertions (~40 s-1), Figure 33 illustrates much more accurate base-calling. 
Table 17 lists the results the derived sequence for a sample genome, with 200 base strands. 
There were 14 mismatches in this example predominately at the very end of the strand as bolded. 
However, further observation reveals that this onset of errors was the cause of a missing nucleotide 
insertion at the double starred position. This missing insertion caused the rest of the sequence 
result, which is correct, to be moved up one position.  Current aligner algorithms would recognize 
this single error and make the appropriate corrections.  IonSeq’s base calling algorithm works well 
with the developed MATLAB model but is not tested for real applications where it must interpret 
the ISFET signals as shown in Figure 22 in Chapter 7. IonSeq will adopt a more reliable base-calling 
algorithm proven to be highly accurate.  
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Table 17: Comparison between Sample DNA Strand and Derived Sequ ence 
 
Genome 
Sequence 
Sequence 
Result 
 Genome 
Sequence 
Sequence 
Result 
 Genome 
Sequence 
Sequence 
Result 
 Genome 
Sequence 
Sequence 
Result 
T T  C C  C C  A A 
A A  G G  G G  G G 
T T  G G  G G  A A 
A A  G G  G G  G G 
A A  C C  T T  T T 
G G  A A  G G  C C 
T T  A A  G G  T T 
T T  A A  G G  G G 
C C  A A  C C  C C 
C C  G G  G G  G G 
C C  T T  T T  A A 
C C  T T  C C  T T 
A A  C C  A A  A A 
C C  A A  A A  C C 
C C  T T  T T  G G 
A A  G G  A A  T T 
T T  A A  C C  G G 
G G  A A  C C  G G 
A A  C C  C C  C C 
T T  G G  A A  A A 
C C  G G  T T  T T 
C C  T T  T T  C C 
T T  C C  T T  G G 
T T  C C  A A  A A 
G G  A A  C C  C C 
C C  T T  T T  C C 
A A  G G  G G  C C 
T T  T T  C C  C C 
A A  C C  G G  C C 
C C  A A  T T  C C 
A A  A A  T T  C C 
C C  A A  T T  C T** 
T T  G G  C C  T C 
A A  T T  T T  C C 
G G  A A  G G  C G 
T T  C C  A A  G G 
T T  C C  A A  G T 
T T  C C  C C  T G 
A A  G G  C C  G A 
T T  A A  G G  A A 
T T  G G  G G  A T 
T T  G G  C C  T A 
C C  C C  G G  A C 
C C  G G  G G  C A 
G G  T T  A A  A T 
C C  G G  T T  T G 
C C  G G  T T  G A 
T T  C C  A A  A A 
G G  A A  C C  A A 
G G  G G  C C  A T 
 
8.C. REALIGNMENT 
 
The Ion Reporter™ Software can be used to reassemble the reads and create a report file 
containing the full genome sequence including variant lists that can be delivered to the customer. 
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The Ion Reporter™ Software can utilize cloud computing technology; thus the realignment can be 
carried out on external servers. The reads can be securely transferred to a centralized server 
hosted by Ion Torrent using secure https protocol and then stored using 256 bit encryption 
technology54.  
The realignment can also be carried out using algorithms such as Novoalign, NextGEne and 
Partek, all of which are compatible with reads from Ion Proton™ Sequencers. The realignment is 
done by mapping the reads to a reference genome, available in the public domain, as opposed to de 
novo alignment. De novo alignment requires more complex alignment algorithms and long read 
lengths; hence, alignment to a reference genome is the best strategy.  
8.D. ERROR RATES 
 
 Measuring the error rates that emerge from sequencing runs is crucial for understanding 
the extent of a sequence’s accuracy and for evaluating the necessary rigor for mapping and 
alignment processes after the sequencing runs. An easy to interpret metric is important for quick 
interpretation throughout the sequencing industry. 
8.D.I. PHRED QUALITY RATING 
  
The Phred quality rating, Q, is common metric to measure the accuracy of base calls.55 
Equation 46 shows that the Phred quality rating is based upon the probability of an error or 
incorrect base call. Table 18 outlines the standard Phred ratings and their respective probabilities 
for error.  
Equation 46 
              
 
                                                             
54 IonTorrent. (Producer). (2012). Learn more about ion torrent software. [Web Video]. Retrieved from 
http://www.youtube.com/watch?v=g0ze9Dp9qu0 
55 Richterich, Peter. "Estimation of Errors in “Raw” DNA Sequences: A Validation Study." Genome Research 8.3 (1998): 
251-259. Web. 31 Mar. 2013. 
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Table 18: Phred Quality Scores and Corresponding Probabilities 
 
Phred Score (Q) Probability of Error (P) Base Accuracy (%) 
10 1 out of 10 bases 90 
20 1 out of 100 bases 99 
30 1 out of 1,000 bases 99.9 
40 1 out of 10,000 bases 99.99 
50 1 out of 100,000 bases 99.999 
 
8.D.II PHRED RATINGS FROM IONSEQ BASE CALLING ALGORITHMS 
 
 Using this metric, IonSeq can easily measure the accuracy of their sequences and compare 
to common standards in the industry. Furthermore, these numbers are important in meeting 
customer requirements. As outlined in section 3.A.iii., IonSeq’s customers require a Phred score of 
50, or 99.999% accuracy.  Error rates will be heavily dependent on polymerase kinetics; higher 
polymerization rate constants for correct nucleotide matches and lower rate constants for 
mismatches will lead to greater accuracy. Three different cases, consisting of different rate 
constants, are evaluated; these values are tabulated in Table 19, based off the values found in Table 
12. The rate constants that are changed from the given values in Table 12 are shown in bold. 
Table 19: Rate Constants for Three Cases 
 
dNTP : Template Base KD (μm) [Case 1/2/3] kpol (s-1) [Case 1/2/3] 
A : T [0.8, 0.8, 0.8] [45, 45, 45] 
T : T [57, 57, 57] [0.013, 0.013, 0.0013] 
C : T [360, 360, 360] [0.038, 0.038, 0.0038] 
G : T [70, 70, 70] [1.16, 0.016, 0.0016] 
C : G [0.9, 0.9, 0.9] [43, 43, 43] 
A : G [250, 250, 250] [0.042, 0.042, 0.0042] 
T : G [200, 200, 200] [0.16, 0.016, 0.0016] 
G : G [150, 150, 150] [0.066, 0.066, 0.0066] 
T : A [0.6, 0.6, 0.6] [25, 40, 40] 
C : A [540, 540, 540] [0.1, 0.01, 0.001] 
G : A [500, 500, 500] [0.05, 0.05, 0.005] 
A : A [25, 25, 25] [0.0036, 0.0036, 0.0036] 
G : C [0.8, 0.8, 0.8] [37, 40, 40] 
A : C [160, 160, 160] [0.1, 0.01, 0.001]  
C : C [140, 140, 140] [0.003, 0.003, 0.003] 
T : C [180, 180, 180] [0.012, 0.012, 0.0012] 
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Using these values, the error rates from the base calling algorithm, discussed in section 8.B.ii and 
found in Appendix G, can be found. Working with 100 strands each with a length of 200 bases, the 
algorithm is run and the counts of mismatched nucleotides are tabulated. These values are 
averaged across all the strands, converted into overall percent error, and then Equation 46 is used 
to derive the Phred score. The results are outlined in Table 20; if compared with the manipulated 
rate constants in Table 19, the Phred score increases by about 10 when the rate constants are 
favorably changed by factor of 10. This is a result of the logarithmic definition of the Phred score. 
To achieve the customer requirement of 50 Phred score, IonSeq will need to develop its own 
proprietary polymerases to significantly reduce mismatches; as the base calling model results 
demonstrate, this can be theoretically be achieved. 
 
Table 20: Phred Scores for the Cases of Different Rate Constants 
 
Case Percent Error Phred Score 
Case 1 0.5% (1 error out of 200 bases) 23 
Case 2 0.09% (0.18 errors out of 200 bases) 30.5 
Case 3 0.005% (0.01 errors out of 200 bases) 43 
 
8.E. FUTURE POTENTIAL OF DATA ANALYSIS 
 
The IonSeq process generates large amounts of data from each microwell and powerful 
computational and bioinformatics tools, like those discussed in Sections 8.B. and 8.C. are required 
to take the raw reads and convert them into the final genome sequence that will be delivered to the 
customer. Through progress and development in both sequencing technology and computational 
technology, there are opportunities of achieving even higher throughput in the future. As more 
complex base calling and realignment algorithms are created, it may be possible to sequence 
genomes with even lower coverage with greater accuracy. There are several opportunities for 
improvements in sequencing technologies as discussed in Section 8.A. By improving polymerase 
kinetics, increasing read lengths, and decreasing signal detection times, it will be possible to reduce 
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time required for the sequencing and sequencing costs. With reductions to the required coverage, 
significant increases to throughput can also be made. Hence, it is important for IonSeq to keep up 
with the rapid advancements being made in these technologies, such that it is possible to take full 
advantage of these advancements and maximize throughput. 
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9. OPTIMIZATION OPTIONS 
 Now that the kinetics and ISFET sensor models have been thoroughly explored and 
developed in Chapters 6 and 7, optimization of the signal strength can be performed. IonSeq seeks 
to decrease attenuation time to improve throughput as well as increase the signal differentiation 
between homopolymers for more accurate base calling. In this chapter, two options will be 
considered and the third choice will be developed by combining aspects of the first two options. 
9.A. OPTION A: GATE INSULATOR MATERIAL – SIGNAL STRENGTH OR ATTENUATION 
TIME AND GENOMIC OUTPUT 
 
 Ion Torrent’s Proton II chip is to be composed of Silicon Dioxide insulator layer on a Silicon 
Nitride gate insulator layer.   Signal strength is a function of the difference in surface potential and 
electrolyte solution potential.  Surface potential of an ISFET is based off the Nernst equation for a 
two proton layers and follows the site-binding model, as previously shown in Equation 3356. The 
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main variables behind the ISFET surface potential are , the selectivity constant, and the difference 
between the bulk fluid pH and pHpzc, the pH at zero potential.  For Silicon Nitride at 298K, the 
selectivity constant is 0.93 and the pHpzc is 6.8. To achieve a positive surface potential, the bulk fluid 
pH must be greater than the pHpzc.  The Proton II chip is run with a bulk pH of 8.0.  By substituting 
the gate insulator layer material, the pHpzc and selectivity constant will change.  By keeping the bulk 
fluid pH at 8.0, the pH difference of the bulk fluid and pHpzc can be maximized for a pHpzc lower than 
that of Silicon Nitride.  For a gate insulator material, pHpzc can be calculated by Equation 4757. 
Equation 47 
             (    )
        (       )  
 
Selectivity constants are a function of a material’s sensitivity value.  Sensitivity is defined 
derivative of the site-binding model with respect to pH; Equation 33 can be rearranged to see this 
dependence58. At 298K, Silicon Nitride has a sensitivity value between 52-58 mV/pH for a pH range 
of 1-13 and a selectivity of 0.93.  By obtaining a material’s sensitivity, the selectivity constant can be 
obtained; the results are listed in Table 21.   
                                                                                                                                                                                                    
56 Woias, P., L. Meixner, D. Amandi, and M. Schönberger. "Modelling the Short-time Response of ISFET Sensors." Sensors 
and Actuators B: Chemical 24.1-3 (1995): 211-17. Print. 
57 Chiang, Jung-Lung. Study on the pH-Sensing Characteristics of ISFET with Aluminum Nitride Membrane. Diss. 2002. 
58 R.E.G. van Hal, J.C.T. Eijkel, P. Bergveld, A novel description of ISFET sensitivity with the buffer capacity and double-
layer capacitance as key parameters, Sensors and Actuators B: Chemical, Volume 24, Issues 1–3, (1995): 201-205. 
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Table 21: Determination of Selectivity Constants  
 
 pHpzc Sensitivity (mV/pH) Obtained  
Si3N4 6.859 52-5860 0.9361 
Ta2O5  2.862 57.1-58.363 0.98 
TiO2  6.164 56.265 0.95 
SnO2 6.066 58.967 1.00 
PbTiO3 1.868 56-5969 0.97 
 
Optimization by materials offers two options: to increase signal strength or shorten 
attenuation time.  Signal strength increase is reliant on the difference in pH of the bulk fluid and the 
pHpzc and the selectivity constant.  In the case of signal strength increase, attenuation time remains 
the same, but signal-to-noise ratio increases.  Shortened attenuation time is reliant on the potential 
of the bulk solution, which influence both the potential of the surface of the gate insulator and the 
potential of the solution after a reaction.  Theoretically, shortened attenuation times decreases the 
amount of base pair mismatches, increases the potential gap between homopolymer reads, and 
decreases the time for nucleotide turnover.  The decrease in base pair mismatches and increase in 
potential gap between homopolymer reads offers a significant increase in accuracy.  The decrease 
in time for nucleotide turnover lower the amount of time required for the sequencing of a single 
strand, thus increases overall output of the chip.   
                                                             
59 Dutta, J. C. “Modeling Ion Sensitive Field Effect Transistors for Biosensor Applications.” International Journal of 
Advanced Research in Engineering and Technology. (2010): 38-57. 
60 Chiang J, Chou J, Chen Y; Sensitivity and hysteresis properties of a-wo3,ta2o5, and a-si:h gate ion-sensitive field-effect 
transistors. Opt. Eng. 0001;41(8):2032-2038. 
61 Ibid. 53 
62 Natishan, P. M., E. McCafferty, and G. K. Hubler. "Surface Charge Considerations in the Pitting of Ion‐Implanted 
Aluminum." Journal of The Electrochemical Society 135 (1988): 321. 
63 Chiang, Jung-Lung, Jung-Chuan Chou, and Ying-Chung Chen. "Sensitivity and hysteresis properties of a-WO3, Ta2O5, 
and a-Si: H gate ion-sensitive field-effect transistors." Optical Engineering 41.8 (2002): 2032-2038. 
64 Preočanin, T., & Kallay, N. (2006). Point of zero charge and surface charge density of TiO2 in aqueous electrolyte 
solution as obtained by potentiometric mass titration. Croatica chemica acta, 79(1), 95-106. 
65 Jung-Chuan Chou, Lan Pin Liao, Study on pH at the point of zero charge of TiO2 pH ion-sensitive field effect transistor 
made by the sputtering method, Thin Solid Films, 476:1. (2005): 157-161. 
66 Liao, Hung-Kwei, et al. "Study on pHpzc and surface potential of tin oxide gate ISFET." Materials chemistry and 
physics 59.1 (1999): 6-11. 
67 Ibid. 
68 Jan, Shiun-Sheng, et al. "Preparation and properties of lead titanate gate ion-sensitive field-effect transistors by the sol-
gel method." Japanese journal of applied physics 41.2A (2002): 942-948. 
69 Ibid. 
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For the scenario of a single base incorporation, where the bulk solution pH is 8, Silicon 
Nitride peaks at 28.95mV, requires 3.20 seconds to degrade the signal to 90% of the maximum 
value, and the signal ratio, defined as the ratio of the difference in signal between the second and 
third nucleotide incorporation to the difference in signal between the first and second nucleotide 
incorporation, of 0.4433. The signal for this base case is shown in Figure 34.  This value must be less 
than one, where a ratio of one indicates the most amount of differentiation between homopolymers 
and smaller ratio indicates a more quickly diminishing homopolymer response signal leading to the 
inability to distinguish between homopolymer at shorter homopolymer chains.   
 
 
Figure 34: Signal Base Case – Silicon nitride 
 
Keeping the bulk solution pH constant, surface potentials for the materials increase 
approximately two-fold and range from 56.18 mV to 187.18mV; the largest surface potential occurs 
for Lead Titanate and the smallest surface potential occurs for Titanium Oxide, shown in Figure 35. 
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Material Maximum Signal 
PbTiO3 187.18 mV 
Ta2O5 158.61 mV 
SnO2 62.25 mV 
TiO2  56.18 mV 
Si3N4 28.95 mV 
 
Figure 35: Signal generation for a single nucleotide incorporation of various materials at bulk pH of 
8 by decreasing order of maximum signal output 
 
 Using Silicon Nitride, several factors limits the bulk fluid pH, which affects both the signal 
strength and the attenuation time.  An optimal bulk solution pH lies at a number which maximizes 
the difference between itself and the pHpzc of Silicon Nitride and is at a suitable pH which would not 
denature the DNA polymerase.  The nature of the high pHpzc of Silicon Nitride limits its bulk fluid 
pH, which limits both, its signal strength and its attenuation time.   
 Of the materials selected, the pHpzc is significantly lower than that of Silicon Nitride, 
allowing for a wider range of allowable bulk fluid pH Because the optimal pH for the DNA 
polymerase lies between 5 and 870, a bulk fluid pH of 7 would be lower than that of the base case 
but offers a conservative pH range for the influx of protons and for the maintaining of integrity of 
                                                             
70 Lopes, D. O., et al. "Analysis of DNA polymerase activity in vitro using non-radioactive primer extension assay in an 
automated DNA sequencer." Genet Mol Res 6 (2007): 250-255. 
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the DNA polymerase.  Application of the new bulk fluid pH causes an attenuation time of 1.156 
seconds and a signal ratio of 0.6058.  The results are illustrated in Figure 36. 
 
 
Material Maximum Signal 
PbTiO3 34.63 mV 
Ta2O5 28.26 mV 
SnO2 6.87 mV 
TiO2  5.87 mV 
 
Figure 36: Signal generation for a single nucleotide incorporation of various materials at bulk pH of 
7 by decreasing order of maximum signal output compared to Si3N4 at bulk pH of 8 
 
Optimization by material shortens attenuation time 3.5-fold, but of the materials selected 
for optimization, Lead Titanate offers a higher maximum signal at pHbulk of 7 than Silicon Nitride at 
pHbulk of 8.   A comparison between Lead Titanate at pHbulk of 7 and Silicon Nitride at pHbulkof 8 can 
be found below in Table 22. The key takeaway from this optimization is the increase in the signal 
ratio, which would imply more accurate base calling when encountering homopolymers. 
Table 22: Comparison of Silicon Nitride at bulk pH of 8 and Lead Titanate at bulk pH of 7 
 
 Silicon Nitride Lead Titanate Fold Change 
Maximum Signal 28.95 mV 34.63 mV 1.20 
Attenuation Time (99%) 6 seconds 2.10 seconds -2.76 
Signal Ratio 0.4433 0.6058 1.37 
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Throughput from the use of Lead Titanate requires the calculation of a cycle time.  
Nucleotides are washed following the rise time for signal generation.  Because Silicon Nitride’s rise 
time is insignificant (<0.1 seconds), the total cycle time is equal to the attenuation time plus the 
buffer flow time of 2 seconds.  For the case of Lead Titanate, the rise time for the signal is 0.21 
seconds, 10% of the total attenuation time, and is extremely significant.  The cycle time for a Lead 
Titanate insulator gate chip would be the sum of the rise time, the attenuation time (2.31 seconds) 
and the buffer time, which would yield a cycle time of 4.31 seconds.  A comparison of throughput 
from Proton II to a theoretical Proton III, based off the Proton II, made of Lead Titanate, and at bulk 
pH of 7, can be seen below in Table 23.  These changes reduce throughput by a factor of 1.85. 
 
Table 23: Comparison of Silicon Nitride at bulk pH of 8 and Lead Titanate at bulk pH of 7 
 
Strand Length (base pairs) Cycle Time (sec) Cycles Throughput 
(hr/genome) 
Current Proton II 8 1600 3.56 
Proposed Proton III 4.31 1600 1.92 
 
9.B. OPTION B: WELL-SIZE AND ORGANIZATION – ATTENUATION TIME AND GENOMIC 
OUTPUT 
 
At present, Ion Torrent’s Proton II chip contains 660 million wells at a well diameter 0.70 
µm on a nodal length of 110 microns.  With those methods, it takes about almost 3 hours for a single 
genome. However, current technology has driven node length to a commonly available 32nm, with 
a 22nm node length in development71. By decreasing node length, more wells could be fitted within 
a single chip, allowing two optimization options for throughput: decreased strand size for faster 
turnover or the ability to apply genetic tags for the sequencing of one more genomes. 
 
 
                                                             
71 "3-D, 22nm: New Technology Delivers An Unprecedented Combination of Performance and Power Efficiency." Intel, 
Web. <http://www.intel.com/content/www/us/en/silicon-innovations/intel-22nm-technology.html>. 
 
9. Optimization Options  Chow, Hasan, Lau, Liu 
 
94 
 
Table 24: Comparison of well changes between Proton II and Proton III  
 
 Well Diameter 
(μm) 
Attenuation Time Potential Ratio Maximum Signal 
Current Proton II – 
110nm 
    
660M 0.70 6 seconds 0.4433 28.95mV 
Proposed “Proton III” – 
32nm 
    
660M 0.85 4 seconds 0.4356 29.33mV 
1.0B 0.70 4 seconds 0.4433 28.95mV 
1.5B 0.54 4 seconds 0.4958 25.96mV 
 
Applying a 32nm node length to a chip allows for three different scenarios: 660 million 
wells at 0.85µm per well, 1 billion wells at 0.70µm per well, or 1.5 billion wells at 0.54µm per well, 
outlined in Table 24.  By decreasing well size, the significance in the difference between 
homopolymers increased, indicated by the potential ratio.  This decrease in well size also decreased 
the maximum signal output, where a decrease in well size decreased the maximum signal output, 
which lowers the signal-to-noise ratio.   
By implementing a genetic tag at approximately 40 base pairs in length, the amount of 
cycles required increases but allows for the possibility of increasing throughput by increasing total 
genome output.  For a genetic tag attached to 200 base pair strands, it would require approximately 
750 million wells for a single genome.  Utilizing the 32nm case, two genomes would be completed 
in 2.13 hours. Table 25 gives a potential workflow.  
 
Table 25: Theoretical Workflow 
 
Description Well Diameter 
(μm) 
Cycle Time 
(sec) 
Base 
Length 
Cycles Time 
(hr) 
Throughput 
(hr/genome) 
Single Genome 
 
      
Proton II – 660M @ 
110nm 
0.70 8 200 1600 3.56 3.56 
“Proton III” – 1.5B @ 
32nm 
0.54 6 100 800 1.33 1.33 
Barcoded – Two+ 
Genomes 
      
Proton II – 1B @ 
110nm 
0.51 8 240 1920 4.27 2.13 
“Proton III” – 1.5B @ 
32nm 
0.54 6 240 1920 3.20 1.60 
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Implementation of a shorter sequence in more wells allows for less nucleotide cycles for 
faster genomic output.  For a 32nm chip at a 100 base pair strand, it would require 1.5 billion wells 
but would halve the amount of nucleotide cycles to 800.  The single strand output would have the 
same attenuation time, 4 seconds, and a total output time of 0.89 hours.  Utilizing a lower base pair 
strand limits the possibility of longer homopolymer sequences, allowing for increased accuracy in 
homopolymer readings in addition to the increase in potential ratio.    
 
9.C. OPTION A+B: APPLICATION OF 32NM TECHNOLOGY TO LEAD TITANATE GATE 
INSULATOR LAYER 
 
With Ion Torrent’s technology, the Proton II, being at 660 million wells utilizing 110nm 
nodal length, it requires approximately 3.5 hours to generate the full raw data from a genome.  
Applying both optimization cases leads to a Lead Titanate gate insulator chip with 1.5 billion wells 
at a 32nm node. This resulting theoretical signal response is shown in Figure 37. 
 
 
Figure 37: Proposed signal generated from Theoretical Proton III Chip 
 
Using the 32nm technology with the Lead Titanate layer effectively shortens the attenuation 
time to 2.23 seconds, offers a maximum signal of 24.67, and offers an extremely high potential ratio 
of 0.632.  However, unlike the case for the Proton II, where the rise time determines when dNTPs 
are washed out of the well and is insignificant (~0.1 seconds), the time required for the maximal 
signal is 0.31 seconds, approximately 14% of the amount of time required for 99% signal 
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attenuation.  Cycle time, thus, is now the sum of the 99% signal attenuation time and the time 
required to reach the maximum signal.  Two options remain: one genome per chip with 100 base 
pair strands or two genomes per chip with 240 base pair strands.    
 
Table 26: Proposed Proton III Technology 
 
 Attenuation Time 
(Seconds) 
Potential Ratio Maximum Signal 
Current Proton II – 110nm node, 
660 Million Wells 
6 0.4433 28.95mV 
Proton III – 32nm node, 1.5 
Billion Wells 
2.23 0.6632 24.67mV 
     
Strand Length (base 
pairs) 
Cycle Time (sec) Cycles Time (hr) Throughput 
(hr/genome) 
Current Proton II     
200 8 1600 3.56 3.56 
Proposed Proton III     
100  4.63 800 1.03 1.03 
240  4.63 1920 2.47 1.23 
 
 
9.D. OPTIMIZATION CONCLUSIONS 
 
The potential ratio of the proposed Proton III, shown in Table 26, would have a 1.5 fold 
increase over the Proton II, effectively showing a significant accuracy increase by maximizing 
difference between homopolymers sequences.  Accuracy with homopolymers can further be 
increased by utilizing a shorter base pair length.  This allows for less dephasing and shortened 
possible homopolymer lengths.  Sequencing throughput of the proposed Proton III using a 32nm 
node and Lead Titanate chip leads to a greater than a 3-fold increase in the sequencing throughput 
required compared to the Proton II.  However, described in Chapter 11, the current, stock Proton 
sequencer has a run time of 8 hours, four of which is devoted to actual base flows and the 
remaining four is devoted to base-calling and alignment. The 3-fold increase in sequencing 
throughput described in this section only influences one half of the machine’s run time. Therefore, 
throughput for the machine overall is only increased by 1.5 times. Implications on the IonSeq’s 
overall throughput is further discussed in Chapter 11. 
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10. MARKET ANALYSIS 
Next Generation Sequencing (NGS) has the potential to become a disruptive technology that 
will allow scientists to access DNA data like never before. It is the fastest growing and “most 
attractive” segments of a potentially $7.1 Billion Genomics Space72. The NGS market itself was 
worth just over one billion dollars in 2011, and is expected to double by 2016. The market is 
currently in a highly volatile growth stage, where new biotech companies sprout up constantly. 
However, IonSeq is confident in our ability to provide a novel service and occupy a niche in the 
biotechnology sector. This chapter will paint the market landscape and describe some of the 
competitors with which IonSeq must contend in order to achieve success. 
10.A. MARKET OUTLOOK 
 
Approximately 25 companies compete in the U.S. next-generation sequencing services market, with 
new competitors entering the market every year. Given the high expected growth rate, several 
                                                             
72 Decisive Bio-Insights. (2013). Next generation sequencing: Market size, segmentation, growth and trends by provider. 
(2nd ed.). Culver City, CA: DeciBio, LLC. 
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competitors are expected to enter the market through 201673. Advancements in technology are 
reducing the cost of sequencing systems, and making them more appealing to those who could not 
previously afford the equipment74. In addition, manufacturers are expanding their product line to 
include smaller, “personal sized” machines. Most importantly, the throughput processes themselves 
have improved, reducing cost and time per run’. There are also great advancements in the data 
processing software and data processing capabilities. 
However, there does appear to be potential barriers in the NGS market that is of interest to 
IonSeq. NGS Service Providers are starting to appear, and we must work to take our market share. 
NGS Service Providers prove attractive to smaller laboratories as there is a lower cost, and quicker 
response time. We will not be competing with the four key players in the US: Illumina, Roche, Life 
Technologies, and Qiagen75, but rather use them as vendors if necessary. We feel this is a 
relationship that will benefit all parties.  
 As previously mentioned, IonSeq’s target market is a Direct-to-Consumer 
Sequencing Services market, providing exome and genome sequencing to individual customers and 
physicians. The NGS-DTC market is expected to form and mature over the next five years76. The 
average market price per genome is expected to decrease over the next few years, from the current 
price of approximately $4,00077, to reach the X-Prize goal of $1,000 per genome. Services offered by 
companies targeting this market include whole-genome sequencing, exome sequencing, de novo 
sequencing. However, the scope of IonSeq’s operations will be limited to genome and small chain 
                                                             
73 Bird, C. (2012, May 1). Next-gen sequencing services: An expanding role in clinical applications opens new 
markets. Genetic Engineering & Biotechnology News, 32(9), Retrieved from http://www.genengnews.com/gen-
articles/next-gen-sequencing-services/4088/ 
74 Companies and Markets. (2011). Strategic analysis of the u.s. next generation sequencing markets. Frost and SUllivan. 
Retrieved from http://www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market-Research/Strategic-
Analysis-of-the-U-S-Next-Generation-Sequencing-Markets/RPT915231 
75 Companies and Markets (2011). Strategic 
76 Bird, C. (2012) Next-gen 
77 Bird, C. (2012) Next-gen 
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sequences, with further expansion likely in the future. This NGS-DTC market is expected to reach 
$550 million by 2015, nearly half of the entire NGS market78. 
Due to the above circumstances, IonSeq is confident that its ability to offer customers a 
unique personal sequencing service will lead it to successes in the market. IonSeq’s innovation 
spans across five categories critical to a successful business: Customer Value, Products and 
Services, Technical Differentiation, Process Technology, and Material Technology. The relationship 
between each of IonSeq’s unique offerings is diagramed below, in Figure 38. As stated previously, 
IonSeq’s value proposition lies in sequencing speed and throughput, which emerge as a result of the 
CMOS chips with ISFET sensors. IonSeq’s services also allow customers to avoid burdening high 
capital costs for sequencing equipment and maintenance and labor costs involved in upkeep of that 
equipment. 
 
 
Figure 38: Innovation Map for IonSeq 
 
                                                             
78 Bird, C. (2012) Next-gen 
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10.B. COMPETITOR ANALYSIS 
 
While IonSeq is offering a unique service, it is important to be aware of the other genome 
sequencing technologies and platforms available in the market. Genome sequencing technology 
sees frequent technological advances and increases in efficiency and competitiveness. It will be 
crucial for IonSeq to keep up to date with breakthroughs in throughput achieved by any company 
and IonSeq’s success in the long-run is dependent upon Ion Torrent R&D being able to remain 
competitive in the market. This section examines some of the competing technologies in the market. 
10.B.I. COMPETING GENOME SEQUENCING PLATFORMS 
 
Genome Sequencing Platforms include current NGS market occupiers, who currently act as 
vendors for laboratories. These companies primarily sell equipment and engage in research to 
further sequencing technologies. 
10.B.I.1) ILLUMINA GA / HISEQ SYSTEM 
 
Illumina sequencing platforms are currently the most widely used platforms in the market. 
In 2006, the Genome Analyzer (GA) was released by Solexa and in 2007 Solexa was purchased by 
Illumina. The GA, like Ion Torrent, also uses the sequencing-by-synthesis approach, however it 
differs vastly in that reads are conducted through optical detection. The single DNA fragments are 
grafted onto the flowcell and are made to form clusters by bridge amplification. All four kinds of 
nucleotides, each attached to a different cleavable fluorescent dye and a removable blocking group, 
are flowed over the flowcell at the same time. Each nucleotide incorporation results in chain 
termination, and the fluorescence from each cluster is detected using a CCD camera. Reagents then 
need to be flown in to remove the fluorescent moiety and unblock the chain so that next round of 
nucleotides can be flowed79.  
                                                             
79 Liu (2012). Comparison 
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The greatest strength of the Illumina technology lies in the fact that it can generate an 
immense amount of data. The latest Illumina GA can yield outputs of 85 GB/run. In 2010, Illumina 
launched HiSeq 2000, which can yield outputs of 600 GB/run. The reported accuracy of this 
technology is very high, above PHRED scores of Q30.  The dominant error type is substitutions 
rather than insertions or deletions80. Yet there are limitations to advancements in the technology. It 
is unlikely that the technology can yield read lengths greater than 200 bp because of signal decay 
and dephasing due to incomplete cleavage of fluorescent labels or terminating moieties. Limitations 
in CCD technology also pose obstacles to increases in throughput81. 
10.B.I.2) ROCHE 454 SYSTEM 
 
Roche 454 was the first commercially successful next generation system. It makes use of 
pyrosequencing, which makes its method of detection of incorporation different from Ion Torrents, 
but otherwise the technology is almost identical. Clonal amplification is achieved by emulsion PCR, 
which creates copies of each fragment on individual beads and the sequence on each bead is 
determined by pyrosequencing, which detects nucleotide incorporation using a flash of light, which 
is emitted when diphosphate, the bi-product of nucleotide incorporation, reacts with the enzymes 
sulfurylase and luciferase. The nucleotides are flown over the wells one at a time and the platform 
keeps track of which cells emit the flash of light for a particular nucleotide. 
In 2005 Roche 454 was able to achieve read lengths of 100-150 bp and 20 Mb of data per run. In 
2008 the 454 GS FLX Titanium System was launched which could attain 700 bp read lengths with 
99.9% accuracy within 24 hours82.  
However, this technology has had trouble competing in the market with Illumina, given that 
it has not been able to generate nearly as much data, has greater per-base cost of sequencing and is 
greatly limited by homopolymers. Since there is no terminating moiety preventing multiple 
                                                             
80 Quail, M., & et al, (2012). A tale of three next generation sequencing platforms: comparison of ion torrent, pacific 
biosciences and illumina miseq sequencers.BMC Genomics, 13, 341. 
81Shendure, J., & Ji, H. (2008). Next generation dna sequencing. Nature Biotechnology, 26(10), 1135-1145.  
82 Liu (2012). Comparison 
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consecutive incorporations in a given cycle, the length of all homopolymers has to be inferred from 
signal intensity. At longer homopolymer lengths this becomes difficult. Hence, indel errors are more 
dominant than substitution errors83. 
While Ion Torrent faces the same problem of homopolymers, it has greater potential of 
being able to read longer homopolymer lengths because it relies on rapidly evolving transistor 
technology and is not limited by advancements in CCD technology. Given the similarities in the two 
technologies, Ion Torrent also has the potential to achieve longer read lengths in the future. 
10.B.I.3) ABI SOLID SYSTEM 
  
The SOLiD platform was purchased by Applied Biosystems in 2006. It makes use of 
emulsion PCR to amplify the DNA fragments, but unlike the other platforms, which use sequencing 
by polymerization, the SOLiD platform uses sequencing by ligation. All possible 8-mer 
oligonucleotides are hybridized to the template simultaneously, but only those with a specific two-
base-pair combination can bind strongly enough to be ligated onto the growing strand. The identity 
of the fifth base can be decoded by the color of the fluorescent dye at the unligated end of the 8-mer. 
After several rounds of ligation, the newly synthesized strand is melted off, and a second round of 
ligation is initiated with the new primer offset from the first by one base. In this way five rounds are 
ligation are carried out, which allows the complete sequence to be inferred. 
Between 2007 and 2010 several SOLiD platforms were released, but none of these have 
managed to outcompete the yield of Illumina or the read lengths of 454. Hence its applications have 
become restricted to targeted resequencing and transcriptome research84. 
10.B.I.4) THIRD GENERATION SEQUENCER TECHNOLOGY 
 
The third generation of genome sequencing is already under development, the most 
prominent technologies being those employed by Pacific Biosciences (PacBio) and Oxford 
                                                             
83 Shendure (2008). Next-Generation 
84 Liu (2012), Comparison  
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Nanopore. These technologies eliminate the need for PCR, which shortens DNA preparation time, 
and also reduces bias and error caused by PCR. PacBio has introduced the single-molecule real-time 
(SMRT) sequencing, which makes use of direct observation of the enzymatic reaction in real time. 
While this technology is able to achieve the longest read lengths, 1300 bp, its throughput is much 
lower than those of second generation sequencers, making this technology unsuitable for service 
companies such as IonSeq. The Nanopore technology uses the concept of putting a thread of single-
stranded DNA across α-haemolysin pore, which can cause different levels of disruptions in a 
continuous ionic flow based on which base is passed through it. While this technology is also very 
promising, it has not been developed sufficiently to determine its market competitiveness85. 
10.B.II. COMPETING GENOME SEQUENCING SERVICES COMPANIES 
 
As the cost of genome sequencing is rapidly declining, the genomics service industry is also 
becoming increasingly lucrative. As such IonSeq is likely to face competition from several sources. 
10.B.II.1) COMPLETE GENOMICS 
 
Complete Genomics (CG) provides genome sequencing and analysis services. Much like 
IonSeq, CG is also dedicated solely to human DNA sequencing. CG provides two primary services – 
the Standard Sequencing Service and the Cancer Sequencing Service. The services largely differ 
from those of IonSeq’s primarily because with each service from CG, the customers receive reports 
on summary statistics, variants including SNPs, indels, etc. These services are aimed at directly 
allowing customers to efficiently characterize the full spectrum of genetic variants that exist in the 
population and conducting large-scale genome-wide association studies. 
There are two primary components of the CG sequencing technology: DNA nanoball (DNB) 
arrays and combinatorial probe-anchor ligation (cPAL) reads. The DNA fragments are packed onto 
a silicon chip and amplified such that all copies are connected in a head-to-tail configuration, 
                                                             
85 Liu (2012), Comparison 
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forming long single molecules which then ball up into DNBs, which are approximately 200nm in 
diameter. A ligase enzyme attaches a different fluorescent molecule to each type of nucleotides in 
every DNB. The sequence is determined by imaging the fluorescence86.   
Complete Genomics has one of the most competitive sequencing platforms in the market, 
and has been successfully competing with the Illumina HiSeq 2000, especially in applications that 
seek to identify single nucleotide variants in human populations. CG is very likely to be IonSeq’s 
biggest competitor. 
10.B.II.2) GENE BY GENE DNA DTC 
 
DNA DTC was launched at the end of 2012, as a division of Gene by Gene, a company that 
provides on DNA testing focusing on ancestry, health, research and paternity. The company’s 
newest division, DNA DTC, aims to utilize next generation sequencing of exomes and whole 
genomes for genome-wide association studies, human mitochondrial tests, and offer whole genome 
sequencing services. DNA DTC plans to use the Illumina HiSeq platform and is currently offering a 
price of $695 for exome sequencing87.  
DNA DTC is likely to provide competition for IonSeq going forward, but at present enough 
information is not available to determine at what level. DNA DTC’s services also appear to be 
targeted more towards genomics research centers rather than clinical institutions, so it is likely that 
its market will not have a major overlap with that of IonSeq’s. 
10.B.II.3) EDGEBIO 
 
EdgeBio is a bioinformatics company specializing in next generation sequencing 
technologies and applications. EdgeBio has provided genomics services since 2009. They serve as a 
sequencing and bioinformatics provider for many companies and research institutions worldwide. 
                                                             
86 Complete Genomics. (2011). introduction to complete genomics’ sequencing technology. In Complete Genomics Media. 
Moutain View, CA: Complete Genomics. Retrieved from http://media.completegenomics.com/documents/Technology 
White Paper.pdf 
87 Croft, K. (2012, November 29). Gene by gene launches dna dtc: Offers highly reliable, cost-effective dna testing to 
institutional clients worldwide. Market Watch: The Wall Street Journal. Retrieved from 
http://www.marketwatch.com/story/gene-by-gene-launches-dna-dtc-2012-11-29 
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EdgeBio uses a broad range of high throughput sequencing platforms including Illumina HiSeq2000 
and MiSeq, as well as Ion Torrent PGM and Proton. Their clients are able to create an online account 
with them through which they can monitor the progress of their projects88. 
EdgeBio’s genomics services are likely to be in direct competition with those provided by 
IonSeq. There are even instances of technology overlap, so customers wishing to use Ion Torrent 
technology are going to have choices among service companies. However, since EdgeBio simply 
purchases equipment from Illumina, Ion Torrent and other companies, and has no affiliation 
whatsoever with them, they are not able to take advantage of the rapid advancements of the 
sequencing technologies. This is where IonSeq has a major advantage. 
10.B.II.4) 23ANDME 
 
23andMe is a personal genomics company operating since 2007. 23andMe focuses more on 
providing DNA testing services rather than DNA sequencing ones. The company genotypes the DNA 
using microarray technology (specifically, the Illumina OmniExpress Plus) to identify which genetic 
variant the individual possesses.  This allows the customers to assess their inherited traits, 
genealogy and congenital risk factors. Genotyping services offered for $9989. 
23andMe will not be a direct competitor for IonSeq since it does not provide genome 
sequencing services. Genome sequencing has an inherent advantage over genotyping because it can 
provide the entire sequence as opposed to simply the information regarding which known variant 
an individual possesses. Genotyping by means of microarrays is also unable to identify previously 
unknown variants.  
  
                                                             
88 Edge Bio. (n.d.). Next generation dna sequencing services. Retrieved from http://www.edgebio.com/sequencing 
89 23andMe. (n.d.). How it works. Retrieved from https://www.23andme.com/howitworks/ 
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11. STRATEGY AND IMPLEMENTATION 
 IonSeq’s success will not only rest on its technical soundness and strong market position, 
but it will also require impeccable execution. This chapter will review the timeline for meeting 
Series A and Series B goals, delineate the structure of each work day, outline the general labor and 
material requirements, and review other business requirements. 
11.A. MEETING SERIES A AND SERIES B GOALS 
 
Series A will serve as the prototype stage, a proof-of-concept, of the Ion Torrent technology. 
IonSeq will purchase the capital equipment, support labor costs, and procure the materials 
necessary to sustain the sequencing of 10 genomes/day. For the first quarter of the first year, 
IonSeq will purchase one Proton Sequencer/Server and perform practice sequence runs using the 
DNA samples from the founding members. The CEO, CTO, CFO, secretary, and the engineers will be 
employed at this stage. IonSeq will be in frequent contact with research laboratories that employ 
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this technology for collaboration purposes. By the end of the first quarter, IonSeq intends to prove a 
throughput of 1 genome per day.  For the second quarter, IonSeq will purchase an additional 
Sequencer/Server package, and this period will be devoted to proving the work flow that consists 
of running each sequencer twice in a 16 hour working day. By the end of the second quarter, a 
throughput of 4 genomes per day should be achieved.  Once this is proven, a marketing manager 
will begin efforts in promoting IonSeq to potential clients. The third quarter will include the 
additional purchase and incorporation of the remaining three sequencers. Technicians will be hired 
and trained during this period as well. At the end of the third quarter, expected throughput is 8 
genomes/day. The fourth quarter will involve perfecting the work flow, and achieving consistent 10 
genomes/day throughput. A sales manager will be hired at this time and trained. 
Series B investments will be expected at the end of the first year in preparation for 
commercial launch at the beginning of the second year.  At the beginning of this phase, 15 
additional sequencers/servers will be purchased. The engineers and technicians will train new, 
incoming technicians. The sales/marketing manager will be working in tandem to generate sales.  
Over the first three quarters during this year, IonSeq will have put online 5 sequencers in each 
quarter. During the fourth quarter, IonSeq will be able to prove 40 genomes/day output – though 
actual sales may prove to be less than throughput. 
11.B. WORK DAY 
 
The Gantt chart in Figure 39 illustrates Series A start-up phase of IonSeq, which supports a 
throughput of 10 genomes per day or 2,500 genomes over a year, using five Proton II machines (at 
specifications) with any multiplexing. Pre-sequencing steps can be executed in parallel during the 
day in preparation for sequencing in the next day. Each sequencer runs for 8 hours, out of which 2-
4 hours is committed to collecting raw data from the sequencing chip and the remaining time is 
committed to base calling, alignment, and genome reconstruction.  Mapping and alignment is 
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completed on an accompanying server, off of the sequencer machine; this process will take an 
additional 4 hours. The Gantt chart is built upon these specified times. 
 
Figure 39: Gantt chart for work day flow for Series A startup period.  
 
For Series B, at a throughput of 40 genomes per day or 10,000 genomes over a year, IonSeq 
will employ 20 Proton II machines, organized over a similar work flow as shown for 5 Proton II 
machines.  However, another option is to employ barcoding of the genomes, which would allow the 
sequencing of two genomes on one run of the Proton Sequencer. Figure 40 shows a revised Gantt 
chart, illustrating the need for only 3 Proton Sequencers in order to sequence at least 10 genomes 
in a day. The additional change is the continuous running of the servers to finish the mapping and 
alignments of the increased number of genomes processed per sequencer. 
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Figure 40: Gantt Chart for Series A with barcoding option shows a need for fewer Proton II machines 
but the mapping & alignment servers will be run more often.  
 
Taking into consideration the optimizations covered in section 9, the sequencer run time 
can be reduced to about 6 hours. It was shown that by choosing lead titanate as the sensor surface 
material, the attenuation time can be cut down almost by a factor of 4. However, this will only affect 
the actual sequencing run and not the data analysis time (4-6 hours on the sequencer). Therefore, 
the run time for the sequencer is only reduced from 8 to 6 hours even despite the significant drop in 
signal attenuation time. As Figure 41 shows, this results in the mapping & alignment time to 
become the bottleneck. 
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Figure 41: This Gantt chart for the optimized sequencing chip  shows that the mapping & alignment 
processes become the bottlenecks.  
 
The additional down time for the sequencers will prove wise as the extra time can be used for 
upkeep and maintenance. However, it is obvious that cutting down on the machine and server run 
times will also depend on optimizing the data analysis steps, not just the sequencing cycles on the 
chip. 
 
11.C. BUSINESS REQUIREMENTS 
11.C.I. SUPPLY CHAIN REQUIREMENTS 
 
IonSeq’s main suppliers will include Ion Torrent/Life Technologies for the sequencing chips 
and sequencing kits, and distributors such as Sigma Aldrich and Fischer Scientific for raw materials 
and wet laboratory supplies. 
11.C.II. FACILITY REQUIREMENTS – SPACE 
 
There will be the need for sufficient dry and wet lab space to hold the 5 and 20 
sequencers/servers required in Series A and Series B phases including the pre-sequencing 
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equipment.  In addition, space will be needed for administrative purposes. For Series A, IonSeq will 
use a 1,400 sq. ft. lab space. For Series B, IonSeq will expand into a 3,700 sq. ft. facility. The 
sequencers can be stacked in pairs using a special rack, taking up approximately 5 sq. ft. of space. 
Each server will be placed next to the sequencers, and each server takes up about 2 sq. ft. Other 
important pieces of equipment include a storage refrigerator, the Ion Touch 2 systems, and the DNA 
extraction materials along with space reserved for administrative purposes. 
11.C.III. EQUIPMENT REQUIREMENTS 
 
The Ion Proton System itself consists of the Sequencer and the Torrent Server. In-depth 
specifications are listed in Appendix D. The Sequencer not only performs the raw sequencing, but 
also carries out preliminary base-calling actions. The rest of the genome’s base calling and 
alignment is performed off the Sequencer and on the Torrent Server. The Sequencer, weighing in at 
130 lbs., consists of dual 8-core Intel® processors with 128 MB of memory, 11 TB of storage, and an 
NVIDIA® GPU processor all run by open-source Ubuntu® operating system. The Server is similarly 
specified, but includes 27 TB of storage, and two NVIDIA® GPU processors, weighing about 120 lbs. 
The entire Ion Proton™ system is connected to a cloud server with a large enough disk space to 
store the data generated from the Sequencer at a throughput of 40 genomes/day.  
The size of a haploid human genome is roughly 3 giga-base pairs (Gb). The hardware space 
required to store 1 Gb is 250 megabytes (MB)90. Thus the space required to store data on the server 
for a 40 genomes/day throughput with 30X coverage is shown in the calculations in Equation 48. 
 
Equation 48 
           
    
      
              
     
  
        
 
This is approximately 1 TB generated per day. After realignment, discussed below, the data from 
the raw reads will be discarded and the final report will be stored on the cloud computing server 
                                                             
90 Discussion with Dr. Brian Gregory, Assistant Professor of Biology, University of Pennsylvania 
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for a period of one month. Within this time the customers will be able to securely access the server 
and download the report. Over the course of the month, 20 TB of storage on the cloud server will be 
needed. Delivery of the product will be carried out over this cloud service to eliminate the need for 
physical shipping. IBM SmartCloud Enterprise services will be considered and priced to handle the 
large genome files that IonSeq will be producing.  
11.C.IV. INFORMATION TECHNOLOGY PLAN  
 
Apart from the equipment needed for sequencing, capable business computers will be 
needed for administrative purposes. Four machines will be purchased for Series A for use by the 
CEO, CTO, CFO, and secretary. Furthermore, IonSeq will invest into security systems for its IT 
infrastructure to protect its equipment and its products from outside interference. Considering the 
ambiguous HIPAA privacy regulations around DNA sequences and the potential for future rules, 
IonSeq will ensure that the data collected in the sequencing runs are safely stored and are 
transferred to the client over secure servers91.  
11.C.IV. LABOR 
 
The Chief Executive Officer will be in charge of the major strategy decisions for IonSeq and 
will have significant experience in field of next-generation DNA sequencing. The Chief Technology 
Officer will be the chief engineer in charge of coordinating the other engineers and R&D direction of 
the company. The Chief Financial Officer will be responsible for ensuring the financials of the 
company are in order and consistent positive cash flow is maintained. Furthermore, they will be in 
contact with investors. The sales manager will be responsible for reaching out to pharmaceutical 
companies and other potential clients. The marketing manager will be responsible for promoting 
IonSeq among the DNA sequencing community, both in industry and in academia. The secretary will 
                                                             
91 "HIPAA, the Privacy Rule, and Its Application to Health Research." NCBI, Web. 
<http://www.ncbi.nlm.nih.gov/books/NBK9573/>. 
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be organizing the administrative side of the office, receiving incoming samples, and aiding the CFO 
in accounting needs. The engineers will be the managers of the technicians, contribute to R&D 
efforts, troubleshoot, and aid the workflow. The technicians will be responsible for pre-sequencing, 
running the sequencers, carrying out alignment on the servers, and troubleshooting. Details 
regarding the breakdown on compensation, equity, and working hours can be found in the 
following Financials section. 
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12. FINANCIAL ANALYSIS 
 As prefaced, IonSeq will be the service arm of Ion Torrent, engaging in a rapidly developing 
market. As a high-risk, high-reward biotechnology firm, IonSeq must be projected to perform well 
to satisfy its investors. The following financial analysis will address the profitability of this venture, 
exploring the investor’s rate of return and net present value, after evaluating various income 
statements and cash flows. 
 Assuming that the base Ion Torrent technology is thus far market proven by research labs, 
the financial landscape for IonSeq will be addressed in the two phases: the scale-up stage and the 
revenue-generating stage. The first phase will generate no revenue, and will be funded with a Series 
A investment, covering the necessary equipment, labor, materials, and administrative costs to 
achieve a throughput of 10 genomes/day over 250 days/year, or 2,500 genomes/year. After the 
first year, with the assistance of a significant Series B funding, IonSeq will ramp up its facilities and 
labor requirements in order to achieve a four-fold increase in throughput – 10,000 genomes per 
year – through the remaining three years in this financial forecast.  At that point, the rapid 
advancement of the field may pose new challenges for IonSeq, and new technologies will influence 
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the business model beyond this evaluation. IonSeq will seek acquisition by a major pharmaceutical 
corporation, aiming to create a significant footprint in personalized medicine. 
12.A. REVENUE PROJECTIONS 
 
Projecting sales is a crucial part for a profitability analysis. IonSeq will not intend to meet 
the $1,000 sequencing cost per genome that has been an established goal of the Archon XPrize; 
instead, understanding the value-add of a genome sequencing service, will price each genome at a 
premium. Sensitivity analyses performed later in this section as well as the history of cost/genome 
in Figure 42b will show a $2,000/genome price tag to be appropriate for healthy investors’ rates of 
return. 
 Observing the rate of increase of human genomes sequenced over the past few years in 
Figure 42a, there is an exponential increase in the number of genomes, limited primarily by the 
sequencing technology. While it is difficult to forecast IonSeq sales, it is not difficult to see the 
growing demand for human genome sequencing. This growth can give some direction in revenue 
projections for IonSeq. Over the Series B, three year period, IonSeq predicts sequencing sales of 
5,000, 7500, and 10,000 genomes as outlined in Table 27. 
 
 
Figure 42a: The number of genomes sequenced over the past six years has exponentially grown92. b: This 
rapid increase has primarily been the result of decreasing costs per genome 93.   
                                                             
92 Duncan, D. (2011, September 23). A dna tower of babel: As more and more people’s genomes are decoded, we need 
better ways to share and understand the data. MIT Technology Review, Retrieved from 
http://www.technologyreview.com/news/425521/a-dna-tower-of-babel/ 
93 Wetterstrand, K. (2013, Feburary 11). dna sequencing costs: Data from the nhgri genome sequencing program (gsp) . 
Retrieved from http://www.genome.gov/sequencingcosts/ 
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Table 27: Projection of Revenue for Years 1-4 
  
Year 1 Year 2 Year 3 Year 4 
Units Sold 
 
2,500  5,000  7,500  10,000  
Price per Unit 
 
$0.00  $2,000.00  $2,000.00  $2,000.00  
      Net Revenue 
 
$0  $10,000,000  $15,000,000  $20,000,000  
 
12.B. VARIABLE AND FIXED COSTS 
  
To help inform IonSeq’s price tag per genome, costs must be evaluated, including variable 
costs (per genome), fixed equipment costs, overhead costs, and budgets for R&D and 
sales/marketing. These costs are extensively catalogued in Table 28and Appendix H.  
Table 28: Variable Costs of a Sequencing Run 
 
Equipment Price 
- PII™ Chip $350.00 
- Ion Plus Fragment Library Kit $25.00 
- Ion PI™ Template OT2 200 Kit $83.00 
- Ion PI™ Sequencing Kit  $67.50 
- Ion Proton Controls Kit $100.00 
- 10 M NaOH [$71.40 for 100 mL] $1.40 
- Isopropanol (99.7%) [$265 for 20 kg] $0.34 
- Nuclease-free Water [$96.70 for 5 L] $0.19 
- 10 L of 1N HCl [$91.20 for 10 L] $0.09 
- Ethanol (200 proof) [$315 for 6-500 mL bottles] $1.05 
- 500 mL TE Buffer, 1X Solution pH 8.0, low EDTA $0.63 
- Pipette Tips  
    P2 $0.27 
    P20 $0.27 
    P200 $0.27 
    P1000 $0.32 
- Thin Wall PCR Tubes, Flat Cap $5.00 
- 1.5 mL microcentrifuge tubes $0.20 
- Agencourt AMPure XP - PCR Purification $2.11 
- Agilent® High Sensitivity DNA Kit $4.61 
- MagaZorb DNA Common Kit-200 $2.00 
- Ion Xpress™ Barcode Adapters 1-96 Kit (partial 
purchase) 
$1.56 
- Bioruptor® NGS 0.65 ml Microtubes for DNA Shearing 
(500 tubes) 
$0.34 
- Pippin Prep™ Kit 2010  $4.50 
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The significant assumption is the cost of the Proton chips.  There is a lack of information 
regarding the actual production cost of a single chip. Based off Ion Torrent retail price, IonSeq 
decided to base the variable cost of the chip to be half of the quoted sales price. Instead of the 
quoted $700 price, IonSeq used a variable cost of $350 to evaluate profitability. In total, including 
reagents and other materials, the cost of sequencing a genome is $645. 
 The major pieces of capital equipment are listed in Table 29 and Appendix I. The most 
significant items are the Proton Sequencers and Servers. The bundle is quoted at $249,000. IonSeq 
will take this price as being an accurate value, and it will dominate total capital investment. 
Table 29: Components of Capital Equipment 
 
Equipment Unit Price 
- Ion Proton II, including Ion Server $224,000.00 
- Maxwell Research System $30,000.00 
- Ion OneTouch 2 System $19,000.00 
- Nitrogen (grade 4.8, 99.998% or better) $70.00 
- Water Purification System (Elga Purelab Flex 3) $5,000.00 
- Multistage gas regulator (VWR, 55850-422) $375.00 
- Lab Freezer $1,000.00 
- Uninterruptable Power Supply (UPS) $200.00 
- Microcentrifuge $1,995.00 
- Galaxy Mini Centrifuge $401.25 
- Pipettes  
     P2 $335.00 
     P20 $297.00 
     P200 $297.00 
     P1000 $297.00 
- 1 L Glass Bottles $9.40 
- Vortex Mixer $800.00 
- Thermal Cycler $8,000.00 
- Tygon Tubing $2.00 
- Magnetic Stirrer $230.00 
- Magnetic Stir Bars 10 
- Vacuum filtration system (pore size 0.45 um) $83.40 
- Orion 3-Star Plus Benchtop Meter Kit with probes $752 
- Squirt bottles $5.00 
- 50 mL Syringe $1.85 
- DynaMag™-2 Magnet $531 
- Agilent® 2100 Bioanalyzer® instrument $19580 
- Heat Block/Water Bath $160 
- Incubator $183 
- BioRuptor® NGS Sonication System $13000 
- Pippin Prep™ System $15000 
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12.C. LABOR 
  
During phase A, labor requirements are less than for Series B when throughput is 
quadrupled. In Phase A, a CEO, CFO, CTO, secretary, 2 engineers, 4 technicians, and a marketing 
manager will be employed.  The engineers and technicians will oversee the pre-sequencing process 
as well as the five Ion Torrent Proton sequencing machines. The work day will be 16 hours, from 6 
AM to 10 PM.  Each technician and engineer will work 8 hour shifts. Two technicians will be 
responsible for all the pre-sequencing processes, over an 8 hour period.  Two other technicians will 
oversee the sequencing machines in 8 hour shifts.  An engineer will be on hand during each 8 hour 
shift as well. 
In Phase B, a CEO, a CFO, a CTO, a secretary, 6 engineers, 10 technicians, a marketing 
manager, and a sales manager will be employed. The engineers and technicians will oversee the 
pre-sequencing process, which is still highly paralleled. However, they will be overseeing 20 Ion 
Torrent sequencing machines. The work day will be 16 hours, from 6 AM to 10 PM.  Each technician 
and engineer will work 8 hour shifts. Two technicians will be responsible for all the pre-sequencing 
processes, over an 8 hour period.  8 other technicians will oversee the sequencing machines in 8 
hour shifts. There will be 4 technicians overseeing 10 machines over their 8 hour shift. Three 
engineers will be on hand during each 8 hour shift. 
12.D. LOCATION 
 
IonSeq will be located in the suburbs of Boston, Massachusetts, due to the abundance of 
research centers around the Boston area (Massachusetts Institute of Technology, Massachusetts 
General Hospital, Harvard Medical School) and pharmaceutical companies located in the vicinity, 
including Merck, Teva Pharmaceuticals, Perkin Elmer Life Sciences, Celgene, and Novartis. The rent 
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for office space and lab space will approximately $30 per square foot for 1,400 sq. ft. for the Series A 
phase.  Expanding for Series B will require 3,700 sq. ft. at $23 per square foot94. 
12.E. OTHER GENERAL AND ADMINISTRATIVE 
  
Delivery of the product will be carried out over a cloud service to eliminate the need for 
physical shipping. IBM SmartCloud Enterprise services were considered and priced to handle the 
large genome files that IonSeq will be producing.  To allow clients to access their sequences at any 
time over the period of a month will require $23,717 per month for the IBM SmartCloud service. At 
the expected throughput of 40 genomes/day or 800 genomes/month, that comes out to a $29 
premium per genome, respectable considering the conveniences of using this cloud service. 
Utilities, legal/accounting fees, telephone service, lab insurance, and other supplies and 
postage will make up the other general and administrative expenses. 
12.F. DEPRECIATION SCHEDULE 
  
IonSeq will employ the 5-year MACRS depreciation schedule to assist in increasing tax 
savings from capital expenditures. The depreciation discounts are 20%, 32%, 19.20%, 11.52%, 
11.52%, and 5.76%. However, since this report is evaluating IonSeq on the four year time scale, 
only the first three percentages will be employed.  Year 0 depreciation will not be tallied. 
Depreciation will count under the operating expenses, distributing the burden of the capital 
expenditures across the life time of the company. 
12.G. WORKING CAPITAL 
  
Working capital is an important element in the financial health of the company, working to 
support the company’s obligations until accounts receivable are on hand. Essentially, it covers the 
difference between the company’s current assets and current liabilities, measuring the firm’s 
                                                             
94 Cummings Properties. (n.d.). Affordable lab space for lease. Retrieved from 
http://www.cummingsproperties.com/lab_space.htm 
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liquidity. This value includes cash reserve, inventory, accounts payable, and accounts receivables. It 
will be factored into the necessary capital investments in the first production year. At the beginning 
of the second production year, with sufficient cash on hand from revenue generated from the 
production year, working capital will not be significant factor. The value of the working capital 
accounted for in the first production year will be added back into the cash flow statement at 
acquisition. 
Inventory for 7 days will be considered, expressed in Equation 49. These will be the 
sequenced genomes, in raw data form, ready to be shipped or transmitted to the customer. 
 
Equation 49 
          ( )  
       
        
        
 
Accounts receivables will be based upon 30 days, assuming that customers will have 30 days to pay, 
and this value is shown in Equation 50. This is based off the revenue generated. 
 
Equation 50 
                     (  )  
       
        
         
 
Accounts payable by the company will be based upon 30 days, which includes the costs of goods 
sold, as shown in Equation 51. 
 
Equation 51 
                 (  )  
             
        
         
 
Cash reserve will cover 30 days of operation expenses, salaries, and other general expenses, and is 
calculated in Equation 52. 
 
Equation 52 
             (  )  
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In sum, the working capital is the difference between the company’s current assets and current 
liabilities and can be expressed by Equation 53, taking all the previous elements above into account. 
 
Equation 53 
                           
12.H. KEY RATIOS 
 
From the income statement, three key ratios can be calculated and each provides key 
information about the health of the company. The gross margin is calculated as the gross profit 
divided by revenue. This paints a picture of the company’s profitability just based upon revenues 
and costs of goods sold. As an advanced biotechnology company, IonSeq seeks incoming revenue to 
be substantially greater than the costs to sequence. In Appendix J, Pro Forma 1 shows a gross 
margin of a healthy 67%. The operating margin is found by dividing pre-tax income by revenue. 
This illustrates the burdens of income taxes levied on the company, and IonSeq still has a healthy 
margin about 40%.  The profit margin is final profitability ratio, the net income after tax divided by 
revenue. IonSeq maintains a profit margin of 25%-32% at the price point of $2,000. 
Furthermore, from the cash flow statement, current and quick ratios are important metrics 
to ensure liquidity95.  Ratios greater than one indicate that the company will be able to cover its 
liabilities with incoming cash. The current ratio is simply current assets divided by current 
liabilities. The quick ratio is the difference of current assets and inventory divided by current 
liabilities. In Pro Forma 1, IonSeq maintains healthy current and quick ratios around 3.60 to 4.74. 
12.I. INVESTMENTS/EQUITY DISTRIBUTION 
 
The Series A investment must cover total working capital, capital equipment, and all costs of 
materials needs to meet cited throughput, in the first year. Series B investment must cover the 
additional capital costs for upgrading our facilities for higher throughput as well as working capital 
                                                             
95 Berman, Karen, and Joe Knight. Financial Intelligence for Entrepreneurs. Boston: Harvard Business, 2008. Print. 
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costs.  Series A investors will receive a greater return on their investment due to the greater risk 
inherited in the startup phase. Series B will invest one year later in the first revenue-generating 
year. In the first year, Series A investors will invest and take 90% equity in the company, with the 
founding members receiving a 10% equity stake. Series B investors will make their investment at 
the beginning of year 2, and they will take a 32% share of the company, reducing Series A investors’ 
equity stake to 61% and the founders to 7%. This breakdown is shown in Appendix J. 
12.J. DETERMINING RATE OF RETURN 
 
In order to determine the return on investments for both Series A and Series B investors, 
the ultimate value of IonSeq needs to be derived. Valuation is highly subjective and is an area of 
dispute among the founders, investors, and potential acquirers.  For this analysis, IonSeq will use 
the Perpetuity Growth Model96, which yields a prospective terminal value as calculated in Equation 
54: 
 
Equation 54 
                         
             
                         
 
 
The discount rate will for the terminal value calculation will be taken to the discount rate 
attributed to Series B investors, or 25%. Series A investors will take a 50% discount rate due to the 
risk in their investment.  At a sample growth rate of 5%, IonSeq’s terminal value is $94,996,923, as 
opposed to $70,311,677 assuming a growth rate of 0%. 
The net present value (NPV) of the company is the sum of present values of each yearly cash 
flow, and the present values can be calculated in Equation 55. 
 
Equation 55 
                           
                    
(               )    
 
 
                                                             
96 Damodaran, Aswath. "Closure in Valuation." NYU Stern, n.d. Web. 31 Mar. 2013. 
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Discounted cash flow is the net earnings minus depreciation. Cash flows are delineated in 
Appendix J. The NPV of IonSeq is $39,322,347 at the end of year 4 at a proposed growth rate of 5%. 
Modified Internal Rate of Return (MIRR), expressed in Equation 56, is a more desirable 
metric to measure the investors’ rates of return97. Straightforward IRR makes a significant 
assumption that positive cash flows are reinvested into the company. 
 
Equation 56 
      √
(                                                       )
(                                               )
 
   
 
Reinvestment rate is the rate of return the company can expect to earn from investing their capital 
in other low-risk financial vehicles—3 year Treasury Yield, 0.38% as of March 21st, 2013, and the 
finance rate is the annual percentage rate paid to lenders—this value can be estimated from the U.S. 
Treasury’s Long Term Rate Data, 2.76% as of March 21st, 201398. In one instance, as seen in Pro 
Forma 1, Series A investors receive a MIRR of 102.98% and Series B investors have a MIRR of 
93.43% after the end of year 4. These are appropriate returns on investments for a high-risk 
biotechnology startup. 
 
12.K. SENSITIVITY ANALYSES 
 
To better understand the impact of price/genome on returns on investment, a sensitivity 
analysis was carried out, where the price tag was changed from $1,000 to $2,000. The results of the 
MIRRs and IRRs are shown in Figure 43. With a price per genome set at $2,000, IonSeq’s investors 
can expect to see very respectable returns on their investments. Furthermore, the use of MIRR over 
IRR is justified as IRR overestimates investors’ true returns. 
                                                             
97 "Modified Internal Rate Of Return - MIRR." Investopedia, Web. <http://www.investopedia.com/terms/m/mirr.asp>. 
98 U.S. Department of the Treasury, (2013). Daily treasury long term rate data. Retrieved from website: 
http://www.treasury.gov/resource-center/data-chart-center/interest-rates/Pages/TextView.aspx?data=longtermrate 
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Figure 43: Sensitivity analysis shows the rate of increase in IRR/MIRR falling off as price grows . 
  
Another important sensitivity analysis includes varying the prospective sales numbers. In 
Figure 44, healthy rate of returns exist even if the sale projections are overestimated by 25%. 
However, there is a steep drop if IonSeq severely underperforms. If the sales projections are 
overestimated by 75%, investors will have suffered losses on their investments. On the opposite 
side, the rates of return are limited by IonSeq’s maximum throughput of 10,000 genomes per year, 
resulting in the leveling out as seen in the same figure. 
 
Figure 44: An overestimation of sales by 75% would lead negative returns for investors.  
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12.L. BARCODING SCHEME – BRIEF FINANCIAL PICTURE 
 
If barcoding is employed with the ‘Proton III’ chip with 30x coverage and 1 billion wells, 
that slashes the capital requirements in half. The labor staff will be maintained as the same number 
of genomes must be processed. At the same price point, $2,000/genome, the MIRR for Series A 
investors is 127.65% and for Series B investors, 102.4%, with a NPV of $47,781,308 and a terminal 
value of $108,422,128 at a proposed 5% growth rate.  The overall pro forma is found in Appendix K. 
 
12.M. FINANCIAL TAKEAWAYS 
 
 From the complete financial analysis performed in this chapter, IonSeq has the potential to 
handsomely reward its investors with returns on investments as expected for this type of high-risk, 
high-reward biotechnology venture. Sensitivity analyses help to support IonSeq’s claims for their 
investors’ returns; even if sales are overestimated, both investors in Series A and Series B phases 
will still receive healthy returns of 103% and 93%, given investments of $3,682,886 in Year 1 and 
$4,510,491 in Year 2.  Furthermore, IonSeq has structured its finances so to maintain high current 
and quick ratios to ensure quick liquidity when the acquisition or liquidity event arrives. At the end 
of the four year window, IonSeq expects an NPV of $39,322,347 and an overall terminal value of 
$94,996,923 at a conservative growth rate of 5%. This financial picture of IonSeq demonstrates a 
remarkably strong candidate for investment. 
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13. CONCLUSIONS 
  
Taking advantage of the scalability of semiconductor technology in the context of genomics 
and competitively entering the marketplace with a unique service business model, IonSeq is 
projected to be a significant player in the rapidly expanding genomics industry. The current Proton 
II technology can be employed to deliver rapid, accurate genome sequences—at a throughput of 
10,000 genomes per year—with healthy returns on investment at a cost per genome of only $2,000.  
As the industry is rapidly evolving, innovations will most certainly challenge IonSeq to 
remain ahead of the curve. The team has a firm understanding of the technology and is fully aware 
of the technical bottlenecks, from nucleotide kinetics to dephasing and error rates, which limit 
genomic throughput. The potential solutions presented here for a proposed Proton III chip, 
including the transition to different sensor materials and more advanced manufacturing standards, 
indicate IonSeq’s commitment to finding new ways to deliver sequenced genomes faster to its 
clients.  The era of personalized medicine is here, and IonSeq is here to deliver. 
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15. APPENDICES 
APPENDIX A 
 
Determining if library amplification is required 
 
The unamplified library can be quantified by quantitative PCR (qPCR) with the Ion Library Quantitation Kit. 
This kit directly determines the library dilution that gives a suitable concentration for template preparation 
(~26 pM).  
 
1. Determine the Template Dilution Factor (TDF) for the unamplified library with the Ion Library 
Quantitation Kit. 
 
2. Dilute the unamplified library for the qPCR as follows.  
- 100 ng-input: 1:1000 dilution  
- 1 μg-input: 1:2000 dilution  
 
3.  Calculate the number of template preparation reactions that can be performed with the unamplified 
library as follows:  
 
                
                  μ       
                                            μ 
 
 
The volume per template preparation reaction is:  
- 20 μL if using the Ion OneTouch™ 200 Template Kit v2 or the Ion OneTouch™ 200 Template  
 
If the estimated number of template preparation reactions is sufficient for the experimental requirements, no 
amplification is necessary. 
 
Source: Ion Torrent User Guide. Ion Xpress™ Plus gDNA Fragment Library Preparation. 2012. Publication Part 
Number 4471989 Rev. E downloaded from Life technologies website. 
http://products.invitrogen.com/ivgn/product/4471269 
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APPENDIX B 
 
Qualifying and pooling barcoded libraries 
 
1. Assess the size distribution of individual barcoded libraries 
Analyze an aliquot of each barcoded library with an Agilent® High Sensitivity DNA Kit, as indicated 
in the following table.  
 
 
2. Pool barcoded libraries using qPCR (unamplified libraries or amplified libraries) 
 
1. Use the Ion Library Quantitation Kit to directly determine the library dilution by quantitative real-time 
PCR (qPCR) for each individual barcoded library  
 
2. Dilute each barcoded library according to its dilution factor. This will result in a library concentration of 
~26 pM.  
 
3. Prepare at least 20 μL of a barcoded library pool by mixing equal volumes of the diluted barcoded 
libraries. The library pool will be at the correct concentration for template preparation using the 
appropriate template kit. No further dilution of the library pool is necessary.  
 
3. Pool barcoded libraries using Bioanalyzer® quantitation (amplified libraries only) 
 
1. From the Bioanalyzer® analysis used to assess the individual barcoded library size distribution, 
determine the molar concentration in pmol/L of each barcoded library using the Bioanalyzer® software.  
 
2. Prepare an equimolar pool of barcoded libraries at the highest possible concentration.  
 
3. Determine the molar concentration of the library pool.  
 
4. Determine the dilution factor that gives a concentration of ~26 pM. This concentration is suitable for 
template preparation using either Ion Xpress™ Template Kits or Ion OneTouch™ Template Kits. Use the 
following formula:  
                
                                
     
  
 
Example  
The library pool concentration is 10,000 pM.  
Dilution factor = 10,000 pM/26 pM = 385  
Thus, 1 μL of library pool mixed with 385 μL of Low TE (1:385 dilution) yields approximately 26 pM. 
Use this library dilution for template preparation. 
 
Source: Ion Torrent User Guide. Ion Xpress™ Plus gDNA Fragment Library Preparation. 2012. Publication Part 
Number 4471989 Rev. E downloaded from Life technologies website. 
http://products.invitrogen.com/ivgn/product/4471269 
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APPENDIX C 
 
Determining Template Dilution Factor for emPCR 
 
For 10–30% of positive Ion Sphere™ Particles, a Template Dilution Factor is required that gives 70 × 106 
molecules per 5 μL 
  
Use a conversion factor of 8.3 nM = 5 × 109 molecules/μL for the region of interest, excluding peaks outside of 
the desired range; and use the following formula: 
 
                                                     
     
         
μ 
      
 
 μ 
               
 
 
Example 
 
If the library concentration is 10 nM, 
                               
     
         
μ 
      
 
 μ 
               
     
 
Thus, 1 μL of library mixed with 429 μL of Low TE (1:430 dilution) yields approximately 70 × 106 molecules 
per 5 μL. 
 
 
 
 
Source: Ion Torrent User Guide. Ion Xpress™ Plus gDNA Fragment Library Preparation. 2012. Publication Part 
Number 4471989 Rev. E downloaded from Life technologies website. 
http://products.invitrogen.com/ivgn/product/4471269 
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APPENDIX D 
Specifications for the Ion Proton™ Sequencer 
Working environment 
(for indoor use only) 
Temperature: 68-77° F (20-25° C) 
Humidity: 40-60%, noncondensing 
Altitude: <6,500 ft (2,000 m) 
Clearances: 
12 in (30.5 cm) in rear 
4 in (10 cm) on left side 
4 in (10cm) on right side 
4 in (10 cm) from front edge of bench to sequencer bezel 
36 in (90 cm) aisle in front of bench for operator access 
Optional rack mounting with two Ion Proton™ Sequencers per rack† 
Gas Supply Connection: 0.25 in push-to-connect fitting 
Pressure: 30 psi 
Composition: nitrogen (grade 4.8, 99.998% or better) 
Other connections Ethernet: 1 GigE  
USB: 2x USB 2.0 
Power Voltage: 100 V (min) to 240 V (max) 
Current: 14 A (max) 
Frequencing: 50/60 Hz 
Power Draw: 1,350 W 
Dimensions Width: 21.3 in/54.2 cm 
Depth: 30.5 in/77.5 cm 
Height: 18.7in/47.4 cm 
Weight Crated for shipment: 200 lb/90.7 kg 
Free-standing: 130 lb/59 kg 
Instrument compute 
hardware 
Processor: Dual 8-core Intel
®
 Xeon
®
 Sandy Bridge 
Memory: 128 GB RAM 
FPGA: Dual Altera
®
 Stratix
®
 V 
GPU processor: 1 x NVIDIA® Tesla® C2075 
Storage: 11 TB (SSD and HDD) 
Operating system: Ubuntu
®
 11:10 
Specifications for the Proton™ Torrent Server* 
Product configuration A single free standing tower computer appliance, included with the purchase of the Ion 
Proton™ System. Includes Torrent Suite Software with all necessary software components to 
deliver signal processing, base calling, read alignment, and variant calling. 
Processor Dual 8-core 2.9 GHz CPUs 
Memory 128 GB RAM 
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GPU processor 2x NVIDIA
®
 Tesla
®
 GPUs 
Storage (approx.) 27 TB (sufficient for storage of >50 Ion PI™ Chip runs) 
Operating system Ubuntu 10.04 
Dimensions (approx.) Width: 8.5 in/21.8 cm 
Depth: 28 in/71.4 cm 
Height: 17 in/43 cm 
Weight (approx.) 120 lb/55 kg 
Power Voltage: 100 V (min) to 240 V (max) 
Frequency: 50/60 Hz 
Current: 12 A (max) 
Power Draw: 1,100 W 
Specifications for the Ion OneTouch™ System 
System Ion OneTouch™ System (Cat No. 4470001) includes: 
• Ion OneTouch™ Instrument 
• Ion OneTouch™ ES 
Dimensions 
and weight 
• Ion OneTouch™ Instrument: 
(12 in x 16 in x 14 in, 23 lb; 30 cm x 41 cm x 36 cm, 10.4 kg) 
• Ion OneTouch™ ES: 
(9.5 in x 12.5 in x 11 in, 12 lb; 24 cm x 32 cm x 28 cm, 5.4 kg) 
System run time 4 hours total time, minutes of hands-on time 
Throughput Supports template preparation for Ion 314™ chips, 
Ion 316™ chips, and Ion 318™ chips* 
Library types Supports template preparation with a broad range of libraries 
used for various applications: 
• Genomic DNA (fragment and mate-paired) 
• Amplicon 
• RNA (cDNA) 
Operating environment Temperature: 15-25°C; humidity: 20–80%, noncondensing 
Consumables Ion OneTouch™ System Template Kit (Cat No. 4468660) 
Power requirements 110/220 V (US/International) 
Multiplexing Up to 384 barcoded libraries for DNA- or RNA-based applications 
 
Source: "The Ion Proton™ System: Rapid Genome-scale Benchtop Sequencing." Life Technologies. 
<http://tools.invitrogen.com/content/sfs/brochures/CO111809_Specification%20Sheet_Ion%20P
roton%20System_0712.pdf>.   
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APPENDIX E 
 
MATLAB Code for Kinetics and Signal Model 
 
%% Design Parameters, changeable 
WellDiameter = 0.70; %um 
BeadSize = WellDiameter/1.25; %um, should be a large fraction of well 
diameter 
dNTPconc = 100; %uM 
Strands = 100000; %number of templates on a bead 
  
Temp = 310; %K, must be aware of temp sensitivity for polymerases 
pHbulk = 8;  
  
select_coeff = 0.93; %material dependent 
pHpzc = 7; %material dependent, "pH at point of zero charge" 
  
tau_0 = 130; %microseconds, material dependent, ranges from 60-200, smaller 
means signal attenuates faster 
  
%Set time 
tf = 4; 
dt_inc = 0.001; 
t_inc = 0:dt_inc:tf; 
  
%Flow 
VolFlowRate = 4; %mL/s 
  
%%do not modify 
 
WellDepth = WellDiameter; %um 
WellVolume = 3.14*((WellDiameter*10^-4)/2)^2*(WellDepth*10^-4); %mL 
  
BeadVolume = 4*3.14/3*(BeadSize/2*10^-4)^3; %mL 
WellVolumeAvail = WellVolume - BeadVolume; %mL 
  
kB = 1.38*10^-23; 
q = 1.60*10^-19; %coulombs, elementary charge 
  
ProtonDiff = 9*10^-9; %m^2/s 
tau_p = WellDepth^2/(ProtonDiff*(10^6)^2); %mean diffusion time for protons 
out of well 
  
%Signal Generation Values 
deltaPSI_deltaPH = ((2.3*kB*Temp)/q)*select_coeff*1000; 
PSI_not = (pHbulk-pHpzc)*deltaPSI_deltaPH; 
  
dielectric = 80.1; 
permittivity = 8.854*10^-12; %Farads/m 
Zs = 1; %charge number of ionic species 
Cs_initial = (10^-pHbulk)*exp(-q/(kB*Temp)*PSI_not/1000); %molar 
concentration of species, M 
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IonicStrength_initial = 0.5*Zs^2*Cs_initial; 
DebyeScreeningLength_initial = 0.3/(IonicStrength_initial^0.5)/10^9; 
C_dl_initial = dielectric*permittivity/DebyeScreeningLength_initial; 
  
%Signal Attenuation 
tau_s = tau_0*(10^(pHbulk/2))/10^6; %seconds 
  
%%Kinetic Data 
%k_pol, s^-1 
AtoA_kpol = 0.0036; 
AtoC_kpol = 0.1; 
AtoG_kpol = 0.042; 
AtoT_kpol = 45; 
  
CtoA_kpol = 0.1; 
CtoC_kpol = 0.003; 
CtoG_kpol = 43; 
CtoT_kpol = 0.038; 
  
GtoA_kpol = 0.05; 
GtoC_kpol = 37; 
GtoG_kpol = 0.066; 
GtoT_kpol = 1.16; 
  
TtoA_kpol = 25; 
TtoC_kpol = 0.012; 
TtoG_kpol = 0.16; 
TtoT_kpol = 0.013; 
  
%KD, uM 
AtoA_KD = 25; 
AtoC_KD = 160; 
AtoG_KD = 250; 
AtoT_KD = 0.8; 
  
CtoA_KD = 540; 
CtoC_KD = 140; 
CtoG_KD = 0.9; 
CtoT_KD = 360; 
  
GtoA_KD = 500;  
GtoC_KD = 0.8; 
GtoG_KD = 150; 
GtoT_KD = 70; 
  
TtoA_KD = 0.6; 
TtoC_KD = 180; 
TtoG_KD = 200; 
TtoT_KD = 57; 
  
% Observed rate constant 
AonA = ((AtoA_kpol*dNTPconc)/(AtoA_KD+dNTPconc)); 
AonC = ((AtoC_kpol*dNTPconc)/(AtoC_KD+dNTPconc)); 
AonG = ((AtoG_kpol*dNTPconc)/(AtoG_KD+dNTPconc)); 
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AonT = ((AtoT_kpol*dNTPconc)/(AtoT_KD+dNTPconc)); 
ConA = ((CtoA_kpol*dNTPconc)/(CtoA_KD+dNTPconc)); 
ConC = ((CtoC_kpol*dNTPconc)/(CtoC_KD+dNTPconc)); 
ConG = ((CtoG_kpol*dNTPconc)/(CtoG_KD+dNTPconc)); 
ConT = ((CtoT_kpol*dNTPconc)/(CtoT_KD+dNTPconc)); 
GonA = ((GtoA_kpol*dNTPconc)/(GtoA_KD+dNTPconc)); 
GonC = ((GtoC_kpol*dNTPconc)/(GtoC_KD+dNTPconc)); 
GonG = ((GtoG_kpol*dNTPconc)/(GtoG_KD+dNTPconc)); 
GonT = ((GtoT_kpol*dNTPconc)/(GtoT_KD+dNTPconc)); 
TonA = ((TtoA_kpol*dNTPconc)/(TtoA_KD+dNTPconc)); 
TonC = ((TtoC_kpol*dNTPconc)/(TtoC_KD+dNTPconc)); 
TonG = ((TtoG_kpol*dNTPconc)/(TtoG_KD+dNTPconc)); 
TonT = ((TtoT_kpol*dNTPconc)/(TtoT_KD+dNTPconc)); 
  
%%%%%%% 
n = 3; %homopolymer length 
NumberofProtonsProduced_AtoT = zeros(n,length(t_inc)); 
NumberofProtonsAfterDiffusion_AtoT = zeros(n,length(t_inc)); 
NumberofProtonsAfterDiffusion = zeros(n,length(t_inc)); 
pH_transient_AtoT = zeros(n,length(t_inc)); 
TotalProtonsProduced = zeros(n,length(t_inc)); 
TotalProtonsAfterDiffusion = zeros(n,length(t_inc)); 
TimeCutoff = zeros(1,n); 
  
dNTPconc_transient = zeros(n,length(t_inc)); 
dNTPconc_transient(1,:) = dNTPconc; 
  
SNR = zeros(n,length(t_inc)); 
Error = zeros(n,length(t_inc)); 
  
for y = 1:length(t_inc) 
    dNTPconc_transient(1,y) = dNTPconc*(1-exp(-t_inc(y)*AonT)); 
    dNTPconc_transient(2,y) = dNTPconc*(1-exp(-t_inc(y)*AonT))*(1-exp(-
t_inc(y)*AonT/2)); 
    dNTPconc_transient(3,y) = dNTPconc*(1-exp(-t_inc(y)*AonT))*(1-exp(-
t_inc(y)*AonT/3)); 
    dNTPconc_transient(4,y) = dNTPconc*(1-exp(-t_inc(y)*AonT))*(1-exp(-
t_inc(y)*AonT/4)); 
end 
  
%% Incorporation 
%for base A to strand T 
d = 0; e = 0; f = 0; 
  
%1 Base 
for i=1:length(t_inc) 
    NumberofProtonsProduced_AtoT(1,i) = 
AonT*dNTPconc*t_inc(i)*WellVolumeAvail*6.022*10^14; 
    if d == 0 
        TimeCutoff(1) = t_inc(i); 
    end 
    if NumberofProtonsProduced_AtoT(1,i)>Strands 
        NumberofProtonsProduced_AtoT(1,i)=Strands; 
        NumberofProtonsAfterDiffusion_AtoT(1,i) = 
NumberofProtonsAfterDiffusion_AtoT(1,t1); 
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        NumberofProtonsAfterDiffusion(1,i) = 
NumberofProtonsAfterDiffusion_AtoT(1,t1)*exp(-t_inc(i)-
(TimeCutoff(1))/tau_p); 
        d = 1; 
        pH_transient_AtoT(1,i) = -
log10((NumberofProtonsAfterDiffusion_AtoT(1,i)/(6.022*10^23)/WellVolumeAvail*
1000+10^-8)); 
    else 
        NumberofProtonsAfterDiffusion_AtoT(1,i) = 
AonT*dNTPconc*WellVolumeAvail*6.022*10^14*(tau_p*t_inc(i)-tau_p^2*(1+exp(-
t_inc(i)/tau_p))); 
        NumberofProtonsAfterDiffusion(1,i) = 
AonT*dNTPconc*WellVolumeAvail*6.022*10^14*(tau_p*t_inc(i)-tau_p^2*(1+exp(-
t_inc(i)/tau_p))); 
        t1 = i; 
        pH_transient_AtoT(1,i) = -
log10((NumberofProtonsAfterDiffusion_AtoT(1,i)/(6.022*10^23)/WellVolumeAvail*
1000+10^-8)); 
    end 
    SNR(1,i) = (NumberofProtonsProduced_AtoT(1,i))^0.5; 
end 
  
TotalProtonsProduced(1,:) = NumberofProtonsProduced_AtoT(1,:); 
TotalProtonsAfterDiffusion(1,:) = NumberofProtonsAfterDiffusion_AtoT(1,:); 
TotalProtonsPostDiffusion(1,:) = NumberofProtonsAfterDiffusion(1,:); 
  
%2 Bases 
for m=1:length(t_inc) 
    NumberofProtonsProduced_AtoT(2,m) = (AonT*dNTPconc*t_inc(m) + 
dNTPconc*(exp(-AonT*t_inc(m))-1)) * 6.022*10^14 * WellVolumeAvail; 
    if e == 0 
        TimeCutoff(2) = t_inc(m); 
    end 
    if NumberofProtonsProduced_AtoT(2,m)>Strands 
        NumberofProtonsProduced_AtoT(2,m) = Strands; 
        NumberofProtonsAfterDiffusion_AtoT(2,m) = 
NumberofProtonsAfterDiffusion_AtoT(2,t2); 
        NumberofProtonsAfterDiffusion(2,m) = Strands*exp((-t_inc(m)-
TimeCutoff(2))/tau_p); %find time at which number of protons produced = 
Strands 
        e = 1; 
    else 
        NumberofProtonsAfterDiffusion_AtoT(2,m) = 
6.022*10^14*WellVolumeAvail*(dNTPconc*(tau_p*exp(-AonT*t_inc(m))/(1-
AonT*tau_p)-tau_p)+AonT*dNTPconc*tau_p*(t_inc(m)-tau_p)); 
        NumberofProtonsAfterDiffusion(2,m) = 
6.022*10^14*WellVolumeAvail*(dNTPconc*(tau_p*exp(-AonT*t_inc(m))/(1-
AonT*tau_p)-tau_p)+AonT*dNTPconc*tau_p*(t_inc(m)-tau_p)); 
        t2 = m; 
    end 
end 
  
%Total for 2 bases 
TotalProtonsProduced(2,:) = NumberofProtonsProduced_AtoT(2,:) + 
NumberofProtonsProduced_AtoT(1,:); 
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TotalProtonsAfterDiffusion(2,:) = NumberofProtonsAfterDiffusion_AtoT(2,:) + 
NumberofProtonsAfterDiffusion_AtoT(1,:); 
TotalProtonsPostDiffusion(2,:) = NumberofProtonsAfterDiffusion(2,:) + 
NumberofProtonsAfterDiffusion(1,:); 
SNR(2,:) = (TotalProtonsProduced(2,:)).^0.5; 
  
%3 Bases 
for o=1:length(t_inc) 
    NumberofProtonsProduced_AtoT(3,o) = (1/3)*dNTPconc*(3*AonT*t_inc(o)-
2*exp(-3*AonT*t_inc(o)/2)+3*exp(-AonT*t_inc(o))+6*exp(-AonT*t_inc(o)/2)-7) * 
6.022*10^14 * WellVolumeAvail; 
    if f == 0 
        TimeCutoff(3) = t_inc(o); 
    end 
    if NumberofProtonsProduced_AtoT(3,o)>Strands 
        NumberofProtonsProduced_AtoT(3,o) = Strands; 
        NumberofProtonsAfterDiffusion_AtoT(3,o) = 
NumberofProtonsAfterDiffusion_AtoT(3,t3); 
        NumberofProtonsAfterDiffusion(3,o) = Strands*exp((-t_inc(o)-
TimeCutoff(3))/tau_p); %find time at which number of protons produced = 
Strands 
        f = 1; 
    else 
        NumberofProtonsAfterDiffusion_AtoT(3,o) = 
6.022*10^14*WellVolumeAvail*( (1/3)*dNTPconc*(3*AonT*tau_p*(t_inc(o)-tau_p) - 
4*tau_p*exp(-(3*AonT*t_inc(o)/2))/(2-3*AonT*tau_p) + 3*tau_p*exp(-
AonT*t_inc(o))/(1-AonT*tau_p) + 12*tau_p*exp(-AonT*t_inc(o)/2)/(2-AonT*tau_p) 
- 7*tau_p) ); 
        NumberofProtonsAfterDiffusion(3,o) = 6.022*10^14*WellVolumeAvail*( 
(1/3)*dNTPconc*(3*AonT*tau_p*(t_inc(o)-tau_p) - 4*tau_p*exp(-
(3*AonT*t_inc(o)/2))/(2-3*AonT*tau_p) + 3*tau_p*exp(-AonT*t_inc(o))/(1-
AonT*tau_p) + 12*tau_p*exp(-AonT*t_inc(o)/2)/(2-AonT*tau_p) - 7*tau_p) ); 
        t3 = o; 
    end 
end 
  
%Total for 3 bases 
TotalProtonsProduced(3,:) = NumberofProtonsProduced_AtoT(3,:) + 
TotalProtonsProduced(2,:); 
TotalProtonsAfterDiffusion(3,:) = NumberofProtonsAfterDiffusion_AtoT(3,:) + 
TotalProtonsAfterDiffusion(2,:); 
TotalProtonsPostDiffusion(3,:) = NumberofProtonsAfterDiffusion(3,:) + 
TotalProtonsPostDiffusion(2,:); 
SNR(3,:) = (TotalProtonsProduced(3,:)).^0.5; 
 
%% Signal 
Signal = zeros(n,length(t_inc)); 
SignalMaintain = zeros(1,n); 
  
Sigmas = 3; %standard deviations 
  
%Signal for 1 base 
for j=1:length(t_inc) 
    if (AonT*dNTPconc*t_inc(j)*WellVolumeAvail*6.022*10^14) < Strands %if the 
number of protons produed is less than the number of possible incorporations 
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        Signal(1,j) = PSI_not*(1-
C_dl_initial/(dielectric*permittivity/(0.3/10^9)*0.5^0.5*Zs*(AonT*dNTPconc*We
llVolumeAvail*6.022*10^14*(tau_p*t_inc(j)-tau_p^2*(1+exp(-
t_inc(j)/tau_p)))/(6.022*10^23*WellVolumeAvail)*1000*exp(-
q/(kB*Temp)*PSI_not/1000)+Cs_initial)^0.5))*exp(-t_inc(j)/tau_s); 
        SignalMaintain(1,1) = Signal(1,j); 
        Error(1,j) = Sigmas*Signal(1,j)/SNR(1,j); 
    else 
        break 
    end 
end 
  
for k = 1:(length(t_inc)-j) 
    Signal(1,k+j-1) = SignalMaintain(1,1)*exp(-t_inc(k+1)/tau_s); 
end 
    
%Signal for 2 bases 
for l = 1:length(t_inc) 
    if TotalProtonsProduced(2,l) < 2*Strands 
        Signal(2,l) = PSI_not*(1-
C_dl_initial/(dielectric*permittivity/(0.3/10^9)*0.5^0.5*Zs*(TotalProtonsAfte
rDiffusion(2,l)/(6.022*10^23*WellVolumeAvail)*1000*exp(-
q/(kB*Temp)*PSI_not/1000)+Cs_initial)^0.5))*exp(-t_inc(l)/tau_s); 
        SignalMaintain(1,2) = max(Signal(2,:)); 
        Error(2,l) = Sigmas*Signal(2,l)/SNR(2,l); 
        if l>1 
            if Signal(2,l)<Signal(2,l-1) 
                break 
            end 
        end 
    else 
        break 
    end 
end 
  
for p = 1:(length(t_inc)-l) 
    Signal(2,p+l-1) = SignalMaintain(1,2)*exp(-t_inc(p+1)/tau_s); 
end 
  
%Signal for 3 bases 
for v = 1:length(t_inc) 
    if TotalProtonsProduced(3,v) < 3*Strands 
        Signal(3,v) = PSI_not*(1-
C_dl_initial/(dielectric*permittivity/(0.3/10^9)*0.5^0.5*Zs*(TotalProtonsAfte
rDiffusion(3,v)/(6.022*10^23*WellVolumeAvail)*1000*exp(-
q/(kB*Temp)*PSI_not/1000)+Cs_initial)^0.5))*exp(-t_inc(v)/tau_s); 
        SignalMaintain(1,3) = max(Signal(3,:)); 
        Error(3,v) = Sigmas*Signal(3,v)/SNR(3,v); 
        if v>1 
            if Signal(3,v)<Signal(3,v-1) 
                break 
            end 
        end 
    else 
        break 
    end 
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end 
  
for w = 1:(length(t_inc)-v) 
    Signal(3,w+v-1) = SignalMaintain(1,3)*exp(-t_inc(w+1)/tau_s); 
end 
  
%% Plotting  
figure 
subplot(2,1,1); 
tInt = 500; 
hold on 
plot(t_inc(1:tInt),TotalProtonsPostDiffusion(1,1:tInt),'b'); 
plot(t_inc(1:tInt),TotalProtonsPostDiffusion(2,1:tInt),'g'); 
plot(t_inc(1:tInt),TotalProtonsPostDiffusion(3,1:tInt),'r'); 
xlabel('Time,sec');ylabel('Total Protons in One Well after 
Diffusion');legend('n = 1','n = 2', 'n = 3'); 
hold off 
subplot(2,1,2); 
hold on 
plot(t_inc,Signal(1,:),'b'); 
plot(t_inc,Signal(2,:),'g'); 
plot(t_inc,Signal(3,:),'r'); 
xlabel('Time,sec');ylabel('Signal, mV');legend('n = 1','n = 2', 'n = 3'); 
hold off 
  
figure 
hold on 
X_Axis = 250; 
errorbar(t_inc(1:X_Axis),Signal(1,1:X_Axis),Error(1,1:X_Axis),'b'); 
errorbar(t_inc(1:X_Axis),Signal(2,1:X_Axis),Error(2,1:X_Axis),'g'); 
errorbar(t_inc(1:X_Axis),Signal(3,1:X_Axis),Error(3,1:X_Axis),'r'); 
xlabel('Time,sec');ylabel('Signal,mV');legend('n = 1', 'n = 2', 'n = 3'); 
hold off 
  
%% Flows 
WellPitch = WellDiameter + 0.22; %um 
Gap = 1; %mm 
DieWidth = 20; %mm 
DieLength = 23.7; %mm 
DieArea = DieWidth*DieLength; %mm 
DieCrossSect = Gap*DieWidth; %mm^2 
VolumeofChip = DieArea*Gap; %mm^3 
  
NumberofWells = 660000000; 
  
HydraulicDiameter = 4*Gap*DieWidth/(DieWidth*2+DieLength*2); 
  
Viscosity = 0.001; %kg/(m-s) 
Density = 1000; %kg/m^3 
KVisc = Viscosity/Density; %m^2/s 
FlowVelocity = (VolFlowRate/60)*1000/DieCrossSect; %mm/s 
Re = FlowVelocity*HydraulicDiameter/(KVisc*1000^2); 
  
TimeforNucleotideCover = VolumeofChip/VolFlowRate; %s 
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APPENDIX F 
 
MATLAB Code for Dephasing 
 
%% Set length of strand, no. of strands,and no. of cycles of nucleotide flow 
% Also pick the bases you want included in the flow cycle 
% 1 = A; 2 = C; 3 = G, T = 4; so each cycle = ACGT 
  
Length = 200; 
Strands = 100; 
FlowCycles = 80; 
F = [1 2 3 4]; 
  
% Set the time for the flow of one base and divide it into segments of time 
dt 
dt = 0.02; % should be less than 0.023 
flowtime = 0.25; %s 
timesegments = round(flowtime/dt); 
  
%% Generate Random Sequence 
% Create empty matrix that will contain the same sequence in each strand 
% Column = strand; Row = Base position 
% Fill up the matrix with each strand (bearing the same sequence) 
  
Sequence = randseq(Length); 
SequenceMatN = zeros(Length,Strands); 
  
for a = 1:Strands 
    SequenceMatN(:,a) = Sequence; 
    SequenceMat = char(SequenceMatN); 
end 
  
%% Set sequence of nucleotides that will be flowed in 
  
FlowSequenceN = repmat(F,1,FlowCycles);  
FlowSequence = transpose(int2nt(FlowSequenceN)); 
  
%% Confirm base incorporation 
ConfirmedBase = zeros(Length,Strands); 
  
%%Nucleotide Concentration 
dNTPconc = 100; %uM 
  
%%Kinetic Data 
  
%k_pol, s^-1 
  
AtoA_kpol = 0.0036; 
AtoC_kpol = 0.01; %0.1 
AtoG_kpol = 0.042; 
AtoT_kpol = 45; 
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CtoA_kpol = 0.01; %0.1 
CtoC_kpol = 0.003; 
CtoG_kpol = 43; 
CtoT_kpol = 0.038; 
  
GtoA_kpol = 0.05; 
GtoC_kpol = 40; %31 
GtoG_kpol = 0.066; 
GtoT_kpol = 0.0116; %1.16 
  
TtoA_kpol = 40; %25 
TtoC_kpol = 0.012; 
TtoG_kpol = 0.016; %1.6 
TtoT_kpol = 0.013; 
  
%KD, uM 
  
AtoA_KD = 25; 
AtoC_KD = 160; 
AtoG_KD = 250; 
AtoT_KD = 0.8; 
  
CtoA_KD = 540; 
CtoC_KD = 140; 
CtoG_KD = 0.9; 
CtoT_KD = 360; 
  
GtoA_KD = 500;  
GtoC_KD = 0.8; 
GtoG_KD = 150; 
GtoT_KD = 70; 
  
TtoA_KD = 0.6; 
TtoC_KD = 180; 
TtoG_KD = 200; 
TtoT_KD = 57; 
  
  
%% Probabilities of incorporating 
AonAProb = ((AtoA_kpol*dNTPconc)/(AtoA_KD+dNTPconc))*dt; 
AonCProb = ((AtoC_kpol*dNTPconc)/(AtoC_KD+dNTPconc))*dt; 
AonGProb = ((AtoG_kpol*dNTPconc)/(AtoG_KD+dNTPconc))*dt; 
AonTProb = ((AtoT_kpol*dNTPconc)/(AtoT_KD+dNTPconc))*dt; 
ConAProb = ((CtoA_kpol*dNTPconc)/(CtoA_KD+dNTPconc))*dt; 
ConCProb = ((CtoC_kpol*dNTPconc)/(CtoC_KD+dNTPconc))*dt; 
ConGProb = ((CtoG_kpol*dNTPconc)/(CtoG_KD+dNTPconc))*dt; 
ConTProb = ((CtoT_kpol*dNTPconc)/(CtoT_KD+dNTPconc))*dt; 
GonAProb = ((GtoA_kpol*dNTPconc)/(GtoA_KD+dNTPconc))*dt; 
GonCProb = ((GtoC_kpol*dNTPconc)/(GtoC_KD+dNTPconc))*dt; 
GonGProb = ((GtoG_kpol*dNTPconc)/(GtoG_KD+dNTPconc))*dt; 
GonTProb = ((GtoT_kpol*dNTPconc)/(GtoT_KD+dNTPconc))*dt; 
TonAProb = ((TtoA_kpol*dNTPconc)/(TtoA_KD+dNTPconc))*dt; 
TonCProb = ((TtoC_kpol*dNTPconc)/(TtoC_KD+dNTPconc))*dt; 
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TonGProb = ((TtoG_kpol*dNTPconc)/(TtoG_KD+dNTPconc))*dt; 
TonTProb = ((TtoT_kpol*dNTPconc)/(TtoT_KD+dNTPconc))*dt; 
  
%% Dephase Counter 
DephaseCounter = zeros(Length*Strands,6); 
drow=1; 
% col 1 = base flow no. 
% col 2 = time segment 
% col 3 = column no. 
% col 4 = position no. 
% col 5 = miss? 
% col 6 = mismatch? 
  
%% Sequencing  
% For every match, place a 1 in the corresponding cell 
% For every mismatch, place a -1 in the corresponding cell 
  
for b=1:length(FlowSequence) % loop through every base flowed in    
    for t=1:timesegments % loop through every time segment     
        for c=1:Strands % loop through every column 
            for d=1:Length % loop through every position (until finding the 
first unfilled position) 
                if ConfirmedBase(d,c) == 0; 
                    r=d; 
                    if     FlowSequence(b,1) == 'A' 
                        if     SequenceMat(r,c) == 'A' 
                                  RN=rand; 
                               if RN<=AonAProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'C' 
                                  RN=rand; 
                               if RN<=AonCProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end                              
                        elseif SequenceMat(r,c) == 'G' 
                                  RN=rand; 
                               if RN<=AonGProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
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                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'T' 
                                  RN=rand; 
                               if RN<=AonTProb; 
                                  ConfirmedBase(r,c)=1; 
                               else 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,5)=1; 
                                  drow=drow+1; 
                               end 
                        end 
                    elseif FlowSequence(b,1) == 'C' 
                        if     SequenceMat(r,c) == 'A' 
                                  RN=rand; 
                               if RN<=ConAProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'C' 
                                  RN=rand; 
                               if RN<=ConCProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'G' 
                                  RN=rand; 
                               if RN<=ConGProb; 
                                  ConfirmedBase(r,c)=1; 
                               else 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,5)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'T' 
                                  RN=rand; 
                               if RN<=ConTProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
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                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        end 
                    elseif FlowSequence(b,1) == 'G' 
                        if     SequenceMat(r,c) == 'A' 
                                  RN=rand; 
                               if RN<=GonAProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'C' 
                                  RN=rand; 
                               if RN<=GonCProb; 
                                  ConfirmedBase(r,c)=1; 
                               else 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,5)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'G' 
                                  RN=rand; 
                               if RN<=GonGProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'T' 
                                  RN=rand; 
                               if RN<=GonTProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        end 
                    elseif FlowSequence(b,1) == 'T' 
                        if     SequenceMat(r,c) == 'A' 
                                  RN=rand; 
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                               if RN<=TonAProb; 
                                  ConfirmedBase(r,c)=1; 
                               else 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,5)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'C' 
                                  RN=rand; 
                               if RN<=TonCProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'G' 
                                  RN=rand; 
                               if RN<=TonGProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        elseif SequenceMat(r,c) == 'T' 
                                  RN=rand; 
                               if RN<=TonTProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  DephaseCounter(drow,1)=b; 
                                  DephaseCounter(drow,2)=t; 
                                  DephaseCounter(drow,3)=c; 
                                  DephaseCounter(drow,4)=d; 
                                  DephaseCounter(drow,6)=1; 
                                  drow=drow+1; 
                               end 
                        end                                                      
                    end 
                    if ConfirmedBase(d,c) == 0; % if no match/mismatch has 
been made, move on, otherwise check the next position 
                        break 
                    end 
                end 
            end 
        end 
    end 
end 
% Details:  
% loops through every base that is flowed in 
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% for every time segment, does the following 
% loops through every column 
% searches for the first open position 
% determines whether there is a match 
% accounts for homopolymers (i.e. checks to see if the position after a 
% match is also a match) 
  
  
%% Counting Mismatches 
  
% MismatchCounter = list of all columns with mismatches extracted from 
% DephaseCounter 
% MismatchColandPos = same list as above (col#1) but also showing the 
position of 
% each mismatch (col#2) 
LengthDC=length(DephaseCounter); 
MismatchCounter = zeros(LengthDC,1); 
mrow=1; 
for mis=1:LengthDC 
    if DephaseCounter(mis,6)==1 
        MismatchCounter(mrow)=DephaseCounter(mis,3); 
        mrow=mrow+1; 
    end 
end 
  
MismatchCounter(MismatchCounter == 0) = []; % gets rid of all unnecessary 
zeros in MismatchCounter 
  
% StrandsAhead = all unique columns that appear in MismatchCounter 
StrandsAhead = unique(MismatchCounter); 
  
% StrandsAheadCounter = the number of times each element in StrandsAhead 
% appears in MismatchCounter (i.e. by how many positions that column is 
ahead) 
  
% StrandsAheadTable = table showing all columns with mismatches (col#1) and 
how many 
% mismatches in each column (col#2) 
  
% AheadNumbers = list of the unique numbers by which strands are ahead 
% (i.e. some strands are ahead by 1, some strands are ahead by 2 and so on) 
  
% AheadNumbersHist = how many times each of the elements in AheadNumbers 
% appears (see next entry) 
  
StrandsAheadTable(:,1)=StrandsAhead; % all col #s that are behind 
if length(StrandsAhead) == 1 % if 1 or more mismatches in 1 column 
   StrandsAheadTable(:,2) = length(MismatchCounter); % no. of mismatches = 
length of MissesCounter 
   AheadNumbers = length(MismatchCounter); 
   AheadNumbersHist = 1; 
elseif isempty(MismatchCounter) == 1 % if no mismatches 
    StrandsAhadTable = zeros(1,2); % column with zeros 
    StrandsAheadCounter = zeros(1,1); 
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    AheadNumbers = 0; 
    AheadNumbersHist = hist(StrandsAheadCounter,AheadNumbers); 
else 
    StrandsAheadCounter = hist(MismatchCounter,StrandsAhead); 
    StrandsAheadTable(:,2)=transpose(StrandsAheadCounter); 
    AheadNumbers = unique(StrandsAheadCounter); 
    AheadNumbersHist = hist(StrandsAheadCounter,AheadNumbers); 
end 
  
% AheadTable = table showing how many strands (col#2) are ahead by how much 
% (col#1) 
if isempty(AheadNumbersHist)==1 
    AheadTable = zeros(1,2); 
else 
    AheadTable(:,1)=transpose(AheadNumbers); 
    AheadTable(:,2)=transpose(AheadNumbersHist); 
end 
  
figure (1) 
bar(AheadTable(:,1),AheadTable(:,2)) 
title('Plot showing strands that have dephased ahead') 
xlabel('Position ahead of undephased strands') 
ylabel('No. of strands') 
  
%% Counting Misses 
  
% MissesCounter = list of all columns with misses extracted from 
% DephaseCounter (only those from the last time segment) 
% MissesColandPos = same list as above (col#1) but also showing the position 
of 
% each miss (col#2) 
LengthDC=length(DephaseCounter); 
MissesCounter = zeros(LengthDC,1); 
msrow=1; 
for miss=1:LengthDC 
    if DephaseCounter(miss,2)==timesegments 
    if DephaseCounter(miss,5)==1 
        MissesCounter(msrow)=DephaseCounter(miss,3); 
        msrow=msrow+1; 
    end 
    end 
end 
  
MissesCounter(MissesCounter == 0) = []; % gets rid of all unnecessary zeros 
in MismatchCounter 
  
% StrandsBehind = all unique columns that appear in MissesCounter 
StrandsBehind = unique(MissesCounter); 
  
% StrandsBehindCounter = the number of times each element in StrandsBehind 
% appears in MissesCounter (i.e. by how many positions that column is behind) 
  
% StrandsBehindTable = table showing all columns with misses (col#1) and how 
many 
% misses in each column (col#2) 
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% BehindNumbers = list of the unique numbers by which strands are behind 
% (i.e. some strands are behind by 1, some strands are behind by 2 and so on) 
  
% BehindNumbersHist = how many times each of the elements in BehindNumbers 
% appears (see next entry) (how many strands are behind by e.g. 1) 
  
StrandsBehindTable(:,1)=StrandsBehind; % all col #s that are behind 
if length(StrandsBehind) == 1 % if 1 or more misses in 1 column 
   StrandsBehindTable(:,2) = length(MissesCounter); % no. of misses = length 
of MissesCounter 
   BehindNumbers = length(MissesCounter); 
   BehindNumbersHist = 1; 
elseif isempty(MissesCounter) == 1 % if no misses 
    StrandsBehindTable = zeros(1,2); % column with zeros 
    StrandsBehindCounter = zeros(1,1); 
    BehindNumbers = 0; 
    BehindNumbersHist = hist(StrandsBehindCounter,BehindNumbers); 
else 
    StrandsBehindCounter = hist(MissesCounter,StrandsBehind); 
    StrandsBehindTable(:,2)=transpose(StrandsBehindCounter); 
    BehindNumbers = unique(StrandsBehindCounter); 
    BehindNumbersHist = hist(StrandsBehindCounter,BehindNumbers); 
end 
  
% BehindTable = table showing how many strands (col#2) are behind by how much 
% (col#1) 
if isempty(BehindNumbersHist)==1 
    BehindTable = zeros(1,2); 
else 
    BehindTable(:,1)=transpose(BehindNumbers); 
    BehindTable(:,2)=transpose(BehindNumbersHist); 
end 
  
figure (2) 
bar(BehindTable(:,1),BehindTable(:,2)) 
title('Plot showing strands that have dephased behind') 
xlabel('Position behind of undephased strands') 
ylabel('No. of strands') 
  
%% Counting All Dephases 
  
% DephasedStrands = how many are ahead (#1) and behind (#2) 
DephasedStrands(1,1) = length(StrandsAhead);  
DephasedStrands(1,2) = length(StrandsBehind); 
  
% CommonLength = longest column of DephasedStrands - giving the future 
% columns enough space 
CommonLength = max(DephasedStrands); 
  
% CommonStrands = list of strands that are both ahead and behind 
% NotCommonStrandsA = list of strands that are only ahead 
% NotCommonStrandsB = list of strands that are only behind 
% col 1 = strand no. 
% col 2 = how much ahead 
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% col 3 = how much behind 
% col 4 = overall dephase (+ve = ahead; -ve = behind) 
  
CommonStrands = zeros(CommonLength,4); 
csrow=1; 
NotCommonStrandsA = zeros(CommonLength,4); 
ncsrow1=1; 
NotCommonStrandsB = zeros(CommonLength,4); 
ncsrow2=1; 
  
for x = 1:length(StrandsAhead) 
    if ismember(StrandsAhead(x),StrandsBehind)==1 
        CommonStrands(csrow,1)=StrandsAhead(x); 
        csrow=csrow+1; 
    else 
        NotCommonStrandsA(ncsrow1,1)=StrandsAhead(x); 
        ncsrow1=ncsrow1+1; 
    end 
end 
  
for y = 1:length(StrandsBehind) 
    if ismember(StrandsBehind(y),StrandsAhead)==0 
        NotCommonStrandsB(ncsrow2,1)=StrandsBehind(y); 
        ncsrow2=ncsrow2+1; 
    end 
end 
  
for xx = 1:CommonLength 
    for yy = 1:size(StrandsAheadTable,1) 
        if CommonStrands(xx,1) == StrandsAheadTable(yy,1) 
            CommonStrands(xx,2) = StrandsAheadTable(yy,2); 
        end 
        if NotCommonStrandsA(xx,1) == StrandsAheadTable(yy,1) 
            NotCommonStrandsA(xx,2) = StrandsAheadTable(yy,2); 
        end 
    end 
    for zz = 1:size(StrandsBehindTable,1) 
        if CommonStrands(xx,1) == StrandsBehindTable(zz,1) 
            CommonStrands(xx,3) = StrandsBehindTable(zz,2); 
        end 
        if NotCommonStrandsB(xx,1) == StrandsBehindTable(zz,1) 
            NotCommonStrandsB(xx,3) = StrandsBehindTable(zz,2); 
        end 
    end 
    CommonStrands(xx,4) = CommonStrands(xx,2)-CommonStrands(xx,3); 
    NotCommonStrandsA(xx,4) = NotCommonStrandsA(xx,2)-
NotCommonStrandsA(xx,3); 
    NotCommonStrandsB(xx,4) = NotCommonStrandsB(xx,2)-
NotCommonStrandsB(xx,3); 
end 
  
% CommonStrandsTable = (#1) strand no. (#2) how much ahead (#3) how much 
% behind (#4) how much dephased - only for strands both ahead and behind 
CommonStrandsLength = nnz(CommonStrands(:,1)); 
CommonStrandsTable = CommonStrands(1:CommonStrandsLength,:); 
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% NotCommonStrandsATable = (#1) strand no. (#2) how much ahead (#3) how much 
% behind (#4) how much dephased - only for strands ahead 
NotCommonStrandsALength = nnz(NotCommonStrandsA(:,1)); 
NotCommonStrandsATable = NotCommonStrandsA(1:NotCommonStrandsALength,:); 
  
% NotCommonStrandsBTable = (#1) strand no. (#2) how much ahead (#3) how much 
% behind (#4) how much dephased only for strands behind  
NotCommonStrandsBLength = nnz(NotCommonStrandsB(:,1)); 
NotCommonStrandsBTable = NotCommonStrandsB(1:NotCommonStrandsBLength,:); 
  
% DephasedStrandsBTable = (#1) strand no. (#2) how much ahead (#3) how much 
% behind (#4) how much dephased - for all strands 
DephasedStrandsTable = 
[CommonStrandsTable;NotCommonStrandsATable;NotCommonStrandsBTable]; 
  
% DephasedTable = (#1) how much dephased (#2) how many strands 
  
DephasedList = sort(DephasedStrandsTable(:,4)); 
DephasedListUnique = unique(DephasedList); 
DephasedListHist = hist(DephasedList,DephasedListUnique); 
  
DephasedTable(:,1) = DephasedListUnique; 
DephasedTable(:,2) = transpose(DephasedListHist); 
  
TotalStrandsAhead = nnz(StrandsAhead) 
TotalStrandsBehind = nnz(StrandsBehind) 
TotalStrandsDephased = length(DephasedStrandsTable) 
TotalStrandsPerfect = Strands-TotalStrandsDephased 
  
for xxx=1:size(DephasedTable,1) 
    if DephasedTable(xxx,1) == 0 
        DephasedTable(xxx,2) = DephasedTable(xxx,2) + TotalStrandsPerfect; 
    end 
end 
  
if ismember(0,DephasedTable) == 0 
        DephasedTable = [DephasedTable;[0 TotalStrandsPerfect]]; 
end 
  
figure (3) 
bar(DephasedTable(:,1),DephasedTable(:,2)) 
title('Plot showing strands that have dephased') 
xlabel('Position relative to strands in phase') 
ylabel('No. of strands') 
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APPENDIX G 
 
MATLAB Code for Base-Calling 
 
%% Set length of strand, # of strands,and # of cycles of nucleotide flow 
% Also pick the bases you want included in the flow cycle 
% 1 = A; 2 = C; 3 = G, T = 4; so each cycle = ACGT 
  
Length = 200; 
Strands = 50; 
FlowCycles = 75; 
F = [4 3 2 1]; 
  
% Set the time for the flow of one base, divide it into segments of time dt 
dt = 0.02; % should be less than 0.023 
flowtime = 0.1; 
timesegments = round(flowtime/dt); 
  
%% Generate Random Sequence 
% Create empty matrix that will contain the same sequence in each strand 
% Column = strand; Row = Base position 
% Fill up the matrix with each strand (bearing the same sequence) 
  
Sequence = randseq(Length); 
SequenceMatN = zeros(Length,Strands); 
  
for a = 1:Strands 
    SequenceMatN(:,a) = Sequence; 
    SequenceMat = char(SequenceMatN); 
end 
  
%% Set sequence of nucleotides that will be flowed in 
  
FlowSequenceN = repmat(F,1,FlowCycles);  
FlowSequence = transpose(int2nt(FlowSequenceN)); 
  
%% Confirm base incorporation 
ConfirmedBase = zeros(Length,Strands); 
  
%%Nucleotide Concentration 
dNTPconc = 100; %uM 
  
%%Kinetic Data 
%k_pol, s^-1 
  
AtoA_kpol = 0.0036; 
AtoC_kpol = 0.01; %0.1 
AtoG_kpol = 0.042; 
AtoT_kpol = 45; %45 
  
CtoA_kpol = 0.01; %0.1 
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CtoC_kpol = 0.003; 
CtoG_kpol = 43; %43 
CtoT_kpol = 0.038; 
  
GtoA_kpol = 0.05; 
GtoC_kpol = 40; %37 
GtoG_kpol = 0.066; 
GtoT_kpol = 0.016; %1.16 
  
TtoA_kpol = 40; %25 
TtoC_kpol = 0.012; 
TtoG_kpol = 0.016; %1.6 
TtoT_kpol = 0.013; 
  
%KD, uM 
  
AtoA_KD = 25; 
AtoC_KD = 160; 
AtoG_KD = 250; 
AtoT_KD = 0.8; 
  
CtoA_KD = 540; 
CtoC_KD = 140; 
CtoG_KD = 0.9; 
CtoT_KD = 360; 
  
GtoA_KD = 500;  
GtoC_KD = 0.8; 
GtoG_KD = 150; 
GtoT_KD = 70; 
  
TtoA_KD = 0.6; 
TtoC_KD = 180; 
TtoG_KD = 200; 
TtoT_KD = 57; 
  
  
%% Probabilities of incorporating 
AonAProb = ((AtoA_kpol*dNTPconc)/(AtoA_KD+dNTPconc))*dt; 
AonCProb = ((AtoC_kpol*dNTPconc)/(AtoC_KD+dNTPconc))*dt; 
AonGProb = ((AtoG_kpol*dNTPconc)/(AtoG_KD+dNTPconc))*dt; 
AonTProb = ((AtoT_kpol*dNTPconc)/(AtoT_KD+dNTPconc))*dt; 
ConAProb = ((CtoA_kpol*dNTPconc)/(CtoA_KD+dNTPconc))*dt; 
ConCProb = ((CtoC_kpol*dNTPconc)/(CtoC_KD+dNTPconc))*dt; 
ConGProb = ((CtoG_kpol*dNTPconc)/(CtoG_KD+dNTPconc))*dt; 
ConTProb = ((CtoT_kpol*dNTPconc)/(CtoT_KD+dNTPconc))*dt; 
GonAProb = ((GtoA_kpol*dNTPconc)/(GtoA_KD+dNTPconc))*dt; 
GonCProb = ((GtoC_kpol*dNTPconc)/(GtoC_KD+dNTPconc))*dt; 
GonGProb = ((GtoG_kpol*dNTPconc)/(GtoG_KD+dNTPconc))*dt; 
GonTProb = ((GtoT_kpol*dNTPconc)/(GtoT_KD+dNTPconc))*dt; 
TonAProb = ((TtoA_kpol*dNTPconc)/(TtoA_KD+dNTPconc))*dt; 
TonCProb = ((TtoC_kpol*dNTPconc)/(TtoC_KD+dNTPconc))*dt; 
TonGProb = ((TtoG_kpol*dNTPconc)/(TtoG_KD+dNTPconc))*dt; 
TonTProb = ((TtoT_kpol*dNTPconc)/(TtoT_KD+dNTPconc))*dt; 
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%% Sequencing  
% For every match, place a 1 in the corresponding cell 
% For every mismatch, place a -1 in the corresponding cell 
  
Counter = zeros(length(FlowSequence),timesegments); 
  
% Details:  
% loops through every base that is flowed in 
% for every time segment, does the following 
% loops through every column 
% searches for the first open position 
% determines whether there is a match 
% accounts for homopolymers (i.e. checks to see if the position after a 
% match is also a match) 
  
for b=1:length(FlowSequence) % loop through every base flowed in 
   time=0; 
    for t=1:timesegments % loop through every time segment     
        for c=1:Strands % loop through every column 
            for d=1:Length % loop through positions (until first unfilled) 
                if ConfirmedBase(d,c) == 0; 
                    r=d; 
                    if     FlowSequence(b,1) == 'A' 
                        if     SequenceMat(r,c) == 'A' 
                                  RN=rand; 
                               if RN<=AonAProb; 
                                  ConfirmedBase(r,c)=-1; 
                                  Counter(b,t) = Counter(b,t) + 1; 
                               end 
                        elseif SequenceMat(r,c) == 'C' 
                                  RN=rand; 
                               if RN<=AonCProb; 
                                  ConfirmedBase(r,c)=-1;           
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end                              
                        elseif SequenceMat(r,c) == 'G' 
                                  RN=rand; 
                               if RN<=AonGProb; 
                                  ConfirmedBase(r,c)=-1;                                                                                                                                    
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        elseif SequenceMat(r,c) == 'T' 
                                  RN=rand; 
                               if RN<=AonTProb; 
                                  ConfirmedBase(r,c)=1;                                                                     
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        end 
                    elseif FlowSequence(b,1) == 'C' 
                        if     SequenceMat(r,c) == 'A' 
                                  RN=rand; 
                               if RN<=ConAProb; 
                                  ConfirmedBase(r,c)=-1;                                                                     
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
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                        elseif SequenceMat(r,c) == 'C' 
                                  RN=rand; 
                               if RN<=ConCProb; 
                                  ConfirmedBase(r,c)=-1;                                 
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        elseif SequenceMat(r,c) == 'G' 
                                  RN=rand; 
                               if RN<=ConGProb; 
                                  ConfirmedBase(r,c)=1;                                   
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        elseif SequenceMat(r,c) == 'T' 
                                  RN=rand; 
                               if RN<=ConTProb; 
                                  ConfirmedBase(r,c)=-1;                                   
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        end 
                    elseif FlowSequence(b,1) == 'G' 
                        if     SequenceMat(r,c) == 'A' 
                                  RN=rand; 
                               if RN<=GonAProb; 
                                  ConfirmedBase(r,c)=-1;                                   
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        elseif SequenceMat(r,c) == 'C' 
                                  RN=rand; 
                               if RN<=GonCProb; 
                                  ConfirmedBase(r,c)=1;                                   
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        elseif SequenceMat(r,c) == 'G' 
                                  RN=rand; 
                               if RN<=GonGProb; 
                                  ConfirmedBase(r,c)=-1;                                   
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        elseif SequenceMat(r,c) == 'T' 
                                  RN=rand; 
                               if RN<=GonTProb; 
                                  ConfirmedBase(r,c)=-1;                                   
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        end 
                    elseif FlowSequence(b,1) == 'T' 
                        if     SequenceMat(r,c) == 'A' 
                                  RN=rand; 
                               if RN<=TonAProb; 
                                  ConfirmedBase(r,c)=1;                                   
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        elseif SequenceMat(r,c) == 'C' 
                                  RN=rand; 
                               if RN<=TonCProb; 
                                  ConfirmedBase(r,c)=-1;                                   
15. Appendices  Chow, Hasan, Lau, Liu 
 
158 
 
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        elseif SequenceMat(r,c) == 'G' 
                                  RN=rand; 
                               if RN<=TonGProb; 
                                  ConfirmedBase(r,c)=-1;                                   
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        elseif SequenceMat(r,c) == 'T' 
                                  RN=rand; 
                               if RN<=TonTProb; 
                                  ConfirmedBase(r,c)=-1;                                   
                                  Counter(b,t) = Counter(b,t) + 1;                                   
                               end 
                        end                                                      
                    end 
                    if ConfirmedBase(d,c) == 0; 
                    % if no match/mismatch has been made, move on,  
                    % otherwise check the next position 
                        break 
                    end 
                end 
            end 
        end 
         
    end 
     
end 
  
CounterSum_PreRounding_Insertions = sum(Counter,2); 
CounterSum = round(round(4*sum(Counter,2)./Strands)/4); 
%rounds to nearest 0.25, then rounds to nearest integer 
Standard = sum(CounterSum); 
%The proper length of the strands if no dephasing 
  
NumberofDephased = 0; 
NumberofDephased_Behind = 0; 
NumberofDephased_Ahead = 0; 
  
for y = 1:Strands 
    if nnz(ConfirmedBase(:,y)) ~= Standard 
        NumberofDephased = NumberofDephased + 1; 
    end 
    if nnz(ConfirmedBase(:,y)) < Standard 
        NumberofDephased_Behind = NumberofDephased_Behind + 1; 
    end 
    if nnz(ConfirmedBase(:,y)) > Standard 
        NumberofDephased_Ahead = NumberofDephased_Ahead + 1; 
    end 
end 
PercentDephased = NumberofDephased/Strands; 
PercentDephased_Behind = NumberofDephased_Behind/Strands; 
PercentDephased_Ahead = NumberofDephased_Ahead/Strands; 
  
subplot(2,1,1) 
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cc = 60; 
hold on 
bar(CounterSum_PreRounding_Insertions(1:cc)); 
xlabel('Base Flow Number');ylabel('Total Insertion Events'); 
hold off 
subplot(2,1,2) 
hold on 
bar(CounterSum(1:cc));xlabel('Base Flow Number');ylabel('Bases in Strand'); 
hold off 
  
%Error rates 
ErrorRates = zeros(1,Strands); %Gives percent error, dephased not counted 
for s=1:Strands 
    Errors = tabulate(ConfirmedBase(:,s)); 
    if Errors(1,1) == -1 
        ErrorRates(1,s) = Errors(1,3); 
    end 
end 
AverageError = mean(ErrorRates); 
  
%Derive Sequence from Base Calling Algorithm 
GeneratedSequence = zeros(Length,1); 
gsrow = 1; 
  
for zz = 1:length(CounterSum) 
    GSRow = CounterSum (zz,1); 
    GeneratedSequence(gsrow:(gsrow+GSRow),1) = char(FlowSequence(zz)); 
    gsrow = gsrow + GSRow; 
end 
  
for yy = 1:length(GeneratedSequence) 
    if GeneratedSequence(yy) == 'A' 
        GeneratedSequence(yy) = 'T'; 
    elseif GeneratedSequence(yy) == 'T' 
        GeneratedSequence(yy) = 'A'; 
    elseif GeneratedSequence(yy) == 'G' 
        GeneratedSequence(yy) = 'C'; 
    elseif GeneratedSequence(yy) == 'C' 
        GeneratedSequence(yy) = 'G'; 
    end 
end 
  
DerivedSequence = char(GeneratedSequence); 
  
%Any errors from the given sequence and derived sequence 
MatchError = zeros(length(DerivedSequence),1); 
for xx = 1:length(DerivedSequence) 
    if DerivedSequence(xx) ~= SequenceMat(xx) 
        MatchError(xx,1) = 1; 
    end 
end 
TotalMatchError = sum(MatchError); 
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APPENDIX H 
 
Components of Costs of Goods Sold 
 
  
Equipment Price 
- PII™ Chip $350.00 
- Ion Plus Fragment Library Kit $25.00 
- Ion PI™ Template OT2 200 Kit $83.00 
- Ion PI™ Sequencing Kit  $67.50 
- Ion Proton Controls Kit $100.00 
- 10 M NaOH [$71.40 for 100 mL] $1.40 
- Isopropanol (99.7%) [$265 for 20 kg] $0.34 
- Nuclease-free Water [$96.70 for 5 L] $0.19 
- 10 L of 1N HCl [$91.20 for 10 L] $0.09 
- Ethanol (200 proof) [$315 for 6-500 mL bottles] $1.05 
- 500 mL TE Buffer, 1X Solution pH 8.0, low EDTA $0.63 
- Pipette Tips  
    P2 $0.27 
    P20 $0.27 
    P200 $0.27 
    P1000 $0.32 
- Thin Wall PCR Tubes, Flat Cap $5.00 
- 1.5 mL microcentrifuge tubes $0.20 
- Agencourt AMPure XP - PCR Purification $2.11 
- Agilent® High Sensitivity DNA Kit $4.61 
- MagaZorb DNA Common Kit-200 $2.00 
- Ion Xpress™ Barcode Adapters 1-96 Kit (partial 
purchase) 
$1.56 
- Bioruptor® NGS 0.65 ml Microtubes for DNA Shearing 
(500 tubes) 
$0.34 
- Pippin Prep™ Kit 2010  $4.50 
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APPENDIX I 
 
Components of Capital Equipment 
 
  
Equipment Unit Price 
- Ion Proton II, including Ion Server $224,000.00 
- Maxwell Research System $30,000.00 
- Ion OneTouch 2 System $19,000.00 
- Nitrogen (grade 4.8, 99.998% or better) $70.00 
- Water Purification System (Elga Purelab Flex 3) $5,000.00 
- Multistage gas regulator (VWR, 55850-422) $375.00 
- Lab Freezer $1,000.00 
- Uninterruptable Power Supply (UPS) $200.00 
- Microcentrifuge $1,995.00 
- Galaxy Mini Centrifuge $401.25 
- Pipettes  
     P2 $335.00 
     P20 $297.00 
     P200 $297.00 
     P1000 $297.00 
- 1 L Glass Bottles $9.40 
- Vortex Mixer $800.00 
- Thermal Cycler $8,000.00 
- Tygon Tubing $2.00 
- Magnetic Stirrer $230.00 
- Magnetic Stir Bars 10 
- Vacuum filtration system (pore size 0.45 um) $83.40 
- Orion 3-Star Plus Benchtop Meter Kit with probes $752 
- Squirt bottles $5.00 
- 50 mL Syringe $1.85 
- DynaMag™-2 Magnet $531 
- Agilent® 2100 Bioanalyzer® instrument $19580 
- Heat Block/Water Bath $160 
- Incubator $183 
- BioRuptor® NGS Sonication System $13000 
- Pippin Prep™ System $15000 
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APPENDIX J 
Pro Forma Case 1 
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APPENDIX K 
Pro Forma Case 2 
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APPENDIX L 
 
Original Problem Statement 
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